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Abstract
Relatedness mapping is concerned with identifying genomic regions that have been inher-
ited from a common ancestor. Such regions are said to be identical by descent (IBD) and
detecting IBD has proven useful in many applications including disease mapping, discov-
ery of familial relatedness and determining loci under selection. Relatedness mapping is
typically performed on humans. As such, methodologies are widely available for diploid
genomes. This readily allows for analysis of autosomal chromosomes; however, algorithms
are generally not applicable to the X chromosome. This is because females have two copies
of the X chromosome while males have one copy of the X chromosome, requiring a more
complicated model to account for the difference in chromosomal numbers between males
and females. As a result, the X chromosome is generally excluded from analysis. This
is unfortunate as an abundance of disorders, such as intellectual disability, epilepsy and
autism, would greatly benefit from X chromosome IBD analysis.
This thesis describes the first probabilistic methodology for identifying pairwise IBD
that is applicable to both the X chromosome and autosomes. Genotype data, extracted
from either SNP arrays or next generation sequencing platforms, is used to infer IBD
and issues surrounding genotyping errors, missing data and linkage disequilibrium are
accounted for. Statistical and bioinformatics analyses are carried out to demonstrate the
performance of the methodology and an analysis of a small cohort of individuals with a
rare form of epilepsy is successfully performed.
The lack of methodologies for haploid chromosomes has implications that extend be-
yond the context of the X chromosome. In particular, microorganisms with haploid
genomes, such as the malaria causing parasite, Plasmodium, and bacterium Staphylococcus
aureus, are unable to be analysed for relatedness. Such analyses would be invaluable for
the study of these, and other, diseases with the recent emergence of antimicrobial drug
resistance, whereby a number of microorganisms have become resistant to first-line and/or
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last-resort antimicrobial treatments. IBD can be used to identify loci under selection that
are associated with antimicrobial resistance as well as monitor the genetic diversity in
populations to track disease control efforts.
One of the main difficulties with analysing genomic data of microorganisms, collected
from a human infection, is the occurrence of multiple genetically-distinct strains within an
infection. The genomic data can no longer be treated as though it is haploid and requires
special treatment. Like the human X chromosome, these samples are commonly excluded
from analysis, which can greatly reduce the power of studies in regions where multiple
infections are common.
As such, this thesis additionally describes the necessary extensions for the X chromo-
some IBD methodology to be applicable to non-human haploid organisms, where multiple
infections may be present. The algorithm successfully identifies antimalarial drug resis-
tance loci under positive selection in a global dataset of the deadliest species of malaria, P.
falciparum, which has recently become resistant to the first-line treatment, prompting a
global health crisis. This thesis also demonstrates the valuable insights that can be gained
from IBD analysis of malaria, which are applicable to other infectious diseases.
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This chapter provides an overview of the terminology required for understanding this the-
sis. It introduces basic biology, identity by descent analysis and the current methodologies
that can infer genomic regions shared identical by descent.
1.1 A recombining genome
The genome contains all the necessary genetic information for the development and func-
tioning of a living organism1. This information is encoded as deoxyribonucleic acid (DNA)
and is composed of four chemical bases; adenine (A), guanine (G), cytosine (C) and
thymine (T). Each base couples with its complement (A with T and C with G) to form a
base pair, which combines with a sugar and phosphate molecule to produce a nucleotide.
Many nucleotides are linked together in a sequence-like structure to form the backbone of
DNA. DNA is located within the nucleus of eukaryotic cells and is packaged into smaller
units called chromosomes. Each chromosome contains a number of short segments of DNA,
known as genes, that encode the physical traits of a species. Slight variations within a gene
can result in different observable traits, introducing genetic diversity into a population.
The variations of a gene or genomic location, called locus (plural: loci), are referred to as
alleles and allow species to adapt to changing environments.
1.1.1 Ploidy, meiosis and recombination
The number of sets of chromosomes within a cell is referred to as the cell ploidy. A
haploid cell contains one complete set of chromosomes and by extension, an organism
is considered haploid if all of its cells are haploid. Such is the case for male bees2 and
1
ants3, as well as microorganisms including the bacterium Mycobacterium tuberculosis 4
and the malaria causing parasite Plasmodium 5. In contrast, diploid cells contain two sets
of chromosomes, where chromosomes from each set form homologous pairs based on the
similarity of chromosome lengths and gene locations. In diploid organisms, all cells need
not necessarily be diploid for an organism to be considered diploid. For example, nearly
all mammals are diploid, although a small proportion of cells are usually haploid6.
Common types of haploid cells are gametes (egg or sperm cells) and these are pro-
duced during sexual reproduction in a process called meiosis (Figure 1.1)1. Initially, two
gametes, one from a male and one from a female, fuse together to create a diploid em-
bryo. Chromosomes from each set form homologous pairs based on the similarity of the
chromosome lengths and gene locations. These homologous chromosomes then duplicate
such that each chromosome consists of two identical strands, called sister chromatids, and
each homologous pair consists of four stands. The homologous chromosomes then undergo
synapsis whereby each pair connects to one another and the sister chromatids begin to
crossover. Here, part of a chromatid on one chromosome breaks off and switches position
with the matching portion of a chromatid on the homologous chromosome. This exchange
of genetic material via crossing over is referred to as recombination and results in offspring
with different combinations of genes to their parents. Following recombination, the ho-
mologous chromosome pairs randomly align in the cell center where they are then pulled
in opposite directions. Cell division occurs and two haploid daughter cells are formed,
each with one complete set of chromosomes, where the sister chromatids remain attached.
In a similar manner, the sister chromatids within each daughter cell randomly align in the
cell’s center and are separated to opposite sides of the cell where cell division follows. The










Figure 1.1: The process of meiosis in diploid cells. A homologous pair of chromosomes undergo
synapsis whereby the sister chromatids of homologous pairs cross over and exchange genetic ma-
terial. The recombined homologous chromosomes divide creating haploid daughter cells, which
divide again to produce four genetically distinct haploid gametes. This figure was adapted from
Griffiths et al.1 and drawn using Adobe Illustrator.
Meiosis is of great importance in diploid organisms as it is a key source of genetic
diversity that allows for a wider variety of genetic traits to be selected within a popula-
tion. This is achieved through the fundamental process of recombination. The genomic
3
locations at which recombination occurs are called crossover points and there is thought
to be at least one crossover point per chromosome pair during meiosis7. While crossover
events can occur anywhere along a chromosome, they are generally suppressed near the
chromosome center (centromere) and amplified towards the chromosome ends (telomeres).
Additionally, loci in close proximity to an existing crossover point are less likely to expe-
rience another crossover in a single meiosis event. Given this relationship, the expected
number of crossovers between two loci on a single chromosome can be used as a measure
of genetic distance, called the genetic map distance 7. The unit of genetic map distance is
Morgan (M), or more commonly used centiMorgan (cM), where 1 M = 100 cM. Formally,
1 cM is the probability of observing a recombination event between two loci during a sin-
gle meiosis7. In humans, 1 M ≈ 1,000,000 bp (or 1 Mb), on average (Figure 1.2). Other
species show a different relationship.










































Figure 1.2: The relationship between the genetic map distance (cM) and the physical distance
(bp) on chromosome 12 for males, females and averaged by sex. This figured was sourced from
Lander et al.8.
4
1.1.2 Single nucleotide polymorphisms
In addition to recombination, there are a number of other sources of genetic variation
that can be more broadly classified as mutations. A mutation is an alteration in the
DNA sequence that includes deleting, inserting, substituting, or rearranging a section of
DNA, among other things1. The most common type of mutation is a single nucleotide
polymorphism, or SNP, which is simply a change in a single base pair9. For the purpose of
this thesis, only SNPs will be discussed. Additionally, only SNPs with two alleles present,
the reference (wild type) allele or alternative allele, will be covered. Such SNPs are said
to be biallelic and constitute the majority of SNPs in the human genome.
Most SNPs are passed down from one generation to the next and only a small number
are produced during meiosis. Many of these SNPs lead to no observable difference in a
species, while some SNPs account for differences in appearances and others affect how a
species develops diseases1. Given the heritability of SNPs, it follows that SNPs tend to
be conserved within a population, however SNPs can vary considerably between popula-
tions10. For example, a locus that is polymorphic in one population may be monomorphic
(does not vary) in another population. Alternatively, a SNP may be present in two pop-
ulations with the wild type allele appearing at different frequencies.
A sequence of SNPs (not necessarily adjacent or uniformly spaced) on a chromosome
that have been inherited from a single parent form a haplotype. It follows that a haplotype
extracted from a haploid chromosome is phased, while phasing algorithms are typically
required to construct the haplotypes for diploid chromosomes. The unphased combina-
tions of alleles at SNPs are instead referred to as genotypes. The genotype of a biallelic
SNP on a diploid chromosome can be classified as homozygous reference, heterozygous
or homozygous alternative, referring to zero, one or two copies of the alternative allele,
respectively. In contrast a haploid chromosome can have either zero or one copy of the
alternative allele at a SNP. Additionally, the genotype of a haploid chromosome is simply
the haplotype.
1.1.3 The human genome
The human genome is organized into 23 pairs of chromosomes encompassing more than 3
billion base pairs and ranging in size from 48 Mb to 250 Mb, where one set of chromosomes
is inherited maternally while the other set is inherited paternally11. Chromosomes 1 - 22
form homologous pairs and are known as autosomes, while chromosome pair 23 is partially
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homologous and referred to as the sex chromosome.
There are two types of sex chromosomes, the X chromosome and the Y chromosome.
These chromosomes differ in size and the genes they contain. The X chromosome spans
more than 155 Mb while the Y chromosome only spans 59 Mb; representing a little under
5% and 2% of the total genome length, respectively12. Females have two homologous X
chromosomes while males have one X chromosome and one Y chromosome. Due to the
different numbers of each sex chromosome between males and females, their inheritance
pattern differs to that of the autosomes.
During sexual reproduction, the autosomes undergo meiosis as described in section
1.1.1, producing offspring that inherit one set of recombined autosomal chromosomes from
their mother and another set from their father (Figure 1.3). Similarly, the X chromosomes
of females undergo meiosis such that all offspring inherit a single maternally-recombined
X chromosome. The sex chromosomes of males however, undergo meiosis in a slightly
different manner. Here, recombination only occurs between the homologous regions of the
X and Y chromosomes, the pseudoautosomal regions, which encompass a small proportion
of the sex chromosomes (<2% of the X chromosome and <5% of the Y chromosome12).
As such, the sex chromosomes of males remain largely unaltered during meiosis. Therefore
daughters inherit their second X chromosome as an almost identical copy from their father,
while sons inherit their fathers Y chromosome as a close replica (Figure 1.3).
We focus on the autosomes and the X chromosome throughout this thesis. This in-
cludes the X chromosomes of both males and females, even though a male’s X chromosome
does not recombine, as recombination can occur in future generations. Furthermore, we
exclude pseudoautosomal regions from our work on the X chromosome.
1.2 Identity by descent
1.2.1 Background
Two alleles are identical by state (IBS) if they have the same nucleotide sequence. These
alleles can be further classified as identical by descent (IBD) if they have been inherited
from a common ancestor13. Thus, alleles that are IBD must also be IBS, however the
converse of this statement is not true.
Given that alleles must be inherited from a common ancestor in order to be IBD, it
follows that IBD regions are only observed in related individuals. Individuals who are
6
autosome inheritance sex chromosome inheritance
X Y X X
X X X Y
Figure 1.3: Two generation pedigrees displaying the inheritance pattern of autosomes and the
sex chromosomes in the human genome. Females are denoted by circles and males by squares, with
founders at the top of the pedigrees and offspring below them. The haplotypes are represented by
coloured blocks above the founders and below the offspring. This figure was adapted from Griffiths
et al.1 and drawn using Adobe Illustrator.
closely related tend to share a large proportion of their genome IBD with many segments
of considerable size. As the relationships become more distant, the amount of genome
shared IBD decreases, as do the lengths of the respective IBD segments. This is the result
of recombination breaking the segments into smaller fragments over multiple generations.
The expected proportion of genome shared IBD between two individuals and the re-
spective lengths of the IBD segments can be estimated if the number of meiosis, m,
separating the pair of individuals is known14,15. The average proportion of genome shared
IBD, i.e. the sum of all IBD segments divided by the genome length, is calculated as
2−(m−1). Here, the proportion of genome IBD is halved for each additional meiosis, as the
probability of an allele being inherited on a single homologous chromosome is 50%. In
contrast, the average length of each IBD segment decreases exponentially as the number of
meiosis increases, with a mean value 100−m cM. For example, third cousins are separated
by eight meioses and share on average 0.8% of their genome IBD (24 cM or ∼ 24 Mb)
with IBD segments spanning 12.5 cM (∼ 12.5 Mb) on average.
Chromosomal inheritance patterns are slightly more complicated for the X chromosome
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identical by descent
Figure 1.4: A four generation pedigree displaying a genomic region that is IBD between second
cousins. The IBD segment has been inherited from their great-great grandfather.
than for autosomes and as such, the genders of the individuals in the lineage separating a
pair of individuals, and the order in which these individuals appear, becomes an important
factor in determining where or not two individuals can be related through the X chromo-
some. This is simply because only daughters can inherit their fathers X chromosome.
Therefore, it is impossible for two individuals to share segments of IBD on the X chro-
mosome in lineages with two or more male transmissions in earlier generations (assuming
there is no consanguinity). At most, every second individual in an X chromosome lineage
can be male for IBD to be possible, while the number of female-female transmission is
unrestricted. This gives rise to the potential for segments of IBD on the X chromosome
to be larger than those inherited on autosomes, simply because the male X chromosome
does not undergo recombination (excluding pseudoautosomal regions), resulting in one less
meiosis event for every male transmission in an X chromosome lineage, excluding initial
founders.
As individuals become more distantly related, the chance of inheriting an IBD segment
diminishes substantially, for both the autosomes and the X chromosome14,15. However,
very small segments of IBD tend to persist are inherited from extremely distant com-
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mon ancestors. Such IBD is the result of non-random allele associations over multiple
loci16, which is commonly referred to as linkage disequilibrium (LD). LD that has resulted
from ancient ancestry is reflective of population substructure, whereby individuals within
populations are more closely related than those in different populations16,17. Although
interesting in its own right, identifying ancient relatedness due to population LD is not
focus of this thesis. Instead, we are concerned with identifying recent common ancestry.
Therefore we impose a timeframe on IBD such that only recent ancestry up to 25 gener-
ations (50 meioses) will be examined. In doing so, the smallest segment that we hope to
identify in individuals separated by up to 25 generations will span 2cM on average15.
Identifying genomic regions shared IBD from recent common ancestry is the basis of
relatedness mapping. Such regions have proven useful in many applications, including
disease mapping15,18,19, identifying unknown relatedness20 and detecting natural selec-
tion21,22, among other things. We expand on these applications below.
1.2.2 Disease mapping
IBD analyses have been extensively performed in disease mapping, which aims to localize
a critical region containing disease susceptibility genes18. This is done by first establishing
some form of relatedness between affected individuals, in which case the disease gene is
likely to have been inherited, and hence IBD. Thus critical regions are simply the IBD
regions that segregate with the affected individuals.
When many affected individuals are analyzed with the same disease susceptibility gene
an abundance of IBD is often observed, producing a genomic signal that readily identifies
the critical region. Albrechtsen et al.18 performed an IBD analysis on seven purportedly
unrelated individuals who have an identical causal variant for breast and/or ovarian cancer
in the BRCA1 gene. Distant relatedness was discovered between the seven individuals and
excessive IBD was observed in a region containing the BRCA1 gene. Similarly, Browning
and Browning15 performed an IBD analysis of two supposedly unrelated families with
multiple cases of gray platelet syndrome (GPS), an extremely rare inherited bleeding
disorder, whereby both families shared an identical variant causal for the disease in the
gene NBEAL2. They too discovered relatedness between the families and were able to
identify a critical region of 7.7 Mb containing the disease gene.
Prior to the discovery of the disease gene NBEAL2, a linkage analysis of six unrelated
families with GPS, excluding the two families analysed in Browning and Browning15, had
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identified a 9.3 Mb critical region containing NBEAL2 23. This analysis was performed
using 14 affected individuals while Browning and Browning were able to better refine the
critical region using IBD analysis of only four affected individuals. Furthermore, IBD
analyses of as little as two affected individuals have also successfully identified disease
critical regions. Shaw et al.19 were able to confirm that a novel variant in the gene L1CAM,
found in two purportedly unrelated individuals with X-linked intellectual disability, was
indeed causal for the disorder through identification of a 5.6 cM IBD segment containing
the gene.
Albrechtsen et al.18, Browning and Browning15 and Shaw et al.19 successfully local-
ized the disease critical region using IBD analysis, which was enhanced by the discovery
of distant relatedness. Analyses containing such distant relatives can better refine disease
critical regions as these individuals share less of their genome IBD with other individu-
als and the segments that are shared have shortened over multiple generations. Linkage
analysis also uses IBD segments to determine critical regions7, however it requires knowl-
edge of an accurate pedigree, which is not always possible for distant relatives. While
linkage analysis is a powerful tool for discovering disease critical regions in Mendelian dis-
orders24,25, analysis of large pedigrees or distant relatives bears computational challenges
and quickly becomes intractable26,27.
Pedigree-based IBD analyses, such as linkage analysis, are concerned with very recent
common ancestry while non-pedigree analyses, including IBD mapping, are useful for more
distant relatedness15,28. This can be extended to extremely distant ancestry, or ancient
ancestry, which is the primary focus of genome wide association studies (GWAS). GWAS
are concerned with finding extremely short segments of IBD that reflect population LD29.
Unlike IBD mapping or linkage analysis, which favors identification of genes with rare
variants at moderate to high penetrance25,30,31, GWAS are designed to identify genes with
common variants at low penetrance32. In order to identify such variants, GWAS require a
cohort of hundreds to thousands of individuals with the same trait and a matched control
cohort for comparison. While GWAS can be extremely powerful for identifying disease
genes29, such sizable datasets are not always available, particularly for rare diseases, which
make them impractical in many instances.
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1.2.3 Identifying recurrent variants
Unlike linkage analysis and GWAS, the individuals contributing to an IBD signature at
a specific locus can be extracted using IBD mapping. This is advantageous as it allows
for the distinction between a variant that is likely to be recurrent, i.e. a variant that has
arisen independently within a species on multiple haplotype backgrounds, and that which
has come from a common ancestor30,33.
1.2.4 Quantifying relatedness
The amount of genome shared IBD and the lengths of the respective segments vary de-
pending on the number of generations separating two individuals. As such, IBD can be
used to verify, or potentially refute, purported relationships as well as identify relatedness
between supposedly unrelated individuals. Pemberton et al.20 performed an IBD analysis
of the HapMap Phase III data and were able to confirm most of the previously reported
relationships. They identified four instances where relationships had been misclassified as
well as an additional 177 closely related individuals who were thought to be unrelated,
among which were parent-offspring pairs, full siblings and half siblings, avuncular and
even monozygotic twins.
Recently, IBD analyses have become available to the general public through com-
mercial genomics companies such as 23andMe (www.23andMe.com) and AncestryDNA
(www.ancestory.com), which allow consumers to explore their heritage via ancestry re-
ports.
1.2.5 Identifying Selection
Natural selection occurs when genetic traits that improve the survival of a species are
passed on to offspring such that the traits increase in prevalence in the population1. In
particular, traits that are beneficial to a species, and thus selected for, undergo positive
selection. For very recent positive selection, an allele that is selected for has typically
undergone few recombination events and is located on longer than expected haplotypes
that are easily identified by IBD analysis21,34. As such, IBD analysis has proven to be
a powerful tool for detecting very recent and very strong positive selection21,22 and we
detail several instances of recent positive selection here (Figure 2).
Positive selection can occur as a hard sweep, whereby an allele introduced into a pop-
ulation reaches a high frequency over a short period of time34. A hard sweep is generally
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characterized by an increase in frequency of shared segments of considerable size over the
favored allele, which produces a strong genetic signature that is readily identified by IBD
algorithms. When the allele reaches fixation in a population, variability from mutations
and recombination are introduced and the signal dissipates.
Albrechtsen et al.21 performed an IBD analysis of the HapMap phase III dataset and
discovered the human leukocyte antigen (HLA), involved in the immune systems response
to foreign invaders, to be positively selected in eleven of twelve populations studied. Han
and Abney22 performed an IBD analysis on individuals from Kenya and also identified
HLA to be under positive selection in addition to the human lactase gene (LCT ), which
is responsible for making the enzyme lactase that enables digestion of milk post infancy
and is most commonly selected for in individuals of European descent.
A more complicated type of recent positive selection is selection on standing varia-
tion, whereby an allele that is already present in the population at a modest frequency
suddenly becomes favored34. Since the favored allele was already present in the popula-
tion, neighboring variants have time to recombine and associate with different background
haplotypes. This results in shorter segments of IBD than a hard sweep, which are more
difficult to identify with IBD analysis, although the frequency of shared segments typically
remains high. Albrechtsen et al.21 performed simulation studies to compare the genomic
signatures of a hard selective sweep and selection on standing variation. They found the
signatures to be more pronounced for selection on standing variation soon after selection
of the favored allele, however these signatures dissipated more rapidly than with a hard
selective sweep.
The last type of recent positive selection that we consider leaves a more subtle, and
therefore harder to identify, signature in the genome36. This type of positive selection is a
soft selective sweep. Here recurrent variants on different haplotype backgrounds increase in
frequency in the population34. A greater number of haplotype backgrounds leads to fewer
pairs with IBD sharing and diluted signals of excess IBD21, compared to a hard sweep
or selection on standing variation. When the selected alleles are at low frequencies in the
population the signature of positive selection may be non-existent. Thus a considerable
number of generations may need to have passed before a signature is detected. The ability
to identify a soft selective sweep via IBD depends on the number of haplotype backgrounds
and the frequency of these haplotypes in the population.
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Selection on standing 
variation
Hard sweep Soft sweep
(recurrent variant)
Figure 1.5: Three ways in which an allele can be positively selected, adapted from Scheinfeldt
et al.35. Each line represents a haplotype and colored circles are unique SNPs on the haplotype.
Black and white circles denote the alleles under selection. A. A hard sweep occurs when an
allele is introduced into a population and increases in frequency rapidly such that the surrounding
haplotype also increases in frequency due to LD and few recombination events. B. Selection on
standing variation occurs when an allele that is already present in the population (grey circle) at
moderate frequency becomes selected for and rapidly increases in frequency, along with neighboring
SNPs. C. A soft selective sweep occurs when the same variant (back and white circles) arises
on multiple haplotype backgrounds, and each haplotype increases in frequency, where a single
haplotype need not dominate.
1.3 SNP technologies
SNPs have gained popularity in recent years as markers of genetic diversity and have
been extensively used to identify the genetic causes and predisposition of disease1. They
are also the foundation of IBD analysis. Large segments of IBD tend to contain many
SNPs with identical alleles and are easily identified27. As SNP technologies continually
allow for increasing SNP density, smaller IBD segments are also becoming more easily
identified. However this comes at the cost of incorrectly identifying IBD from extremely
ancient ancestry, that is the result of population LD, as IBD from more recent common
ancestry17,27. Furthermore, increased SNP density also results in increased computational
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demand, not only from the sheer increase in size of the datasets analyzed but also from
models now having to account for LD. Although somewhat challenging, these issues can
be overcome by clever computing algorithms and segment filtering.
The identification of IBD segments using SNPs has been made possible by advances
in technologies leading to the development of genotyping arrays and next generation se-
quencing (NGS). Genotyping arrays target hundreds of thousands to millions of common
SNPs in the genome, usually within genes. Simply, genotyping arrays work by hybridizing
fragments of sample DNA to fluorescently tagged DNA probes. Genotypes can then be
extracted for SNPs from fluorescence intensity profiles37. Such arrays allow for many dif-
ferent variants to be examined at once and are extremely cost effective. They do, however,
require prior knowledge of the SNPs of interest and may not be suitable for identifying
the causal variant of extremely rare diseases (assuming the causal variant is a SNP).
NGS has become extremely popular in recent years, as it enables the whole genome,
or targeted regions of the genome, to be sequenced at continually decreasing costs. NGS
works by fragmenting the sample DNA into smaller segments then aligning these segments
to a reference genome or performing de novo assembly38. SNPs are then called at loci
that differ to the reference genome. Genome sequencing allows for the exact sequence of
a DNA segment to be identified, which can be used to find known SNPs as well as SNPs
that are unique to the sample.
Both genotyping arrays and NGS suffer from occasional genotyping errors, with higher
rates observed in NGS data. This can affect the identification of IBD when the resultant
SNP switches between homozygous reference and homozygous alternative (or visa versa),
or homozygous to heterozygous (or visa versa), resulting in allele sequences that are in-
consistent with IBD and are less likely to be identified as such.39 performed analyses using
simulated SNP array data and showed that genotyping error rates varying between 0%
and 0.5% had little impact of IBD inference in disease mapping. This is reassuring for
IBD inference. Alternatively, rapid switching between IBD and non-IBD in small genomic
intervals can be used to detect genotyping errors40.
1.4 IBD methodologies
Existing tools for performing IBD mapping differ in many ways. Browning and Browning27
give a nice overview of the methodologies and we expand on this here.
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Algorithms can more broadly be classified as probabilistic or non-probabilistic mod-
els. Probabilistic algorithms include hidden Markov models17,18,27,41,42,43,44,45,46 (HMM;
described in detail in Chapter 2) while non-probabilistic algorithms commonly use thresh-
olds on IBS consistent haplotypes to infer IBD47,48,49. Probabilistic models are generally
preferred to non-probabilistic models as they have the ability to account for LD, which
has become crucial as the density of SNPs continues to increase with advances in geno-
typing technologies. Algorithms can also differ in the way they model IBD status. Binary
states27,43 (IBD vs non-IBD) and ternary states18,41 (the number of alleles shared IBD
from either 0, 1 or 2 alleles) are commonly used to model IBD status. Less commonly
used are are Jacquard’s 15 identity coefficients for phased data17,46 and Jacquard’s 9 con-
densed identity coefficients for unphased data17,44,46,50. In addition to this, some tools
are designed primarily for family based studies where accurate pedigree information is
required42,44 while other tools specialize in population-based cohort studies where relat-
edness between individuals is often unknown. We describe in detail some of the well
used tools available for inferring IBD that have adopted the more popular approaches and
provide a more extensive list in Tables 1.1, 1.2 and 1.3.
1.4.1 Thresholding approaches
Some of the earlier IBD methodologies were simple non-probabilistic methods that in-
ferred IBD based on IBS information33,57,58,59. These methods used genotype data to
find stretches of the genome that were IBS between pairs of individuals and called the
region IBD if its length was larger than a length threshold determined by the number
of generations separating the individuals. Since the expected length of an IBD segment
decreases as a pair of individuals become more distantly related, accurate pedigree infor-
mation is typically required to determine the length threshold used in these algorithms.
Unfortunately however, pedigree information is not always available.
This problem was eliminated by GERMLINE47, which also uses a length threshold
constraint on IBS consistent haplotypes to determine IBD regions. GERMLINE imple-
ments a sliding window approach where a window of predefined length moves along the
genome partitioning it into non-overlapping bins. A dictionary of allele combinations for
all samples is created for each bin, from which IBS is determined, allowing for occasional
genotyping errors. GERMLINE does not require specification of a pedigree so can be used








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SNPs) to be specified which can influence the ability to infer IBD segments. Too large a
window size can result in real IBD segments being missed while too small a value results
in false positive calls. While selecting the window size can cause problems, the main ad-
vantage of GERMLINE is its computational power. GERMLINE can perform analyses
on thousands of individuals using dense genotype or phased haplotype data in a matter
of seconds, making it a very popular method for population-based cohort studies.
Browning and Browning adopted GERMLINE’s computationally efficient haplotype-
dictionary approach in two of their IBD algorithms. Initially, Browning and Browning49
developed fastIBD, which determines IBD from haplotype frequency rather than segment
length. fastIBD uses unphased genotype data to create a localized haplotype cluster
model60 from which multiple phased haplotypes are sampled for each individual. These
haplotypes are themselves used to create a localized haplotype cluster model that defines a
HMM; the BEAGLE HMM61. A sliding window is used to search for identical haplotypes
traversing the same path in the BEAGLE HMM that are then identified as IBD if their
haplotype frequency is less than a predefined threshold. Unlike GERMLINE, fastIBD
models LD through the BEAGLE HMM. However a sufficient number of individuals are
required to build the HMM which is not always available. Additionally, fastIBD does
not allow for genotyping errors, which may be problematic as the density of markers in
SNP arrays increases resulting in more genotyping errors. Furthermore, the accuracy of
fastIBD depends on the ability of the phasing algorithm that is implemented within the
tool, where poorly phased data containing genotyping errors could result in misleading
IBD calls.
Following this, Browning and Browning52 developed Refined IBD which initially uses
GERMLINE to find candidate IBD segments then applies a probabilistic approach to
assess the evidence of IBD and refine the candidate list. In the refinement step, phased
haplotypes are used to build the BEAGLE HMM and the likelihood of one haplotype
shared IBD and no haplotypes shared IBD are calculated for each candidate segment.
LOD scores are then calculated using the likelihood ratios and tracts with LOD scores less
than a user defined threshold are removed. The additional step allows for higher accuracy
than GERMLINE, however as with fastIBD the accuracy of this method depends on the
ability of its built-in phasing algorithm, and genotyping errors are not accounted for.
More recently, Rodriguez et al.55 developed Parente2, which slides a block of user-
defined length (in cM) beginning at each marker across each chromosome. The blocks
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are subset into smaller windows of possibly non-consecutive SNPs, from which scores
are calculated based on the log likelihood ratio (LRR) of an IBD vs non-IBD model.
Window scores are summed for each block and a block is called IBD if its score is greater
than a predefined threshold. Rodriguez et al.55 have demonstrated that Parente2 is more
computationally efficient than GERMLINE and fastIBD in addition to it accounting for
LD. Parente2 accounts for LD by explicitly modeling haplotype frequencies in the LLR
from a phased training dataset that appropriately match the input dataset. Unfortunately,
such datasets are not always available.
1.4.2 Hidden Markov model
One of the first probabilistic IBD methodologies was PLINK41. PLINK implements a
continuous time HMM on two diploid chromosomes to infer whether 0, 1 or 2 alleles are
shared IBD between pairs of individuals using genotype data. PLINK can be applied to
cohorts of unrelated individuals and does not require any user specified parameters. Un-
fortunately however, PLINK requires the genotype data to be in approximate LE which
often involves thinning SNPs prior to use. Thinning SNPs can result in a substantially
smaller dataset to analyze, and in some instance less than 5% of the original data may
remain. Reducing datasets like this can result in the loss of potentially informative SNPs,
however in doing so PLINK becomes computationally efficient and comparable to some of
the fastest algorithms designed for cohorts with thousands of individuals. PLINK’s algo-
rithm requires population allele frequencies which are calculated from the input dataset.
Frequency bias can arise from this if the input dataset is too small or the individuals are
of mixed ethnicities.
Albrechtsen et al.18 extend the HMM proposed by PLINK to allow for LD, genotyping
errors and missing data. This method was implemented in RELATE, which accounts for
LD through the emission probabilities where the current genotype probability is condi-
tioned on the genotype of a single previous marker. Since RELATE allows for LD there is
no need to prune the dataset like PLINK, however all LD cannot be accounted for in very
dense datasets using this algorithm which can result in false positive IBD calls. Allele fre-
quencies and haplotype frequencies can be calculated from a reference dataset if available,
otherwise these values are calculated from the input dataset which may not reflect true
population frequencies for small datasets.
Prior to fastIBD and Refined IBD, Browning62 implemented a HMM to model binary
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IBD status between pairs of haplotypes, which was then extended in BEAGLE IBD to
identify IBD between pairs of diploid individual27. BEAGLE IBD first builds a localized
haplotype cluster model to phase genotype data and model LD using the BEAGLE HMM;
it then adds an IBD model to calculate the posterior probability of IBD for each marker.
Regions with probabilities above a threshold are considered IBD. BEAGLE IBD is com-
putationally intensive and, as BEAGLE continually releases improved IBD methodologies,
has been superseded by BEAGLE fastIBD and BEAGLE Refined IBD.
Han and Abney44 further extended the models of Purcell et la.41 and Albrechtsen
et al.18 to better account for LD in IBDLD. IBDLD implements a nine-state HMM for
Jacquard’s condensed identity coefficients50 and accounts for LD by conditioning on mul-
tiple marker genotypes using a linear model with ridge regression. Although IBDLD
implements a more polished model for LD than Albrechtsen et al.18, IBDLD requires
relationships between the individuals must be known.
1.4.3 Tools for NGS data
With the advent of NGS, algorithms for IBD detection are now exploring how to bet-
ter account for increasing SNP density and higher genotyping error rates, as well as the
genomic patchiness that can be produced with targeted sequencing. Browning and Brown-
ing53 implemented a likelihood ratio approach in IBDseq for unphased sequencing data.
Unfortunately, IBDseq requires LD thinning as LD is not directly accounted for in the
model. Despite this, IBDseq achieves high power and accuracy in sequencing data and is
computationally efficient for analyses with many SNPs.
Fu et al.56 have recently developed ExIBD, an algorithm for exome sequencing data
which infers IBD segments using fastIBD then implements BEAGLE IBD to refine can-
didate segments. These algorithms were developed for array data, however when used
together in ExIBD, perform relatively well on exome-sequencing data, excluding regions
with low exon density.
While these tools were designed specifically for use with sequencing data, we note that
all algorithms can be applied to sequencing data once SNPs have been extracted, although
filtering procedures may be required to reduce false positive IBD detection that is the result
of population LD. Additionally, some algorithms may be computationally inefficient with
many SNPs and are better suited for array data. Furthermore, non-uniformly spaced
SNPs may result in undetected IBD segments.
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1.4.4 IBD methodologies incorporating haploid chromosomes
Few software can perform IBD analyses on haploid chromosomes. Of all the methodologies
in Tables 1.1, 1.2 and 1.3, only GERMLINE can be implemented on haploid chromosomes
as it does not involve any probability distributions. All other methodologies have been
designed for diploid chromosomes, and while haploid chromosomes can be duplicated to
give the appearance of a diploid chromosome, the probability distributions governing the
algorithms do not correctly account for this. For example, fastIBD uses the localized
haplotype cluster model in the BEAGLE HMM to generate phased data and calculate
haplotype frequencies from diploid chromosomes. While a haploid chromosome is triv-
ially phased and will not be altered by the BEAGLE phasing algorithm, the haplotype
frequencies in the model will be incorrect if such chromosomes are duplicated to form a
pair of homozygous chromosomes. In a dataset containing 20 haploid chromosomes and
20 diploid chromosomes, the haploid chromosomes will contribute 50% (40/80) to the
haplotype frequency calculations if duplicated, whereas they should only contribute 33%
(20/60).
Similarly, tools such as PLINK and RELATE, which implement three-state HMMs to
determine whether 0, 1 or 2 alleles are shared IBD at each SNP, have incorrect probability
distributions if haploid chromosomes are duplicated to form a pair of homozygous chromo-
somes. Here the emission probabilities are functions of the population allele frequencies,
the observed genotype for a pair of diploid chromosomes and the state space. If a pair
of diploid chromosomes each have the genotype AA at the same SNP, where A is the
reference allele, then the probability of observing the pair of genotypes {AA,AA} given
there is no IBD sharing is p4A, where pA is the population reference allele frequency. If one
of these chromosomes is haploid, then the probability of observing the pair of genotypes
{AA,A} given there is no IBD sharing is p3A, however PLINK and RELATE are unaware
that one chromosome is haploid and still calculate the probability as p4A.
While one methodology does exist to correctly perform IBD analyses between haploid
chromosomes, the algorithm is nonprobabilistic and as such it does not account for LD,
which has become an important criterion in an IBD model with increasing SNP density
from NGS data. As such, a probabilistic model is required that can correctly analyse
haploid chromosomes as well as account for LD.
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1.5 Aims of study
This thesis describes a novel algorithm for inferring pairwise IBD using SNP genotype
data that correctly accounts for haploid and diploid chromosomes. Chapter 1 serves as
a general introduction into common sources of genetic variation, including recombination
during meiosis and SNPs, and describes how recombination influences genetic relatedness.
This chapter describes applications that take advantage of relatedness through IBD, and
reviews the current methodologies for IBD detection.
Most algorithms for inferring IBD are for analysis of diploid genomes. This typically
results in exclusion of the X chromosome from analysis as it is diploid in females and
haploid in males. Therefore, in Chapter 2 we detail an algorithm for inferring IBD on
both diploid and haploid chromosomes. It is necessary to extensively examine the per-
formance of new algorithms. As such, we perform statistical and bioinformatics analyses
on simulated data to demonstrate the power and accuracy of this model. This work is
presented in Chapter 3 and aims to fill a void in what is lacking from IBD methodologies.
Chapter 4 presents an application of the IBD methodology described in Chapter 2 to
a small cohort of individuals affected with familial adult myoclonus epilepsy (FAME); a
rare form of epilepsy with causal variants yet to be determined. This analysis investigates
two critical regions that were identified using linkage analysis, and provides novel insights
for future investigations of this disorder.
Following applications and analysis of the human genome, we modify our algorithm
such that it can be applied to non-human organisms with haploid genomes. We are
specifically interested in microorganisms that cause infectious disease, such as the malaria
causing parasite, Plasmodium, with the aim of identifying loci under positive selection us-
ing IBD. The shift in focus to haploid microorganisms comes amid the global antimicrobial
resistance crisis, whereby a number of microorganisms have become resistant to first-line
and/or last-resort antimicrobial treatments, threatening to increase disease incidence and
mortality rates (WHO, 2015). Therefore, identifying the genomic mechanisms underlying
antimicrobial resistance is essential to reduce the burden of this crisis.
The remainder of this thesis delves into the disease, malaria, and the parasite respon-
sible for this disease, Plasmodium. Chapter 5 presents an introduction into the biology of
the parasite and a brief history on antimalarial drug resistance. We discuss the popular
tools that are used to identify loci under selection associated with resistance and what is
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required from an IBD methodology in order to identify such loci in Plasmodium.
Chapter 6 describes the modifications of the algorithm in Chapter 2 that are required
for IBD analysis of Plasmodium, then performs an in-depth analysis of a global malaria
dataset. This analysis uncovers novel insights into the disease, including antimalarial drug
resistance, and demonstrates the importance of IBD analysis of disease-causing microor-
ganisms.
Finally, Chapter 7 serves as a general discussion of the IBD methodology presented in
this thesis and the importance of its development for both human and non-human studies.
We discuss implications of our results, specifically with regards to the Plasmodium, and




XIBD: pairwise identity by
descent methodology
This chapter details the XIBD methodology that was developed to detect IBD segments in
both diploid and haploid chromosomes. The algorithms implemented are an extension of
Purcell et al.41 and Albrechtsen et al.18, both of which developed hidden Markov models.
As such, this chapter also provides an extensive overview of a hidden Markov model.
This work has been published63 and the XIBD tool is available as an open source R
package (https://github.com/bahlolab/XIBD). The relevant manuscript has been included
as Appendix A and we extend our description below.
2.1 An introduction to hidden Markov models
A Hidden Markov model (HMM) is a probabilistic model that describes a sequence of
events which gave rise to a set of observations. These models have been used in speech
recognition systems64, predicting the financial market65 and copy number variation anal-
ysis66, among other things. In order to understand the mechanisms behind a HMM it is
helpful to first understand a Markov model. We briefly discuss a Markov model below
and its extension to a HMM, where the definitions and notations are summarized from
Rabiner64.
2.1.1 Markov model
A Markov model is a stochastic model that describes a randomly changing system67. At
any time t, the system is assumed to be in a particular state, where the collection of all
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possible N states determines the state space S = {S1, S2, . . . , SN}. To predict the most
likely state at time t, information on the previous states of the system must be known
such that
Pr(qt = Sj |qt−1 = Si, qt−2 = Sk, . . . , q1 = Sl),
where 1 ≤ j, i, h, l ≤ N . As t increases, the number of probabilities that need to be
calculated increases rapidly so a simplifying assumption is made. We assume the system
satisfies the Markov property that, given the present state, the future and past states are
independent. i.e.,
Pr(qt = Sj |qt−1 = Si, qt−2 = Sk, . . . , q1 = Sl) ≈ Pr(qt = Sj |qt−1 = Si) (2.1)
This is a first-order Markov assumption since the state of the system at time t only depends
on the state at time t− 1. An nth-order Markov assumption occurs when the state of the
system at time t depends on the state at time t− 1, t− 2, . . . , t− n. The right hand side
of equation 2.1 is independent of time, meaning
Pr(qt+1 = S1|qt = S2) = Pr(qt = S1|qt−1 = S2).
This allows us to calculate the state transition probabilities, aij , which are simply the
probabilities of transitioning between states in a single time step;






The collection of state transition probabilities forms the models transition matrix, A =
{aij}. In addition to a transition matrix, the system requires initial state probabilities, i.e.,
the probabilities associated with beginning the system in a particular state. We denote
the set of initial probabilities as Π = {πi} where
πi = Pr(q1 = Si), 1 ≤ i ≤ N. (2.3)
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Using both the initial state probabilities and the state transition probabilities we can
calculate the joint probability of a sequence of states Q = q1q2 · · · qT from this system as
Pr(Q|A,Π) = Pr(q1) Pr(q2|q1) Pr(q3|q2) · · ·Pr(qT |qT−1)
= πq1aq1q2aq2q3 · · · aqT−1qT .
A system with states that obey the Markov assumption is called a Markov model, and the
random sequence of states that result from the system is called a Markov chain.
2.1.2 Hidden Markov model
In contrast to a Markov model where the states are observed, a Hidden Markov model
(HMM) has unobservable states and instead has observations that are probabilistic func-
tions of the states. Following the notation above, let S = {S1, S2, . . . , SN} donate the N
states, and Q = q1q2 · · · qT denote the hidden sequence of states of length T that we wish to
determine. Additionally, let M define the number of distinct observations produced from
all states and let V = {v1, v2, . . . , vM} represent the observation symbols in the model. In
addition to the initial state probabilities Π and transition probability matrix A defined in
equations 2.2 and 2.3, a HMM requires one more probabilistic measure to be complete,
namely the emission probabilities. Emission probabilities are the probabilities associated
with the observations from the states, B = {bj(k)}, where
bj(k) = Pr(vk at t|qt = Sj), 1 ≤ j ≤ N, 1 ≤ k ≤M. (2.4)
As with Rabiner we let
λ = (A,B,Π)
denote the set of model parameters. In summary, a HMM is characterized by the following
components:
1. The state space S = {S1, . . . , SN} comprised of N states.
2. M distinct possible observations that make up the observation set V = {v1, . . . , vM}.
3. An observation sequence O = o1 · · · oT over T positions where ot ∈ V .
4. The initial probability distribution Π = {πi} where
πi = Pr(q1 = Si), 1 ≤ i ≤ N.
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5. A state transition probability matrix A = {aij} where
aij = Pr(qt+1 = Sj |qt = Si) 1 ≤ i, j ≤ N.
6. The emission probability distribution B = {bi(k)} where
bj(k) = Pr(vk at t|qt = Sj), 1 ≤ j ≤ N, 1 ≤ k ≤M.
2.1.3 Three basic problems of a HMM
According to Rabiner64 there are three problems that need to be solved in order for an
HMM to be useful in real-world applications;
1. How do we efficiently compute the probability of an observation sequence
O = o1o2 · · · oT , where oi ∈ V , given the model λ = (A,B,Π)? i.e.,
calculate Pr(O|λ).
2. Given an observation sequenceO = o1o2 · · · oT and the model λ = (A,B,Π),
how do we find a sequence of states Q = q1q2 · · · qT , where qi ∈ S, that
best explains the observations?
3. How do we adjust the model parameters λ = (A,B,Π) to maximize the
probability of the observation sequence O? i.e., maximize Pr(O|λ).
Problem 1 The first problem of an HMM is how to efficiently calculate the probability
of an observation sequence O = o1o2 · · · oT , where oi ∈ V , given the model λ = (A,B,Π).
That is, we wish to calculate Pr(O|λ). One way of calculating this probability is by
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πq1bq1(o1)aq1q2bq2(o2)aq2q3 · · · bqT (oT )aqT−1qT . (2.5)
Computing Pr(O|λ) from equation 2.5 requires in the order of 2TNT calculations and
quickly becomes computationally demanding as T and N increase. Fortunately a compu-
tationally efficient method for calculating Pr(O|λ) exists, known as the forward-backward
algorithm. The forward-backward algorithm avoids summing the probability of the ob-
servation sequence over an exponential number of paths Q, by calculating probabilities of
reaching various states as time progresses as well as probabilities of finishing the sequence
starting from a given state. These probabilities are called the forward probabilities and
backward probabilities respectively and are derived below.
Let αt(j) denote the forward probability given by
αt(j) = Pr(o1o2 · · · ot, qt = Sj |λ).
We can compute αt(j) for all t and j using induction as follows:
1. Initialization:





αt(i)aijbj(ot+1), 1 ≤ t ≤ T − 1, 1 ≤ j ≤ N.
Since aij and bj(ot+1) are generally less than 1, we see that as t increases the forward
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probabilities tend to zero. This is a problem as the computational precision required
to calculate these probabilities will quickly exceed that available from most standard
computers resulting in underflow. To avoid such problems, the forward probabilities are





















However the product of the scaling coefficients is likely to result in underflow also so the





Calculating the log probability of the observation sequence requires in the order of N2T
computations as apposed to 2TNT from equation 2.5, which scales linearly rather than
exponentially with N and T . The forward probabilities enable us to calculate Pr(O|λ)
without having to calculate the backwards probabilities, however, the backwards proba-
bilities are required to solve problem 2 so are defined below.
Let βt(i) denote the backwards probabilities given by
βt(j) = Pr(ot+1 · · · oT |qt = Sj).
Similarly to the forwards probabilities, we can compute βt(j) for all t and j using
induction:
1. Initialization:






aijbj(ot+1)βt+1(j), t = T − 1, T − 2, . . . , 1, 1 ≤ i ≤ N.
To avoid underflow, these probabilities are scaled using the same scaling coefficient as the
forward probabilities. The scaled backwards probabilities are given by






Problem 2 The second problem of a HMM is, given an observation sequence O =
o1o2 · · · oT and the model λ = (A,B,Π), how do we find the most likely sequence of states
Q = q1q2 · · · qT , where qi ∈ S, that could have generated O? As with problem 1, there is
more than one solution to this problem and we describe two methods that are commonly
used as a solution, namely the posterior state probability and the Viterbi algorithm.
The posterior state probability calculates the probability of being in a particular state
at a specific time given the observation sequence and the model. These probabilities can
then be used to find the state that most likely generated the observation for each time.
Let γt(i) be the probability of being in state Si at time t given the observation sequence
O and model λ, i.e.,
γt(i) = Pr(qt = Si|O, λ), 1 ≤ i ≤ N.







, 1 ≤ i ≤ N, 1 ≤ t ≤ T,
and we can determine the most probable state sequence by selecting the state at each time
that maximizes γt(i),
qt = argmax1≤i≤N [γt(i)], 1 ≤ t ≤ T. (2.6)
A potential problem of using the posterior state probability to find the optimal state
sequence is that the resultant sequence may be invalid if some of the state transitions
are not permitted and therefore have a transition probability of zero. In order to avoid
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such invalid sequences the Viterbi algorithm can be used to determine the optimal state
sequence.
The Viterbi algorithm finds the single most likely state sequence that could have gen-
erated the observation sequence. It differs from the posterior state probability method
because it chooses the state sequence that is globally optimum rather than individually
selecting states at each position that are locally optimum. To compute the Viterbi algo-
rithm, let δt(i) denote the highest log probability of the sequence of states that ends in
state Si at time t, then
δt(i) = max
q1,q2,··· ,qt−1
log[Pr(q1q2 · · · qt = Si, o1o2 · · · ot|λ)]. (2.7)
Logarithms are used throughout the Viterbi calculations to avoid underflow. In order to
retrieve the most likely state sequence, we need to keep track of the states giving rise
to δi(i). Let ψt(i) be the state at t − 1 that produced the most probable state sequence
ending in state Si at time t. The Viterbi algorithm finds the most likely state sequence
using the following procedure:
1. Initialization:
δt(i) = log(πi) + log[bi(o1)], 1 ≤ i ≤ N
ψt(i) = 0.
2. Recursion:
δt(j) = max1≤i≤N [δt−1(i) + log(aij)] + log[bt(j)], 2 ≤ t ≤ T 1 ≤ j ≤ N
ψt(j) = argmax1≤i≤N [δt−1(i) + log(aij)], 2 ≤ t ≤ T 1 ≤ j ≤ N.
3. Termination:
logP ∗ = max1≤i≤N [δT (i)]
q∗T = argmax1≤i≤N [δT (i)].
4. State sequence backtracking:
q∗ = ψt+1(q
∗
t+1) t = T − 1, T − 2, . . . , 1.
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Problem 3 The third problem of a HMM is concerned with estimating model parameters
such that the probability of the observation sequence is maximized. This is generally solved
using the Baum-Welch algorithm however we do not go into detail of the algorithm here
as we do not make use of it. Instead we explain how we estimate parameters as they are
introduced in our model.
2.2 XIBD
We implement a first order continuous time HMM to infer IBD between pairs of individuals
using genotype data for SNPs, where we consider time here to be the genetic map distance
(M) along a chromosome. Although the memoryless assumption of a Markov process is
unlikely to hold for dense datasets in the presence of LD, McPeek and Sun68 have shown
it to be a good approximation and like Albrechtsen et al.18 and Epstein et al.69, we make
this assumption also. Graphical representations of the model for different pairwise-ploidy
combinations are shown in Figure 2.1 and we describe the model in more detail below.
2.2.1 State space
The state space in the model is the number of alleles shared IBD between a pair of
individuals. A pair of diploid chromosomes (a pair of autosomes or the X chromosomes
of two females), can either share 0, 1 or 2 alleles IBD. When the analysis includes at least
one haploid chromosome (i.e., a male X chromosome) then at most 0 or 1 allele can be
shared IBD. Therefore, the state space for a pair diploid chromosomes is S = {0, 1, 2}
while the state space when at least one chromosome is haploid is S = {0, 1}.
2.2.2 Initial probabilities
The probabilities associated with sharing 0, 1 or 2 alleles IBD are denoted ω0, ω1 and ω2
respectively, and are used as the initial probabilities in our model. For known relationships,
these probabilities can be calculated using identity coefficients. We use IdCoefs70 for
autosomes and have implemented the equivalent for the X chromosome (Appendix B). For
example, a pair of siblings share 0, 1 and 2 alleles IBD on autosomes with probabilities
ω0 = 0.25, ω1 = 0.5 and ω2 = 0.25. However if the relationships are unknown then these
probabilities need to be estimated before we implement the HMM. We estimate the initial
probabilities using the method of moments approach of Purcell et al.41, described below.
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Figure 2.1: XIBD HMM for different pairwise-ploidy combinations. The states are the number
of alleles shared IBD while the observations are genotypes for a pair of individuals. Dashed lines
connect states to observations where the emission probability is zero. All other lines have non-
zero probability distributions associated with them, calculated as in Tables 2.1-2.7. A The model
used for pairs of haploid chromosomes. B The model used for pairs of chromosomes where one
chromosome is haploid and the other chromosome is diploid. C The model used for pairs of diploid
chromosomes.
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Let V,Z ∈ S denote IBS states and IBD states respectively. We wish to determine the
probabilities of sharing 0, 1 and 2 alleles IBD, i.e.,
ω0 = Pr(Z = 0),
ω1 = Pr(Z = 1),
ω2 = Pr(Z = 2).
The prior probability of IBS sharing can be expressed as a function of IBD sharing
Pr(V = v) =
z=v∑
z=0
Pr(V = v|Z = z) Pr(Z = z). (2.8)
where Pr(V = v|Z = z) can be expressed for each SNP in terms of population allele
frequencies as in Table 2.1 while Pr(V = v) is either 1 or 0 depending if v matches the IBS
state of the SNP. The allele frequencies can either be calculated from the input dataset
if the individuals are of homogeneous population and the dataset is of sufficient size,
otherwise a reference dataset such as HapMap (http://hapmap.ncbi.nlm.nih.gov/) can be
used. These values can be averaged over all SNPs to obtain the observed and expected
IBS values, after which equation 2.8 can be expanded and rearranged into




Pr(V = 0|Z = 0)
,
Pr(Z = 1) =
T∑
t=1
Pr(V = 1)− Pr(V = 0) Pr(V = 1|Z = 0)
Pr(V = 1|Z = 1)
,
Pr(Z = 2) =
T∑
t=1
Pr(V = 2)− Pr(V = 1) Pr(V = 2|Z = 1)− Pr(V = 0) Pr(V = 2|Z = 0)
Pr(V = 2|Z = 2)
.
Purcell et al.41 constrain the estimates such that Pr(Z = z) are between 0 and 1,
inclusive, and
∑2
z=0 Pr(Z = z) = 1. Furthermore;
1. If Pr(Z = 0) > 1 then Pr(Z = 0) = 1, Pr(Z = 1) = 0 and Pr(Z = 2) = 0
2. If Pr(Z = 0) < 1 then Pr(Z = 0) = 0, Pr(Z = 1) = Pr(Z = 1)/U and Pr(Z = 2) =
Pr(Z = 2)/U where U = Pr(Z = 1) + Pr(Z = 2).
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Table 2.1: Calculating Pr(V = v|Z = z) for a pair of individuals l and k; used when estimating
the initial probabilities as described by Purcell et al.41. A diploid chromosome has ploidy = 2 while
a haploid chromosome has ploidy = 1. The population allele frequency of the reference allele, A,
is pA and the allele frequency of the alternative allele, a, is pa = 1− pA, where pA + pa = 1.
ploidyl ploidyk V Z Pr(V = v|Z = z)
1 1 0 0 2pApa
1 1 1 0 p2A + p
2
a
1 1 0 1 0
1 1 1 1 1
2 1 0 0 p2Aqa + pAq
2
a







2 1 0 1 0
2 1 1 1 1
2 2 0 0 2p2Ap
2
a
2 2 1 0 4p3Apa + 4pAp
3
a







2 2 0 1 0
2 2 1 1 2p2Apa + 2pAp
2
a







2 2 0 2 0
2 2 1 2 0
2 2 2 2 1
3. If at least one chromosome is haploid then Pr(Z = 2) = 0 and Pr(Z = 1) =
1− Pr(Z = 0).
2.2.3 Transition probability matrices
There are two state spaces in the model and as such we require two transition proba-
bility matrices. A transition probability matrix A(t) can be computed by solving the
Kolmogorov’s forward equation
A′(t) = A(t)Q
subject to A(0) = I
where Q is the transition rate matrix and t is the distance between adjacent markers in
M . The solution of which is
A(t) = exp(Qt).
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Assuming the individuals are distantly related and there is no inbreeding, the transition




αω0 −α(ω0 + ω2) αω2
0 αω1 −αω1
 ,





where qij (i 6= j) is the rate of departing from state i and arriving at state j and π =
(ω0, ω1, ω2) and π = (ω0, ω1) are the stationary distributions, respectively. For example,
the rate of departing from IBD = 0 to IBD = 1 for a pair of male X chromosomes is αω1.
The parameter α controls the frequency of transitions between states and is a function of
the number of meiosis m separating the pair of individuals and the recombination rate θ;
α = −m ln(1− θ).





while the number of meiosis is estimated according to Purcell et al.41 and Albrechtsen et
al.18 as follows;
m = m1 +m+ 2, mi = 1− log(xi)/ log(2)
where
x1 =
ω1 + 2ω2 +
√







Here, m1 and m2 are the number of meioses from both lineages from a common ancestor
for a pair of individuals.
To avoid computing the Taylor series for Q, which is often difficult, we can transform
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Q into Jordan canonical form
Q = CJC−1
and solve for the simpler expression
A(t) = exp(Qt) = C exp(Jt)C−1. (2.9)








and after some algebraic manipulation and substitution we get the following transition
probability matrix
A(t) =
ω0 + ω1 exp(−αt) ω1(1− exp(−αt))
ω0(1− exp(−αt)) ω1 + ω0 exp(−αt)
 .
The transition matrix for a pair of diploid chromosomes, as from Albrechtsen et al.18, is
given by

1− (1− exp(−αt))ω1 − T0,2 (1− exp(−αt))ω1 T0,2
(1− exp(−αt))ω0 (1− exp(−αt))ω1 + exp(−αt) (1− exp(−αt))ω2


















Ti,j is the probability of transitioning from state i to j.
2.2.4 Emission probabilities
Our methodology detects IBD between pairs of individuals using genotype data for biallelic
SNPs. Therefore the observations in the model are pairs of genotypes, where the pairwise
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combination of genotypes depends on the ploidy of the chromosomes under consideration.
A haploid chromosome can either have the reference allele or the alternative allele at
a SNP, producing the genotypic set G = {A, a}. In contrast, a diploid chromosome
can either be homozygous reference, heterozygous or homozygous alternative at a SNP,
giving the genotypic set G = {AA,Aa, aa}. This results in three pairwise combinations of
observation sets, Φ2;
{{A, a} × {A, a}},
{{A, a} × {AA,Aa, aa}},
{{AA,Aa, aa} × {AA,Aa, aa}}.
It follows that there are three sets of emission probabilities (Table 2.2), one for each obser-
vation set, which are functions of the chromosome ploidies (dependent on the individual’s
genders), the state space, the observed genotype pair, and the population allele frequen-
cies. Emission probabilities can be extended to account for genotyping errors, missing
data and LD as follows.
Table 2.2: Emission probabilities for a pair of individuals. A diploid chromosome has ploidy = 2
while a haploid chromosome has ploidy = 1. By symmetry Pr(Gl,ki |Zi = z) = Pr(G
k,l





i Zi = 0 Zi = 1 Zi = 2
1 1 A A p2A pA 0
1 1 A a 2pApa 0 0
2 1 AA A p3A p
2
A 0
2 1 AA a p2Apa 0 0
2 1 Aa A 2p2Apa pApa 0





2 2 AA aa 2p2Ap
2
a 0 0
2 2 AA Aa 4p3Apa 2p
2
Apa 0








Most genetic datasets will contain a small number of genotyping errors, which can result
in incorrect IBD inference and/or reduced performance39. As such, we account for geno-
typing errors in our model. Let ε denote the error rate, Ggi denote the observed genotype
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of individual g at SNP i and let Gg
′
i denote the true genotype individual g at SNP i.
The probabilities of the observed genotypes given the true genotypes are in Tables 2.3
and 2.4 for haploid and diploid chromosomes respectively. Like Albrechtsen et al.18, these
probabilities are included in the calculation of emission probabilities as follows, where ε is
assumed known prior to analysis.











g′ , ε)) (2.10)
Table 2.3: Genotyping error probabilities of the observed genotype Gli given the true genotype
Gl
′
i and an error rate of ε for a haploid chromosome.
P (Gli|Gl
′
i , ε) G
l





i = A 1-ε ε
Gl
′
i = a ε 1-ε
Table 2.4: Genotyping error probabilities of the observed genotype Gli given the true genotype
Gl
′
i and an error rate of ε for a diploid chromosome.
P (Gli|Gl
′
i , ε) G
l
i = A G
l





i = A (1− ε)2 2(1− ε)ε ε2
Gl
′
i = Aa (1− ε)ε (1− ε)2 + ε2 (1− ε)ε
Gl
′
i = AA ε
2 1-ε (1− ε)2
Missing data
SNPs with missing genotypes are sometimes removed from analyses, resulting in reduced
datasets and a loss of information. To avoid this we allow for missing data by calculating
the summation of the emission probabilities over the genotypic observation sets for SNPs
with missing genotypes.
Linkage disequilibrium
The assumption of a memoryless Markov chain is unlikely to hold in the presence of LD.
To overcome this, Purcell et al.41 recommends pruning SNPs such that the remaining
SNPs are in approximate LE. However, reducing datasets in such a way can result in the
loss of potentially informative SNPs and in some instances less than 5% of the original
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data may remain. Alternatively, one could account for LD in the model. Albrechtsen et
al.18 account for LD through conditional emission probabilities, where the genotype of
SNP i is conditioned on by the genotype of a single SNP h amongst the previous s SNPs
that is in the highest LD with SNP i.
Accounting for LD by conditioning on even a single SNP can add considerable time
to the already computationally inefficient model. Additionally, single SNP conditioning
may not account for all LD in a dataset, especially dense SNP datasets, which can result
in detection of unwanted background sharing. As such, we implement two models to
accommodate for LD.
1. Like Purcell et al.41, model 1 assumes the SNPs are in LE, which typically requires
thinning of datasets prior to use. However, datasets with dense SNPs in LD can be
used at the expense of false IBD segments being reported17
2. Like Albrechtsen et al.18, LD is implicitly accounted for in model 2 using conditional
emission probabilities (Equation 2.11). This required calculation of joint genotype
probabilities, which are provided in Tables 2.5, 2.6 and 2.7. Haplotype frequencies
are calculated from genotype data as described in Clayton and Leung72. While it
may be desirable to calculate haplotype frequencies from phased data rather than
unphased data, we acknowledge that phased data is not always available and phasing
can be time consuming to perform. Furthermore, large datasets are typically required
for phase inference.
Unlike Purcell et al.41 and Albrechtsen et al.18, reference datasets are provided with
XIBD. These datasets are the combined HapMap Phase II and III genotypes and allele
frequencies from build 1973; allowing the user to choose between the 11 HapMap popu-
lation. Furthermore, given a homogeneous population, we allow the user to calculate the
necessary frequencies from the input dataset itself or to specify their own homogeneous
reference dataset of matching population.
2.3 Summary
Here we introduced a model for IBD inference of both haploid and diploid chromosomes,
namely XIBD. XIBD allows for pairwise analysis of the X chromosome without the need
41
to duplicate the male X chromosome. Furthermore, the model can be used for analysis of
non-human organisms with haploid (or diploid) genomes.
Simply, XIBD implements a HMM to infer the numbers of alleles shared IBD between
a pair of individuals using SNP genotype data. With advances in technologies producing
datasets with increasing SNP density, it is important to account for both genotyping errors
and LD when developing a model. We account for genotyping errors through the inclusion
of an error term in the calculation of the emission probabilities, while LD is accounted
for by either thinning the dataset prior to analysis to produce a collection of SNPs in
approximate LE, or implementing emission probabilities that condition on the genotypes
of a pervious SNP. The model presented here fills a void in what is missing from IBD
methodologies and allows for a more complete analysis of the human genome and the

































































































































































h Zi = 0 Zi = 1
B B A A p2BA pBA
B B A a 2pBApBa 0
B b A A 2pBApbA 0
B b A a 2pBApba + 2pBapbA 0
Table 2.6: Joint probabilities for observing a female/male pair of X chromosome genotypes at







h Zi = 0 Zi = 1
BB B AA A p3BA p
2
BA
BB B AA a p2BApBa 0
BB B Aa A 2p2BApBa 2pBApBa
BB b AA A p2BApbA 0
BB b AA a p2BApba 0
BB b Aa A 2pBApBapbA 0
Bb B AA A 2p2BApbA 2pBApbA
Bb B AA a 2pBApbApBa 0
























































































































































































































































































































































































































































































































































































Simulation studies and software
description for XIBD
We performed simulation studies to assess the power and accuracy of XIBD in deter-
mining IBD segments of varying lengths in the presence of varying levels of LD. This
study was designed to assist with model and SNP selection for use with XIBD. We also
show a surprising difference in power and accuracy between pairs of chromosomes with
different ploidy combinations. Furthermore we perform comparisons with other popular
IBD methodologies, GERMLINE47 and fastIBD49, and provide a critical summary of the
efficiency of XIBD.
3.1 Simulating artificial IBD segments
We simulated SNP genotype data for the X chromosome for pairs of individuals separated
from 1 to 25 generations (siblings to 24th cousins). All generation were simulated using
all female lineages such that individuals separated by 25 generations were likely to have on
average IBD segments of length 2cM, which is the smallest length detected with high power
by many IBD algorithms. For each of the 25 generations we simulated 1,000 diploid pairs of
related chromosomes (mimicking a pair of female’s X chromosomes or a pair of autosomes),
1,000 diploid/haploid pairs of chromosomes (mimicking a pair of X chromosomes belonging
to one female and one male) and 1,000 haploid pairs of chromosomes (mimicking a pair
of male’s X chromosomes). We selected SNPs to be included in the analysis from the
Illumina HumanOmni2.5 platform. This platform contains 16,382 X chromosome SNPs
for which HapMap Phase II data was available for the CEU population. This reflects a
46
dataset of SNPs that could typically be extracted using LINKDATAGEN74 from either
SNP or NGS data. All SNPs with minor allele frequencies (MAF) less than 1% were
excluded from analyses as these SNPs are not considered common to the population and
are likely to result in false positive IBD calls due to extremely distant relatedness, which
we are not interested in identifying. 13,509 SNPs remain following minor allele frequency
filtering, corresponding to approximately 1 SNP per 0.01 cM.
Data was simulated to reflect X chromosome inheritance patterns using pedigree infor-
mation as follows. Given a pedigree with all female lineage, haplotypes were generated for
all male founders using algorithm 1. This algorithm was repeated twice to generate two
haplotypes for female founders. Simulating haplotypes in such a way provides knowledge
of haplotype phase, which is not necessary for XIBD, however can improve the perfor-
mance of GERMLINE. Algorithm 1 requires population allele frequencies and haplotype
frequencies, which were calculated using the HapMap phase II CEU genotype data. Hap-
lotype frequencies between adjacent SNPs were calculated as described in Clayton and
Leung72. While it may be desirable to calculate haplotype frequencies from phased data,
this is time consuming to perform and frequency inference using Clayton and Leung for
pairs of SNPs is sufficient for our purposes. Following founder haplotype simulation, re-
combination could be used to generate haplotypes for all non-founders in the pedigree
according to algorithm 2. Here we assume that recombination follows an exponential dis-
tribution with mean 1 Morgan and that recombination only occurs between a female’s
two X chromosomes. All non-founders inherit a mosaic of their X chromosomes, while
female non-founders also inherit their father’s non-recombined X chromosome. Data was
simulated to ensure that each pair of individuals shared at least one segment of IBD and
only female siblings could share regions with two alleles IBD. Table 3.1 gives the number
of IBD segments of certain lengths simulated for different ploidy combinations. Unphased
genotype calls were generated from the phased haplotype data for use with XIBD and
fastIBD.
3.1.1 Estimating power, accuracy, under- and overestimation of IBD
We use the same definitions of power, accuracy, under- and overestimation of IBD segments
as defined in Browning and Browning52. We define power as the average proportion of
a segment that is detected as a function of the size of the true IBD segment in cM;
where undetected segments are included in this calculation. Accuracy is calculated as the
47
Algorithm 1 Simulating a haplotype
let N equal the total number of SNPs;
let pi denote the population allele frequency at SNP i;
let pi,i−1 denote the conditional probability of allele A at SNPi given the allele at
SNPi − 1;
for SNP = 1 do
generate y ∼ Unif(0,1)
if y < pi then
allele A is chosen for SNP = 1
else
allele B is chosen for SNP = 1
end if
end for
for SNP i = 2 to N do
calculate pi,i−1
generate y ∼ Unif(0,1)
if y < pi,i−1 then
allele A is chosen for SNPi
else
allele B is chosen for SNPi
end if
end for
probability that at least 50% of a detected segment is true as a function of the reported
size of the detected segment. Underestimation is defined as the average length of an IBD
segment that was not detected as a function of the size of the true IBD segment in cM,
conditional on at least part of the segment being detected. This includes multiple gaps
throughout a segment as well as underestimation of segment ends. Finally, overestimation
of IBD is calculated as the average amount that a true IBD segment was overestimated by,
conditional on at least part of the segment being detected. In instances where a detected
IBD segment overlaps multiple true IBD segments, overestimation of one IBD segment is
measured until the nearest IBD segment that was also detected by the same segment.
3.2 Evaluating XIBD by varying LD with different ploidies
We performed an analysis to assess the power and accuracy of each model under varying
levels of LD. We pruned SNPs according to pairwise SNP correlations (R2) greater than
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, 0.99, and 1, where R2 > 0.3 removes all SNPs
with pairwise correlations greater than 0.3 while R2 > 1 does not remove any SNPs
in LD. SNP correlations were calculated from genotype allele counts for all individuals
using PLINK41. Table 3.2 displays the number of SNPs remaining after LD filtering was
48
Algorithm 2 Simulating recombination
let XL = 1.8 denote the length of the X chromosome in Morgans;
let X1 and X2 denote two homologous chromosomes;
generate y ∼ Unif(0,1);
if y < 0.5 then
X1 is chosen as the start chromosome;
else
X2 is chosen as the start chromosome;
end if
generate z ∼ Exp(1);
t = z;
if t < XL then
recombination occurs at t;
else
recombination does not occur and the offspring inherits a non-recombined chromo-
some;
end if
while t < XL do
generate z ∼ Exp(1);
t = t+ z
if t < XL then
recombination at t;
else




Table 3.1: The number of IBD segments simulated for various segment lengths (cM)
IBD segment length (cM) diploid pairs diploid/haploid pairs haploid/haploid pairs
(0, 0.5] 4,839 4,761 4,579
(0.5, 1] 3,488 3,358 2,923
(1, 1.5] 2,433 2,710 3,112
(1.5, 2] 2,198 2,221 2,335
(2, 3] 3,130 3,267 3,146
(3, 4] 1,961 1,707 1,941
(4, 5] 1,391 1,414 1,434
(5, 10] 3,377 3,423 3,481
> 10 7,030 6,001 6,214
Table 3.2: The number of SNPs remaining once SNPs in LD are removed. Pairs of SNPs were
removed if their pairwise correlation (R2) based on genotype allele counts was more than the












performed. Figures 3.1, 3.2 and 3.3 each display the results for model 1 and model 2 for
pairs of diploid chromosomes, pairs of chromosomes where one chromosome is diploid and
the other chromosome is haploid, and pairs of haploid chromosomes, respectively.
For all ploidy combinations, model 1 (pruning) has similar power to detect IBD seg-
ments of all lengths as model 2 (conditioning), however IBD segments less than 2cM are
more likely to be true positives when detected by model 2. This suggests that greater cau-
tion should be taken when interpreting the results from model 1 if stringent post-analysis
filtering of small IBD segments has not been performed. In contrast, if an IBD segment of
less than 2cM is detected with model 2, there is at least a 50% chance that it will be real.
Accounting for LD in the algorithm, even if not complete, results in better performance

































































































































































































































Figure 3.1: Power and accuracy results for XIBD between 2 diploid chromosomes, calculated
across various segment sizes and LD filtering levels.
We also find that pruning SNPs using lower thresholds of LD (i.e. R2 = 0.3) reduces
the power of XIBD to detect segments of many sizes, using both models, while the accuracy
of model 1 (pruning) is highest for heavily pruned datasets (i.e. R2 = 0.3) whereas the
accuracy of model 2 (conditioning) is highest for least pruned datasets (i.e. R2 = 1).
This difference is likely attributed to the choice of SNP that is conditioned on when using
model 2, which may be poorly selected when datasets are heavily filtered according to LD
thresholds. Additionally, there is little difference in XIBD performance when SNPs are
pruned according to R2 ≥ 0.8. This suggests that it is beneficial to keep more SNPs in the
51

































































































































































































































Figure 3.2: Power and accuracy results for XIBD between one diploid and one haploid chromo-
some, calculated across various segment sizes and LD filtering levels.
Lastly, there is a considerable difference in the performance of XIBD for different ploidy
combinations (Figure 3.4). In particular, XIBD performs exceptionally well when applied
to pairs of haploid chromosomes, while performance decreases as diploid chromosomes are
included in the analysis. This result is not surprising as the state space and probability


































































































































































































































Figure 3.3: Power and accuracy results for XIBD between 2 haploid chromosomes, calculated



























































































































































































































Figure 3.4: Power and accuracy results for XIBD across ploidies, calculated across various seg-
ment sizes with R2 = 0.99. Ploidy = 2/2 denotes a pair of diploid chromosomes, ploidy = 2/1
denotes a pair of chromosomes where one chromosome is diploid and the other chromosome is
haploid, and ploidy = 1/1 denotes a pair of haploid chromosomes.
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3.3 Comparison of XIBD, GERMLINE and fastIBD
3.3.1 Model parameters
We compared the performance of XIBD to GERMLINE and fastIBD using the simulated
data described earlier. Specifically, the dataset containing 13,509 SNP was used, where
SNPs with MAF < 1% were removed and no LD filtering was performed. GERMLINE can
be implemented on haploid chromosomes, however the same cannot be said for fastIBD.
We chose to assess the performance of fastIBD, even though haploid chromosomes are not
properly accounted for in the probability distributions, as the localized haplotype cluster
model that defines the BEAGLE HMM61, which is the basis of fastIBD, is used by all
BEAGLE IBD algorithms and thus is widely used in IBD tools.
GERMLINE version 1.5.1 was implemented with parameters “-bits 32 -min m 0.5 -
err hom 1 -err het 1 -haploid”, as in in Gusev et al.75 with the exception of “-min m”. The
parameter “-min m” defines the minimum reported length of an IBD segment in cM. We
selected this parameter to be 0.5 cM (opposed to 1 cM as in Gusev et al.75) to determine
IBD performance of smaller segment lengths. The parameter “-haploid” makes use of
haplotype phase, and although XIBD performs analyses on unphased data, we assessed
GERMLINE using phased data for optimal performance.
We performed analyses of fastIBD using version 3.3.2. We performed ten runs of
fastIBD using different random number seeds and merged the results as recommended49.
Within each run we performed ten iterations of the phasing algorithm and used default
values for all other parameters. The dataset was large for ten iterations to be performed,
so we created subsets of 500 individuals to perform analyses on and merged results. Each
subset contained 10 pairs of individuals from each generation from siblings to 24th cousins,
where each individual shared IBD with only one other individual per subset. We chose
subsets of 500 individuals as this has been shown to achieve high power and accuracy with



















































































































































































































Figure 3.5: Comparison of IBD power, accuracy, under- and overestimation of XIBD,
GERMLINE and fastIBD between 2 diploid chromosomes, calculated across various segment sizes.
3.3.2 Results
Performance results are displayed in Figures 3.5, 3.6 and 3.7, for pairs of diploid chromo-
somes, pairs of chromosomes where one chromosome is diploid and the other chromosome
is haploid, and pairs of haploid chromosomes, respectively. When performing IBD analy-
ses on diploid chromosomes, all algorithms have approximately the same level of power to
infer segments of all sizes, however there are differences in the accuracy of each tool. XIBD
model 2 (LD accounted for) is more likely to detect segments that are real than other tools.
GERMLINE tends to underestimate segment lengths more than other tools, with on av-
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erage 0.2 cM of a segment undetected, while fastIBD does not underestimate segments
at all. This is likely due to fastIBD overestimating segments by considerable amounts
(0.75 cM), resulting in little chance of underestimation of a segment’s breakpoints, while


















































































































































































































Figure 3.6: Comparison of IBD power, accuracy, under- and overestimation of XIBD,
GERMLINE and fastIBD between between one diploid and one haploid chromosome, calculated
across various segment sizes.
As haploid chromosomes are included in the analysis, the results from GERMLINE are
very similar to analyses of diploid chromosomes, with the exception that accuracy increases
for smaller segments as analyses include more haploid chromosome. XIBD achieves higher
power and accuracy with segments estimated more accurately as haploid chromosomes
57



















































































































































































































Figure 3.7: Comparison of IBD power, accuracy, under- and overestimation of XIBD,
GERMLINE and fastIBD between 2 haploid chromosomes, calculated across various segment sizes.
The results from fastIBD are more dramatic as haploid chromosomes are included in
the analysis. While the power of fastIBD increases slightly with the inclusion of haploid
chromosomes, the accuracy of fastIBD increases markedly. FastIBD has the highest prob-
ability of detecting a segment that is real for all segments lengths. Furthermore, extremely
small segments (< 0.5 cM) that are detected in cohorts of entirely haploid chromosomes
are almost guaranteed to be real, although overestimation of segment breakpoints remains
58
high for fastIBD in analyses of all ploidy combinations.
3.3.3 Discussion
The overall performance of all tools increases with the inclusion of haploid chromosomes
in analyses. This is most likely because there is no uncertainty surrounding haplotype
phase for haploid chromosomes, which reduces noise in IBD estimation, allowing for more
easily identified segments. Furthermore, reduced accuracy is expected for diploid chro-
mosomes, since diploid chromosomes contribute two haplotypes to analyse, creating more
opportunities for false detection of IBD segments.
The power of GERMLINE remains largely unchanged between haploid and diploid
chromosomes, which is not surprising since phased haplotypes were used in the analysis of
both diploid and haploid chromosomes. Therefore, the probability of detecting a segment
should be approximately the same when analysing diploid or haploid chromosomes with
known phase.
FastIBD performs exceptionally well on haploid cohorts, which is somewhat surprising
given the BEAGLE HMM does not correctly account for haploid chromosomes. This
implies that IBD analyses are largely robust to misspecification of probability distributions
in terms of haploid chromosomes. While fastIBD outperforms all tools in terms of accuracy
for extremely small segments in cohorts containing haploid chromosomes, it comes at a
cost of overestimating segment boundaries.
XIBD performs consistently well across the four summary measures evaluated, and
achieves the highest power for detecting small segments when haploid chromosomes are
included in analyses. One important thing to note when evaluating these methods is
that XIBD analyses were performed using unphased data, while GERMLINE used phased
data and fastIBD phases data prior to IBD analysis. Thus, when considering diploid
chromosomes, XIBD performance is comparable to methods that make use of haplotype
phase information. If phased diploid data were available, one could run XIBD using
a haploid model. This has the advantage of detecting homozygosity by descent (IBD
between homologous chromosomes within an individual) with potentially improved power
for IBD detection. However, we note that changes in power is exclusively determined by
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Figure 3.8: Computation times for XIBD on cohorts of varying sizes with SNPs in different
states of LD. The cohort sizes of 2, 10, 20, 50, 100 and 250 individuals correspond to 1, 45, 190,
1125, 4950 and 31125 pairwise analyses respectively. Run times are the real elapsed run times as
calculated by the proc.time function in R and the analysis was performed on a dual socket Xeon
E5-2690v3, 512GB memory machine. XIBD was running using 5 cores.
Given that we are interested in recent common ancestry (up to 25 generations and 50
meiosis), the threshold on IBD segment lengths detected with high power and accuracy is 2
cM. However, our results show that, for XIBD and fastIBD at least, the threshold on IBD
length can possibly be reduced for haploid chromosomes to 1 cM or 1.5 cM, identifying
individual with more distant ancestry, potentially separated by up to 50 generations (100
meiosis).
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3.4 Computation time of XIBD
HMMs are notorious for being computationally intensive algorithms to run, and XIBD
is no exception. Computational time increases linearly with the number of SNPs and
quadratically with the number of individuals (Figure 3.8), with an analysis of 250 indi-
viduals (31,125 pairwise analyses) and 13,509 SNPs taking slightly longer than 1 hour.
Accounting for LD in model 2 increases the computational burden as conditional emission
probabilities increase the complexity of the model. Furthermore, datasets which include
diploid chromosomes take longer to analyse as the observation state space increases, re-
sulting in more genotypic combinations to account for.
XIBD computation time can be reduced by running model 1 with potentially fewer
SNPs at little cost to performance. Furthermore, XIBD allows parallelization of analyses
on multicore processors. While XIBD is not computationally comparable to tools like
GERMLINE and fastIBD, which took less than 5 seconds and less than 10 minutes to
analyze 13,509 SNPs for 250 individuals, respectively, it is still a valuable tool for analysis
of small to medium sized datasets containing tens to hundreds of individuals.
3.5 XIBD graphical representations of relatedness
The results from IBD analyses are typically returned as plain text files containing in-
formation on the genomic locations of inferred segments. These can be cumbersome to
sift through if many IBD segments have been detected, particularly when cohorts con-
tain mixed phenotypes. XIBD is implemented in R which allows us to make use of the
graphical interface that R provides. As such, we have developed a number of graphical
functions to facilitate with interpreting results. All figures are produced using ggplot276,
unless otherwise stated.
3.5.1 Kinship confirmation using IBD coefficients
The first of such functions allows one to check that, for individuals with a known degree
of relatedness, the reported relationship is likely to be correct. XIBD calculates identity
coefficients ∆k (k = 1, . . . , 9) for a given pedigree using IdCoefs
70 for autosomes and our
implementation for the X chromosome (Appendix B), from which IBD coefficients, ω0, ω1
and ω2, can be approximated. Following this, the theoretical proportion of genome shared
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Figure 3.9: Two pedigrees for a 3 generation family containing 8 individuals. A An incorrectly
reported pedigree for the family. B Correct pedigree showing consanguinity between individuals 4
and 5, where individual 7 is actually the daughter of individual 5, not individual 6. The red lines
depict the incorrectly reported relationship.
SNP genotype data can be used to approximate π from IBD coefficients calculated in
Chapter 2, without the use of pedigree information. The estimated values of π can be
compared to the theoretical values in XIBD using a heat map to identify individuals with
misspecified relationships. For example, consider the two pedigrees in Figure 3.9. Figure
A represents the reported pedigree for a small family while Figure B represents the actual
pedigree for the same family, which contains consanguinity between a pair of siblings.
Identity coefficients were calculated for all pairs of individuals given the relationships
specified in each pedigree from which values of π were calculated. These denote the
theoretical IBD proportion for each pedigree. We also simulated values of π for all pairs
assuming an approximate normal distribution with mean value of πi for pair i in pedigree
B (actual pedigree) and standard deviation between 0.01 and 0.1. These were taken to
represent estimates from SNP genotype data.
Figure 3.10 displays a heat map of estimated and theoretical IBD proportions for each
pedigree, for autosomes and the X chromosome respectively. The theoretical proportions
should approximately match the estimated proportions, producing symmetrical figures,
which is not the case for pedigree A. Specifically, the reported father (individual 6) of
individuals’ 7 and 8 is not predicted to be related to individual 7. In fact, individual 7
shares more of their genome than expected with all other individuals in this pedigree,
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particularly individual 5. If we assume that individual 5 is the father of individual 7, as
in pedigree B, we get approximately symmetrical heat maps, confirming the suspected
relationships. Visual displays such as this allow for rapid assessment of moderate to large

















































































Pedigree A, autosomes Pedigree A, X chromosome
Pedigree B, autosomes Pedigree B, X chromosome
Figure 3.10: Example figures produced by XIBD displaying the approximate proportion of
genome shared IBD between pairs of individuals, given a pedigree. Theoretical identity coeffi-
cients for autosomes were calculated using the IdCoef70 R package while our implementation was
used for the X chromosome. Estimated proportions are calculated from SNP genotype data as in
Section X, although have been simulated for this example. Grey coloured boxes represent IBD
proportions with oneself, which are not reported by XIBD and hence are NA values. All values of
π estimated with individual 7 in pedigree A have been highlighted with red boxes as suspicious.
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3.5.2 IBD segments and excess IBD
Following IBD analysis, inferred segments can be displayed in a brick-style plot to vi-
sualize the break points, IBD sizes and overlap of segments detected in multiple pairs
(Figure 3.11). Gene annotations can be added to the figure which enables fast identifica-
tion of individuals sharing a common haplotype over a gene(s) of interest.
When many pairs are inferred IBD, displaying segments as in Figure 3.11 may be
impractical. Therefore, we provide an alternative to this function, which simply calculates
the proportion of pairs who are IBD at each SNP and plots this distribution across the
genome. Although this does not identify sharing between specific pairs, it is a quick way of
identifying genomic loci with many IBD pairs. Genomic loci with many shared segments
tend to be associated with natural selection.
In particular, Albrechtsen et al.21 and Han and Abney22 have used similar figures to
successfully identify the HLA region as under positive selection in a number of populations,
in addition to the human lactase gene (LCT ). We calculated the proportion of pairs IBD
at each SNP in the example data used in Figure 3.11 and display the results in Figure 3.12.


















































Figure 3.11: An example figure produced by XIBD displaying segments of IBD across the genome.
Each coloured segment denotes an IBD region with either 1 or 2 alleles inferred IBD. Data used in
this figure was simulated from a 5 generation pedigree according to algorithms 1 and 2, respectively,
using SNPs extracted from the Illumina HumanOmni2.5 platform. A haplotype on chromosome






















Figure 3.12: An example figure produced by XIBD displaying the proportion of pairs IBD at
each SNP. The data used in this figure is the same as that used in Figure 3.11
3.6 Summary
Here we evaluate the performance of XIBD. We show that XIBD achieves high power and
accuracy to infer IBD segments of 2cM and larger, and it also performs remarkably well
for segments as small as 0.5cM when haploid chromosomes are included in the analysis.
Furthermore, we demonstrate that XIBD is just as powerful, if not more powerful, than
GERMLINE and fastIBD in many instances. Unfortunately, XIBD is computationally
intensive, unlike GERMLINE and fastIBD, making it unsuitable for large cohorts with
many hundreds or thousands of individuals. Nonetheless XIBD is a valuable tool for
analysis of the X chromosome, and small cohorts in general, as it includes a number of
graphical features that most IBD software do not, making for easier interpretation of
results. We applied XIBD to several applications in human genetics, one of which is
included as Chapter 4, while another is presented in Shaw et al.19.
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Chapter 4
XIBD application to an epilepsy
cohort
4.1 Identity by descent fine mapping of familial adult my-
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mapping, that infers regions of the genome between indi-
viduals that have been inherited from a common ancestor. 
IBD mapping provides an alternative to linkage analysis in 
the presence of allelic and locus heterogeneity by detect-
ing clusters of individuals who share a common allele. 
Succeeding IBD mapping, gene prioritization based on 
gene co-expression analysis can be used to identify the 
most promising candidate genes. We performed an IBD 
analysis using high-density single nucleotide polymor-
phism (SNP) array data followed by gene prioritization on 
a FAME cohort of ten European families and one Austral-
ian/New Zealander family; eight of which had known dis-
ease loci. By identifying IBD regions common to multiple 
Abstract Familial adult myoclonus epilepsy (FAME) 
is a rare autosomal dominant disorder characterized by 
adult onset, involuntary muscle jerks, cortical myoclonus 
and occasional seizures. FAME is genetically heterogene-
ous with more than 70 families reported worldwide and 
five potential disease loci. The efforts to identify potential 
causal variants have been unsuccessful in all but three fam-
ilies. To date, linkage analysis has been the main approach 
to find and narrow FAME critical regions. We propose an 
alternative method, pedigree free identity-by-descent (IBD) 
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families, we were able to narrow the FAME2 locus to a 
9.78 megabase interval within 2p11.2–q11.2. We pro-
vide additional evidence of a founder effect in four Italian 
families and allelic heterogeneity with at least four distinct 
founders responsible for FAME at the FAME2 locus. In 
addition, we suggest candidate disease genes using gene 
prioritization based on gene co-expression analysis.
Introduction
Familial adult myoclonus epilepsy (FAME), also known as 
familial cortical myoclonic tremor with epilepsy (FCMTE), 
autosomal dominant cortical myoclonus and epilepsy 
(ADCME), and benign adult familial myoclonic epilepsy 
(BAFME), is a rare autosomal dominant disorder charac-
terized by rapid involuntary muscle jerks of cortical origin 
mimicking essential tremor and sporadic seizures affecting 
more than 70 families worldwide (Licchetta et al. 2013). 
Onset of the disorder can range between 10 and 60 years of 
age and is typically slowly progressing or non-progressive 
and non-disabling (Crompton et al. 2012).
FAME was first described in two individuals of Japa-
nese descent (Ikeda et al. 1990). Thereafter, a number of 
Japanese families were reported with features of the disorder 
and genomic analyses identified linkage to a 7.16 megabase 
(Mb) region spanning chromosome 8q24 (FAME1) (Mikami 
et al. 1999; Plaster et al. 1999; Mori et al. 2011). Linkage to 
this region has only been identified in families of Japanese 
descent and as yet no causal variants have been identified.
Elia et al. (1998) and Guerrini et al. (2001) were first to 
report European families with characteristics of FAME in 
addition to mild-to-moderate intellectual disability. Guerrini 
et al. (2001) performed a genomic analysis and identified a 
second disease locus (FAME2) on chromosome 2. Following 
this, multiple European families with FAME characteristics 
have been described and the FAME2 locus was refined to 
a 10.4 Mb region spanning chromosome 2p11.1–q12.2 and 
containing 61 RefSeq genes (Madia et al. 2008; Saint-Mar-
tin et al. 2008; Crompton et al. 2012; Licchetta et al. 2013). 
de Fusco et al. (2014) sequenced candidate genes within 
the FAME2 locus and identified a novel in-frame insertion/
deletion in the ADRA2B gene potentially causal for the dis-
order in two families from Tuscany, Italy. This gene was also 
sequenced in a number of families from southern Italy linked 
to the FAME2 locus; however, mutations in the ADRA2B 
gene were not detected. The FAME2 locus overlaps the cen-
tromere of chromosome 2. Centromeres undergo suppressed 
recombination and usually contain large gaps in marker 
information (Choo 1998). This makes the FAME2 critical 
region especially difficult to assess; likely contributing to the 
lack of success in finding causal variants.
A third disease locus (FAME3) was mapped to chro-
mosome 5p15.31–5p15.1 in a single large French family 
(Depienne et al. 2010), and more recently, a fourth disease 
locus was reported on chromosome 3q26.32–3q28 (FAME4) 
in a Thai family (Yeetong et al. 2013). In addition to this, a 
consanguineous Egyptian family with features of FAME has 
been reported to have a homozygous mutation in the CNTN2 
gene on chromosome 1q32 (FAME5) (Stogmann et al. 2013).
A founder effect has been proposed for six families, 
residing within close proximity in Italy, that have been 
mapped to the FAME2 locus and have a likely, identical 
microsatellite marker-based haplotype segregating in all 
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families (Madia et al. 2008; Licchetta et al. 2013). How-
ever, the identification of a pathogenic variant has been 
unsuccessful so far. In addition to this, de Fusco et al. 
(2014) proposed a founder effect in two more families from 
Italy with an identical variant in ADRA2B, within FAME2, 
based on shared haplotypes. This variant was not present in 
other families linked to FAME2.
To date, linkage analyses have been the primary method 
of analysis applied to FAME data sets to narrow the 
search space for causal variants. We propose an alternative 
method, identity-by-descent (IBD) mapping, which infers 
that the regions of the genome have been inherited from a 
common ancestor and can be applied to cohorts of unre-
lated individuals without a pedigree (Browning and Brown-
ing 2010). IBD analyses can lead to the identification and 
reduction in size of the critical regions in which likely 
causal variants should be located. In addition to this, they 
can lead to the discovery of distant relatedness between 
families unknown to be related (Albrechtsen et al. 2009).
Whole exome sequencing (WES) and whole genome 
sequencing (WGS) have failed to identify a variant for 
FAME thus far. This could be attributed to a variety of rea-
sons, including the use of a poor reference genome with 
missing genetic information (Anvar et al. 2014); disease-
causing variants are non-coding SNPs or splice-site muta-
tions (Koboldt et al. 2013). To identify candidate disease 
genes within FAME loci, we propose in silico gene prioriti-
zation. In silico prioritization aims at discovering candidate 
disease genes by making use of deposited gene expression 
data and known disease-causing genes for the same or a 
related disorder to build a network that can be used to rank 
candidate genes (Aerts et al. 2006; Oliver et al. 2014). To 
date, no reported gene prioritization has been performed 




Eleven families were recruited for the analysis accord-
ing to the relevant ethics of each country. Of these, 6 
families have their clinical features described elsewhere 
(see Table 1). Families 1 to 7 have had their disease locus 
mapped to 2p11.1–q12.2, family 8 has been mapped to 
5p15.31–p15.1, while families 9, 10 and 11 have unknown 
disease loci. Additionally, family 1 has a suspected disease 
variant in the ADRA2B gene while family 2 has had vari-
ants in ADRA2B excluded as causal (de Fusco et al. 2014). 
Two affected individuals were selected from each family as 
representatives for further analyses to determine related-
ness and thus the extent of the locus and allelic heterogene-
ity in this cohort of FAME families. There were no known 
relationships between individuals from different families, 
although relatedness had been hypothesized between fami-
lies 2, 3, 4, and 5 using microsatellite marker allele-based 
haplotype sharing comparisons.
All 22 individuals were SNP genotyped at the Dépar-
tement de Génétique Hôpital Pitié-Salpétrière using the 
Illumina HumanCytoSNP-12 chip, as already described 
(Nava et al. 2014). This chip has over 290,000 SNPs with 
a median physical map distance of 6.2 Kb (first and third 
quartiles of 4.3 and 14.3 Kb, respectively) and a median 
map distance of 0.004 cM (first and third quartiles of 0.001 
and 0.013 cM, respectively). SNP genotype calls were gen-
erated using the Illumina’s GenomeStudio Software.
Data processing and IBD methodology
HapMap Tuscan (TSI) allele frequency data were used in 
the analysis, after this HapMap population was found to be 
Table 1  Description of the FAME cohort data set






Family 1 Guerrini et al. (2001), De 
Fusco et al. (2014)
Italian province of 
Livorno, Tuscany
11 2p11.1–q12.2 ADRA2B
Family 2 Striano et al. (2005) Italian province of 
Caserta, Campania
18 2p11.1–q12.2 –
Family 4 Licchetta et al. (2013) Italian province of 
Caserta, Campania
25 2p11.1–q12.2 –
Families 3, 5 – Italian province of 
Caserta, Campania
12, 4 2p11.1–q12.2 –
Family 6 Saint-Martin et al. (2008) Spain 13 2p11.1–q12.2 –
Family 7 Crompton et al. (2012) Australia/New Zealand 55 2p11.1–q12.2 –
Family 8 Depienne et al. (2010) France 16 5p15.31–p15 –
Families 9, 10, 11 – France 3, 7, 2 – –
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a good fit (The International HapMap 3 Consortium 2010) 
(Supplementary Material). We used XIBD (Henden et al. 
2016) to estimate relatedness and infer genomic regions 
shared IBD between pairs of individuals. Briefly, XIBD 
implements a first-order continuous-time hidden Markov 
model to detect IBD using unphased genotype data and 
can account for linkage disequilibrium (LD), genotyping 
errors, and missing data. The Viterbi algorithm is used to 
find the most likely sequence of IBD states between a pair 
of individuals, where the states are the number of alleles-
shared IBD with possible values of 0, 1, or 2 alleles (Rabi-
ner 1989).
XIBD model 2 was run which uses haplotype frequen-
cies to account for LD. The HapMap Phase 3 TSI geno-
type data were used as a reference data set to calculate 
the haplotype frequencies and allele frequencies. Mark-
ers in near perfect LD (R2 >0.99) were removed from the 
analysis along with markers that had low minor allele 
frequencies (MAF <0.01) and markers with missing data 
for more than 50 % of individuals; this included seven 
adjacent SNPs overlapping the FAME2 critical region 
with missing genotype calls for all 22 individuals. Finally, 
IBD segments less than 0.5 cM or containing less than 20 
SNPs were not considered as candidates, as they represent 
population-background LD or deeper ancestral LD which 
will lead to IBD inference that is not of relevance to the 
disease. This has been previously noted and discussed 
(Brown et al. 2012).
Gene prioritization using a combined resource 
of human brain expression data
The microarray gene expression data sets used for the in 
silico gene prioritization were all generated with tissues 
from population-based samples of post-mortem human 
brains. Supplementary Table 1 includes a detailed descrip-
tion of the five publicly available data sets that were used 
in combination to assess the network proximity for the 
candidate genes (in silico prioritization). Since the data 
sets were very different in their sampling design and tech-
nology used, advanced data cleaning was applied using 
RUVcorr (Freytag et al. 2015) (Supplementary Material). 
We used 421 known epilepsy genes (listed in Supplemen-
tary Table 2) to form the basis for defining putative rel-
evant epilepsy genetic co-expression networks against 
which we assess our list of candidate FAME genes. Each 
of the known epilepsy genes was available in at least one 
data set. Finally, we removed all expression data derived 
from the prenatal brains, as it has been previously shown 
that brain gene expression patterns are very different from 
post-natal and adult brains, with greater variability (Kang 
et al. 2011). We argued that since FAME is mid-to-late 
age onset, genes of relevance would be best identified by 
focusing on post-natal brain expression which is domi-
nated in the six data sets by adult brains (90 % of arrays 
that are >20 years old).
We chose to perform gene prioritization on candi-
date disease genes in the FAME1, FAME2, FAME3, and 
FAME4 critical regions, hypothesizing that the disease 
genes from the four loci should all be affecting the same 
pathway and hence be in the same network.
To prioritize the candidate disease genes, we con-
structed a network for every combination of candidates 
(one for each of the FAME1, FAME2, FAME3, and 
FAME4 loci) with the known epilepsy genes. Network 
construction was based on a weighted Pearson correlation 
coefficient combined with a thresholding approach similar 
to the approach in Oliver et al. (2014). In particular, we 
weighted each sample by the inverse of the squared num-
ber of samples that were also extracted from this brain. 
This approach takes into account that some brains have 
several hundred samples, while some brains only have one 
sample. Only correlations exceeding 0.60 were deemed to 
represent true co-expression. The thresholding approach 
allowed the construction of an adjacency matrix (a binary 
matrix indicating the presence or the absence of co-expres-
sion) corresponding to the network for every combination 
of genes. Note that due to the unavailability of some gene 
combinations, we had to assume that the genes in question 
did not interact, as otherwise, we would have had to con-
siderably reduce the number of investigated genes.
Standard in silico gene prioritization approaches con-
sider only single gene candidates. Here, we have combi-
nations of four causal genes that we wish to identify, one 
from each of the four loci. This leads to a much longer 
candidate list. Therefore, using the adjacency matrices, 
we performed filtering to determine the most likely can-
didate genes and then prioritized these. We first filtered by 
removing combinations of genes that were not directly, or 
indirectly, interacting, i.e., they were not a member of the 
same pathway. Following this, we removed all gene com-
binations where the four candidate genes did not belong 
to the same cluster and did not share at least one neigh-
bor. These conditions assume that all four candidate genes 
regulate the same gene in the pathway connected to the 
disease. Thus, we assume that dysfunctional regulation of 
the gene shared as a neighbor by all candidate genes leads 
to the pathway breaking down. This filtering procedure 
makes strong assumptions regarding the function of these 
genes, but this is necessary to reduce the number of can-
didate genes. We ordered the results of the final filtrations 
according to the sum of the PageRank [an algorithm for 
determining node importance (Brin and Page 1998)] of the 





Pairwise IBD analyses were performed for all individuals 
in the data set. The individuals from families 1, 3, 9 and 11 
are parent-offspring pairs. With the exception of consan-
guinity, a parent-offspring pair is an uninformative rela-
tionship to assess for IBD as one allele will be shared IBD 
across all autosomes; providing no opportunity to iden-
tify a critical region between these pairs alone. However, 
parent-offspring pairs can be useful for validating IBD 
between families, since they act as replicates, and thus add 
value to the analysis. More distant relatives would have 
been desirable for this analysis; however, sample availabil-
ity and consent limited pair selection. Pairs chosen from 
the remaining seven families are cousins of the first degree 
or higher. We also inferred some families to be distantly 
related to the closest pair estimated as second cousins 
between families 8 and 10 (see Supplementary Table 3 for 
a full list of estimated parameters). The number of meiosis 
and initial probabilities of IBD sharing for the estimated 
relationships were used in the model to detect IBD tracts 
rather than those calculated from kinship coefficients for 




Our analysis identified several IBD tracts shared within 
families as well as between families over the FAME2 criti-
cal region (Figs. 1, 2; Supplementary Table 4). Families 
1–7, which had been previously mapped to this region, had 
IBD tracts inferred that span part of or the entire FAME2 
interval. Families 9 and 11 also have IBD tracts overlap-
ping FAME2; however, it is unclear whether this is the 
critical region for these families due to the uninformative 
nature of their relationships. We could, however, exclude 
FAME2 as the critical region for family 10, as no IBD tract 
was inferred over this region.
All pairwise IBD analyses between families 2, 3, 4, 
and 5 resulted in shared IBD tracts over the FAME2 criti-
cal region (Fig. 1, wedged y-axis labels), suggesting relat-
edness of these four Italian families through a common 
ancestor. All four families are either from, or reside in close 
proximity to, Naples, Italy, and this result is consistent 
with the previous findings of a shared haplotype between 
Neapolitan families by identity by the state analysis using 
microsatellite data (N = 4 markers) (Madia et al. 2008; 
Licchetta et al. 2013). Relatedness between these families 
suggests that the same causal variant should be responsible 
for the FAME disorder in these cases.
There was no evidence of IBD sharing between fami-
lies 1, 6, and 7 with any other family previously mapped 
to the FAME2 locus. This suggests that there are likely 
to be at least four distinct founders at the FAME2 locus 
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Fig. 1  IBD results across part of chromosome 2, drawn using R. The 
y-axis shows that the pair identifiers, e.g., F2_1/F3_1, represent the 
inferred IBD tracts between family 2, individual 1 and family 3, and 
individual 1. The x-axis displays the genetic map position in base pairs 
along chromosome 2 using hg19 reference. Solid blue horizontal rec-
tangles are regions, where pairs share one allele IBD, while checkered 
yellow rectangles represent two alleles-shared IBD (none detected). 
The dotted vertical lines mark the FAME2 linkage region as in Lic-
chetta et al. (2013). The dashed vertical lines mark an IBD region com-
mon to all pairs with IBD inferred over the FAME2 locus. The wedged 
labels on the y-axis highlight all pairwise results from four Italian fami-
lies (families 2–5) suspected of having a common founder. Positions of 
SNPs included in the analysis can be seen below the IBD tracts along 
with an ideogram highlighting the interval plotted. For ease of interpre-
tation, all parent-offspring IBD segments have been excluded from the 




corresponding to family 1 (Tuscany), the Neapolitan fami-
lies 2, 3, 4, and 5, family 6 (Spanish), and family 7 (Aus-
tralasian). Figure 2 displays an IBD network of relatedness 
between all individuals over the FAME2 critical region.
We investigated IBD tracts overlapping in multiple indi-
viduals within the FAME2 critical region. Taking the inter-
section of all IBD tracts produces an 11.2 Mb region-shared 
IBD between markers rs10179529 and rs1357719 (Fig. 1, 
dashed vertical lines). Towards, the start of this interval is a 
6.56 Mb region containing only a single marker out of 203 
IBD markers in the interval. This 6.56 Mb region coincides 
with the centromere of chromosome 2 and affects our abil-
ity to potentially refine the IBD boundary further.
Guerrini et al. (2001) first defined the FAME2 locus 
as 12.4 cM (21.3 Mb) spanning markers D2S2161 to 
D2S1897 within 2p11.1–q12.2 using an unspecified human 
genome build. Subsequent to this, using hg19 coordinates, 
the FAME2 critical region was refined several times to the 
most recent interval of 10.4 Mb spanning markers D2S2216 
and D2S2175 within 2p11.2–q11.2 (Fig. 1, dotted vertical 
lines) (Madia et al. 2008; Saint-Martin et al. 2008; Cromp-
ton et al. 2012; Licchetta et al. 2013). Combining our IBD 
region with the most resent FAME2 interval further short-
ens the FAME2 critical region to 9.78 Mb region spanning 
markers rs10179529 and D2S2175 within 2p11.2–q11.2 
and containing 53 RefSeq genes (https://genome.ucsc.
edu). Table 2 provides a summary of the new FAME2 criti-
cal region and Fig. 3 shows the refinement of FAME2 over 
time and its current physical map location. We note that the 
ADRA2B gene remains in the critical region. 
5p15.31–p15.1
We identified 3 IBD tracts overlapping the FAME3 critical 
region, in addition to the four parent-offspring IBD seg-
ments (Fig. 4, Supplementary Table 5). Of the families with 
IBD tracts inferred here, only family 8 has been linkage 
mapped to this region. This pair of individuals is inferred 
second cousins, and although they share only 10 % of their 
genome IBD, we were unable to narrow the FAME3 criti-
cal region further, as their IBD tract overlaps the critical 
region entirely (Depienne et al. 2010).
Our analysis also identified an IBD tract between the 
pair from family 4 and another tract between the pair 
from family 10. We believe that family 4 shares the 
same causal variant as families 2, 3, and 5 who have not 
been inferred IBD here; hence, we exclude FAME3 as a 
critical region for family 4 and cannot use this IBD seg-
ment to narrow the FAME3 critical region. Alternatively, 
family 10 has an unknown disease locus, so we cannot 
exclude FAME3 as a critical region for this family. The 
two individuals from family 10 are first cousins and share 
approximately 20 % of their genome IBD. We expect 
the causal variant for this family to be located in an 
IBD region; therefore, the search space has been greatly 
reduced.
Gene prioritization
There were 42, 53, 58, and 149 RefSeq genes identified 
within the FAME1, updated FAME2, FAME3, and FAME4 
critical regions, respectively (see Supplementary Table 6). 
Using the combined microarray data sets, where gene 
names were standardized, we could identify 32 of the 42 
genes within FAME1; 41 of the 53 genes within FAME2; 
34 of the 58 genes within FAME3, and 91 out of the 149 
genes within FAME5 (see Supplementary Table 6). After 
the first filtration step, we reduced the number of combi-
nations of genes (one from each of the FAME1, FAME2, 
FAME3, and FAME4 loci) from over 4 million to 161,302. 
Assuming that all four candidate genes are present in the 
same co-expression network and regulate a common gene 
resulted in 61 prioritized gene combinations (see Supple-
mentary Table 7).
The gene prioritization list contains a small num-
ber of genes that appear in many combinations. In par-
ticular, 9, 8, 4, and 13 genes were prioritized from the 















Fig. 2  IBD network of relatedness between all individuals over the 
FAME2 critical region, drawn using Adobe Illustrator CS6. Each 
node identifies one individual and node colours are unique for each 
family. An edge is drawn between two nodes if an IBD segment 
was inferred between the two individuals. Parent-offspring pairs are 
denoted by an asterisk within their nodes (families 1, 3, 9, and 11) 
(colour figure online)
Table 2  Description of IBD refined FAME2 critical region
Start marker End marker Start position (bp) End position (bp) Length (Mb) No. of markers No. of RefSeq genes
rs10179529 D2S2175 89,001,656 98,784,776 9.78 126 53
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Extensively sequenced and analyzed genes ADRA2B and 
KCNIP3, located within the FAME2 locus, appear in mul-
tiple gene combinations. Specifically, ADRA2B appears 
in 6 of the top 25 prioritized gene combinations. Other 
obvious candidate disease genes, including CTNND2 and 
SEMA5A, located within the FAME3 locus, did not appear 
in our gene prioritization list. In addition, candidate genes 
HTR3D and KCNMB3, located within the FAME4 locus, 
were prioritized highly in the list and multiple times. 
These genes encode ion channel receptors that regulate 
neuron excitability, representing promising candidate dis-
ease genes (Niesler et al. 2003; Uebele et al. 2000). Of 
the genes that were prioritized within the FAME1 and 
FAME3 loci, not much is known about their function and 
in-depth analysis of sequencing data may not have been 
performed.
Discussion
Our analysis demonstrates how difficult the FAME2 criti-
cal region is to analyze, even for the IBD analysis. FAME2 
overlaps the centromere of chromosome 2, which is a 
region that is difficult to sequence and hence not as well 
represented on the SNP genotyping microarrays. We expe-
rienced difficulties with insufficient marker information 
over this region that limited our ability to refine the FAME2 
critical region further.
Considering genes within the FAME1, FAME2, FAME3, 
and FAME4 critical regions, we identified several candidate 
genes using an in silico gene prioritization method utiliz-
ing brain gene expression data, under the assumption that 
the causal genes in the four loci are likely to be part of the 
same pathway. This is a reasonable assumption given that 
the FAME1, FAME2, FAME3, and FAME4 families show 
a distinctively shared phenotype. As opposed to ADRA2B, a 
receptor that regulates neurotransmitter release, prioritized 
candidate genes KCNIP3, HTR3D, and KCNMB3 are ion 
channel receptors that regulate neuron excitability, sug-
gesting a common function of potential disease genes from 
multiple loci. Interestingly, HTR3D regulates neuron excit-
ability in response to serotonin; a neurotransmitter associ-
ated with neurological disorders, including epilepsy (Wada 
et al. 1997). Obvious candidate genes from the FAME1 
and FAME3 loci were not prioritized using this approach, 
suggesting that perhaps, the less-obvious candidate disease 
Guerrini et al.
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Fig. 3  Refinement of the FAME2 critical region over time, drawn 
using Adobe Illustrator CS6. The darker segments mark the bounda-
ries of the reported intervals, and solid horizontal lines through the 
critical regions represent the microsatellite markers in the interval, 
which were included in the analysis. SNPs are not indicated in the 
IBD region derived from the SNP array data due to the large num-
ber of markers (126 SNPs). The double black dashed horizontal lines 
spanning the entire figure indicate the centromere. The base pair 
positions for makers starting with ‘D2’ are from http://rgd.mcw.edu 
(hg19), and the positions of the markers beginning with ‘rs’ are from 
HapMap Phase 3 data using hg19
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genes with unknown functions should be scrutinized more 
deeply for causal variants from these regions.
Our data show that there are multiple founders for each 
of the large families mapped to the FAME2 locus, suggest-
ing that there may be different causal variants in each of 
families. Importantly, these observations reduce the chance 
that FAME2 is due to a common polymorphism that would 
be filtered out by a typical exome analysis. Variant assess-
ment on candidate FAME genes has not included analysis 
of less commonly detected polymorphisms, such as micro-
rearrangements and variants in non-coding regions in many 
families (Guerrini et al. 2001; Saint-Martin et al. 2008; 
Depienne et al. 2010). Our data suggest that the mutations 
causing FAME may implicate genes that have previously 
not been considered and may require the detection of non-
coding variants or unusual mutations that are difficult to 
identify with current short-read-based sequencing methods, 
such as simple repeat expansions.
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Supplementary Table 1 Study design underlying the four large microarray gene 
expression datasets. PCW stands for post conception weeks 
 










(24 years, 57 years) Agilent 64K 
(custom array) 
10 3,546 20,000 




134 1,222 17,500 
Kang et al (4 PCW, 82 years) Affymetrix 
Human 
Exon 1.0 ST 
57 1,329 17,500 
Colantuoni et 
al 
(14 PCW, 80 years) Illumina 
(custom array) 
266 266 20,000 
Hernandez et 
al 
(0.6 years, 102 years) Illumina 
HumanHT-12 
V3.0 
397 908 18,000 
 
 
Supplementary Table 2 List of 421 known epilepsy genes used in gene prioritization  
ABCB1, ABCC1, ABCC2, ABCC5, ABCG2, ACMSD, ACOT7, ADAM22, ADIPOQ, ADK, ADORA1, ADSL, 
ALB, ALDH5A1, ALDH7A1, ALG13, ALPL, ALX4, ANXA7, AP3M2, AP4E1, APLN, APOE, APP, AQP1, 
AQP4, ARF6, ARFGEF2, ARHGAP11B, ARHGEF9, ARPC2, ARX, ASAH1, ATF3, ATN1, ATP1A2, 
ATP1A3, ATP6V0C, ATXN10, BCKDHA, BCS1L, BDNF, BRD2, C10orf2, C3, CACNA1A, CACNA1E, 
CACNA1G, CACNA1H, CACNB4, CACNG3, CALB2, CALHM1, CAPN1, CASP2, CASP3, CASR, CCL2, 
CCL4, CCM2, CCR5, CD40, CD40LG, CDKL5, CHD2, CHL1, CHRFAM7A, CHRNA2, CHRNA4, 
CHRNA7, CHRNB2, CLCN2, CLN3, CLN5, CLN6, CLN8, CNKSR2, CNN3, CNTN2, CNTNAP2, COL4A1, 
COL6A2, COX10, COX15, CPA6, CRH, CRMP1, CSMD3, CST3, CSTB, CTSD, CTSF, CXCL8, CYP2C19, 
CYP2C9, CYP3A4, CYP3A5, D2HGDH, DAPK1, DARS2, DBH, DBP, DCX, DEPDC5, DFFB, DLG2, 
DNAJC5, DNAJC6, DNM1, DNMT1, DNMT3A, DPYSL2, DSCAM, DTNBP1, DYRK1A, EFHC1, EFHC2, 
EGFR, EGR1, EHMT1, EIF2S1, ELP4, EMP1, EMX2, ENO2, EPHX1, EPM2A, EPM2AIP1, ERMN, 
ERN1, FAM3C, FGFR3, FLNA, FOXG1, FOXRED1, GABARAP, GABBR1, GABBR2, GABRA1, GABRA6, 
GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG2, GABRR2, GAD1, GAD2, GBA, GFAP, GHRL, 
GJD2, GLI3, GLUD1, GLUL, GNAO1, GNB3, GOSR2, GPHN, GPR56, GRIA1, GRIA2, GRIA3, GRIK1, 
GRIN1, GRIN2A, GRIN2B, GRM1, GRM5, GRN, GSN, GSTA4, GSTP1, HCN1, HCN2, HCN3, HCN4, 
HCRT, HDAC2, HEPACAM, HIP1, HLA-B, HLA-DQA1, HLA-DQB1, HNRNPU, HP, HSPA8, HSPB1, 
HSPBAP1, HTR1A, HTR7, IDH1, IER3IP1, IGF1, IL1A, IL1B, IL1RN, IL4, IL6, INSR, ITGA2, JRK, 
KCNA1, KCNA2, KCNAB1, KCNB1, KCNC1, KCND1, KCND2, KCNH2, KCNJ10, KCNJ11, KCNJ3, 
KCNK3, KCNK9, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNQ1, KCNQ2, KCNQ3, 
KCNT1, KCNV2, KCTD7, KIF5A, KL, KRIT1, L2HGDH, LAMB1, LAMC3, LEPR, LGI1, LGI2, LGI4, 
LIAS, MAP2, MAPT, MBD5, MC3R, MDM2, ME2, MECP2, MED1, MEF2C, MFSD8, MICAL1, MLC1, 
MMP9, MRI1, MSX2, MT2A, MTHFR, MTOR, MVP, NCAM1, NDUFA1, NDUFA10, NDUFA12, 
NDUFA2, NDUFA9, NDUFAF2, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NEDD4L, NFKB1, NHLRC1, 
NIPA1, NIPA2, NOS1, NPPB, NR1I2, NRG1, NTNG1, NTNG2, NUCB2, OLIG2, OPRM1, OTX1, P2RY1, 
P2RY2, P2RY4, PAFAH1B1, PANX1, PANX2, PCDH19, PDXK, PDYN, PGF, PHF6, PHLDA1, PHOX2A, 
PHOX2B, PLAUR, PLCB1, PNKP, PNOC, PNPO, POLG, PPFIA1, PPP1R3D, PPT1, PRICKLE1, 
PRICKLE2, PRNP, PRODH, PROM1, PRRT2, PSEN1, PTGS2, PTPRD, QARS, QPRT, RALBP1, 
RASGRF1, RBFOX1, RBFOX3, RCN2, RELN, REST, RHOA, RNF115, RORA, RTN4, S100B, SAA1, 
SCARB2, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN5A, SCN8A, SCN9A, SDHA, SERPINI1, 
SEZ6, SGK1, SHH, SLC12A5, SLC13A5, SLC16A1, SLC16A7, SLC18A2, SLC1A1, SLC1A2, SLC1A3, 
SLC25A22, SLC2A1, SLC35A2, SLC35A3, SLC6A3, SLC6A4, SLC6A8, SLIT2, SNAP25, SNIP1, SNX25, 
SOD1, SOD2, SPTAN1, SRPX2, SSTR2, ST3GAL3, ST3GAL5, STAMBP, STIM1, STIM2, STMN1, 
STRADA, STX1A, STX1B, STXBP1, SUCLA2, SURF1, SV2A, SYN1, SYN2, SYNGAP1, SYT1, SYT11, SZT2, 
TACR1, TAP1, TBC1D24, TK2, TLN2, TLR4, TNF, TNK2, TP53, TPP1, TRAPPC10, TRMT44, TRPC4, 
TRPM2, TRPV1, TSC1, TSC2, TSEN2, TSEN34, TSEN54, TSPEAR, TSPO, TUBA1A, UBA1, UBC, UBE3A, 
UCP2, UGT1A4, VAMP2, VDR, WASL, WNT8B, WWOX 
 
Supplementary Table 3 Parameter estimates for all pairs of individuals. Individual 1 from 
family 1 is denoted ‘F1_1’. The meiosis estimates the total number of meiosis separating 
the pair. Meiosis of 14 corresponds to unrelated individuals. The last 3 columns are the 
probability of sharing 0, 1 and 2 alleles IBD respectively. All parameter estimates were 
calculated using formula in Purcell et al. (2007) 
 
Individual 1 Individual 2 Meiosis Pr(IBD=0) Pr(IBD=1) Pr(IBD=2) 
F1_1 F1_2 2.01 0.001 0.996 0.003 
F1_1 F3_1 8.16 0.993 0.007 0 
F1_1 F3_2 14 1 0 0 
F1_2 F3_1 14 1 0 0 
F1_2 F3_2 14 1 0 0 
F1_1 F4_1 14 1 0 0 
F1_1 F4_2 14 1 0 0 
F1_2 F4_1 14 1 0 0 
F1_2 F4_2 14 1 0 0 
F1_1 F5_1 6.8 0.982 0.018 0 
F1_1 F5_2 14 1 0 0 
F1_2 F5_1 14 1 0 0 
F1_2 F5_2 14 1 0 0 
F1_1 F6_1 14 1 0 0 
F1_1 F6_2 14 1 0 0 
F1_2 F6_1 14 1 0 0 
F1_2 F6_2 14 1 0 0 
F1_1 F8_1 14 1 0 0 
F1_1 F8_2 14 1 0 0 
F1_2 F8_1 14 1 0 0 
F1_2 F8_2 14 1 0 0 
F1_1 F9_1 14 1 0 0 
F1_1 F9_2 14 1 0 0 
F1_2 F9_1 14 1 0 0 
F1_2 F9_2 14 1 0 0 
F1_1 F10_1 6.97 0.984 0.016 0 
F1_1 F10_2 14 1 0 0 
F1_2 F10_1 7.38 0.988 0.012 0 
F1_2 F10_2 14 1 0 0 
F1_1 F11_1 14 1 0 0 
F1_1 F11_2 14 1 0 0 
F1_2 F11_1 14 1 0 0 
F1_2 F11_2 14 1 0 0 
F2_1 F1_1 14 1 0 0 
F2_1 F1_2 14 1 0 0 
F2_2 F1_1 14 1 0 0 
F2_2 F1_2 14 1 0 0 
F2_1 F2_2 14 1 0 0 
F2_1 F3_1 14 1 0 0 
F2_1 F3_2 14 1 0 0 
F2_2 F3_1 14 1 0 0 
F2_2 F3_2 14 1 0 0 
F2_1 F4_1 14 1 0 0 
F2_1 F4_2 14 1 0 0 
F2_2 F4_1 14 1 0 0 
F2_2 F4_2 14 1 0 0 
F2_1 F5_1 14 1 0 0 
F2_1 F5_2 14 1 0 0 
F2_2 F5_1 7.64 0.99 0.01 0 
F2_2 F5_2 14 1 0 0 
F2_1 F6_1 14 1 0 0 
F2_1 F6_2 14 1 0 0 
F2_2 F6_1 14 1 0 0 
F2_2 F6_2 14 1 0 0 
F2_1 F7_1 14 1 0 0 
F2_1 F7_2 14 1 0 0 
F2_2 F7_1 14 1 0 0 
F2_2 F7_2 14 1 0 0 
F2_1 F8_1 14 1 0 0 
F2_1 F8_2 14 1 0 0 
F2_2 F8_1 14 1 0 0 
F2_2 F8_2 14 1 0 0 
F2_1 F9_1 14 1 0 0 
F2_1 F9_2 14 1 0 0 
F2_2 F9_1 14 1 0 0 
F2_2 F9_2 14 1 0 0 
F2_1 F10_1 14 1 0 0 
F2_1 F10_2 14 1 0 0 
F2_2 F10_1 14 1 0 0 
F2_2 F10_2 14 1 0 0 
F2_1 F11_1 14 1 0 0 
F2_1 F11_2 14 1 0 0 
F2_2 F11_1 14 1 0 0 
F2_2 F11_2 14 1 0 0 
F3_1 F3_2 2.01 0.001 0.996 0.004 
F3_1 F4_1 14 1 0 0 
F3_1 F4_2 6.88 0.983 0.017 0 
F3_2 F4_1 7.06 0.985 0.015 0 
F3_2 F4_2 6.88 0.983 0.017 0 
F3_1 F5_1 7.27 0.987 0.013 0 
F3_1 F5_2 14 1 0 0 
F3_2 F5_1 14 1 0 0 
F3_2 F5_2 14 1 0 0 
F3_1 F6_1 8.97 0.996 0.004 0 
F3_1 F6_2 14 1 0 0 
F3_2 F6_1 14 1 0 0 
F3_2 F6_2 14 1 0 0 
F3_1 F8_1 14 1 0 0 
F3_1 F8_2 14 1 0 0 
F3_2 F8_1 14 1 0 0 
F3_2 F8_2 14 1 0 0 
F3_1 F9_1 14 1 0 0 
F3_1 F9_2 14 1 0 0 
F3_2 F9_1 14 1 0 0 
F3_2 F9_2 14 1 0 0 
F3_1 F10_1 9.97 0.998 0.002 0 
F3_1 F10_2 8.38 0.994 0.006 0 
F3_2 F10_1 14 1 0 0 
F3_2 F10_2 14 1 0 0 
F3_1 F11_1 14 1 0 0 
F3_1 F11_2 14 1 0 0 
F3_2 F11_1 14 1 0 0 
F3_2 F11_2 14 1 0 0 
F4_1 F4_2 4.92 0.863 0.132 0.005 
F4_1 F5_1 14 1 0 0 
F4_1 F5_2 14 1 0 0 
F4_2 F5_1 7.27 0.987 0.013 0 
F4_2 F5_2 14 1 0 0 
F4_1 F6_1 14 1 0 0 
F4_1 F6_2 14 1 0 0 
F4_2 F6_1 14 1 0 0 
F4_2 F6_2 14 1 0 0 
F4_1 F8_1 14 1 0 0 
F4_1 F8_2 14 1 0 0 
F4_2 F8_1 14 1 0 0 
F4_2 F8_2 14 1 0 0 
F4_1 F9_1 14 1 0 0 
F4_1 F9_2 14 1 0 0 
F4_2 F9_1 14 1 0 0 
F4_2 F9_2 14 1 0 0 
F4_1 F10_1 6.8 0.982 0.018 0 
F4_1 F10_2 14 1 0 0 
F4_2 F10_1 14 1 0 0 
F4_2 F10_2 14 1 0 0 
F4_1 F11_1 14 1 0 0 
F4_1 F11_2 14 1 0 0 
F4_2 F11_1 14 1 0 0 
F4_2 F11_2 14 1 0 0 
F5_1 F5_2 3.07 0.524 0.475 0.001 
F5_1 F6_1 14 1 0 0 
F5_1 F6_2 8.97 0.996 0.004 0 
F5_2 F6_1 14 1 0 0 
F5_2 F6_2 7.97 0.992 0.008 0 
F5_1 F8_1 14 1 0 0 
F5_1 F8_2 7.8 0.991 0.009 0 
F5_2 F8_1 14 1 0 0 
F5_2 F8_2 14 1 0 0 
F5_1 F9_1 14 1 0 0 
F5_1 F9_2 8.16 0.993 0.007 0 
F5_2 F9_1 14 1 0 0 
F5_2 F9_2 14 1 0 0 
F5_1 F10_1 6.51 0.978 0.022 0 
F5_1 F10_2 14 1 0 0 
F5_2 F10_1 14 1 0 0 
F5_2 F10_2 14 1 0 0 
F5_1 F11_1 14 1 0 0 
F5_1 F11_2 14 1 0 0 
F5_2 F11_1 14 1 0 0 
F5_2 F11_2 14 1 0 0 
F6_1 F6_2 4.59 0.832 0.166 0.002 
F6_1 F9_1 14 1 0 0 
F6_1 F9_2 14 1 0 0 
F6_2 F9_1 14 1 0 0 
F6_2 F9_2 14 1 0 0 
F6_1 F10_1 8.64 0.995 0.005 0 
F6_1 F10_2 14 1 0 0 
F6_2 F10_1 6.64 0.98 0.02 0 
F6_2 F10_2 14 1 0 0 
F6_1 F11_1 14 1 0 0 
F6_1 F11_2 14 1 0 0 
F6_2 F11_1 14 1 0 0 
F6_2 F11_2 14 1 0 0 
F7_1 F1_1 14 1 0 0 
F7_1 F1_2 14 1 0 0 
F7_2 F1_1 14 1 0 0 
F7_2 F1_2 14 1 0 0 
F7_1 F3_1 14 1 0 0 
F7_1 F3_2 14 1 0 0 
F7_2 F3_1 14 1 0 0 
F7_2 F3_2 14 1 0 0 
F7_1 F4_1 14 1 0 0 
F7_1 F4_2 14 1 0 0 
F7_2 F4_1 14 1 0 0 
F7_2 F4_2 14 1 0 0 
F7_1 F5_1 14 1 0 0 
F7_1 F5_2 14 1 0 0 
F7_2 F5_1 14 1 0 0 
F7_2 F5_2 14 1 0 0 
F7_1 F6_1 14 1 0 0 
F7_1 F6_2 14 1 0 0 
F7_2 F6_1 14 1 0 0 
F7_2 F6_2 8.38 0.994 0.006 0 
F7_1 F7_2 5.01 0.938 0.062 0 
F7_1 F8_1 9.38 0.997 0.003 0 
F7_1 F8_2 6.88 0.983 0.017 0 
F7_2 F8_1 14 1 0 0 
F7_2 F8_2 7.97 0.992 0.008 0 
F7_1 F9_1 14 1 0 0 
F7_1 F9_2 14 1 0 0 
F7_2 F9_1 7.64 0.99 0.01 0 
F7_2 F9_2 14 1 0 0 
F7_1 F10_1 6.01 0.969 0.031 0 
F7_1 F10_2 14 1 0 0 
F7_2 F10_1 14 1 0 0 
F7_2 F10_2 14 1 0 0 
F7_1 F11_1 14 1 0 0 
F7_1 F11_2 14 1 0 0 
F7_2 F11_1 14 1 0 0 
F7_2 F11_2 14 1 0 0 
F8_1 F6_1 14 1 0 0 
F8_1 F6_2 14 1 0 0 
F8_2 F6_1 14 1 0 0 
F8_2 F6_2 14 1 0 0 
F8_1 F8_2 5.52 0.911 0.087 0.002 
F8_1 F9_1 14 1 0 0 
F8_1 F9_2 14 1 0 0 
F8_2 F9_1 14 1 0 0 
F8_2 F9_2 14 1 0 0 
F8_1 F10_1 5.72 0.962 0.038 0 
F8_1 F10_2 14 1 0 0 
F8_2 F10_1 6.57 0.979 0.021 0 
F8_2 F10_2 14 1 0 0 
F8_1 F11_1 14 1 0 0 
F8_1 F11_2 14 1 0 0 
F8_2 F11_1 14 1 0 0 
F8_2 F11_2 14 1 0 0 
F9_1 F9_2 1 0 1 0 
F9_1 F10_1 7.51 0.989 0.011 0 
F9_1 F10_2 14 1 0 0 
F9_2 F10_1 6.88 0.983 0.017 0 
F9_2 F10_2 6.8 0.982 0.018 0 
F9_1 F11_1 8.16 0.993 0.007 0 
F9_1 F11_2 14 1 0 0 
F9_2 F11_1 7.16 0.986 0.014 0 
F9_2 F11_2 14 1 0 0 
F10_1 F10_2 3.32 0.8 0.2 0 
F10_1 F11_1 14 1 0 0 
F10_1 F11_2 14 1 0 0 
F10_2 F11_1 14 1 0 0 
F10_2 F11_2 14 1 0 0 







Supplementary Table 4 Description of IBD tracts inferred over the FAME2 critical region. All genetic map positions are from hg19 
 



















F1_1 F1_2 2 72184 243020723 15453 242948539 268.8 1 rs300758 rs4973686 
F2_1 F2_2 2 85952162 102205736 538 16253574 7.45 1 rs4832005 rs7603851 
F2_1 F3_1 2 85952162 100615241 394 14663079 6.22 1 rs4832005 rs17437101 
F2_1 F3_2 2 85995648 100403354 377 14407706 5.92 1 rs4832198 rs2115601 
F2_2 F3_1 2 84905096 100679024 494 15773928 7.41 1 rs11126974 rs11681737 
F2_2 F3_2 2 84921433 100665673 491 15744240 7.39 1 rs1192295 rs2028137 
F2_1 F4_1 2 85995648 101337982 438 15342334 6.43 1 rs4832198 rs11123842 
F2_1 F4_2 2 85976645 100421767 382 14445122 6.07 1 rs1465823 rs1568786 
F2_2 F4_1 2 78968942 100474071 825 21505129 12.37 1 rs4853406 rs17023232 
F2_2 F4_2 2 79225690 100403354 803 21177664 11.85 1 rs402221 rs2115601 
F2_1 F5_1 2 85976645 104498739 660 18522094 9.02 1 rs1465823 rs6717408 
F2_1 F5_2 2 87852863 103950575 564 16097712 7.62 1 rs10180746 rs10191917 
F2_2 F5_1 2 85654299 102421978 581 16767679 7.9 1 rs1877954 rs6732726 
F2_2 F5_2 2 89052026 102604649 398 13552623 4.09 1 rs335124 rs12467316 
F3_1 F3_2 2 72184 243020723 15453 242948539 268.8 1 rs300758 rs4973686 
F3_1 F4_1 2 84905096 106053343 856 21148247 12.04 1 rs11126974 rs7583367 
F3_1 F4_2 2 84800898 106045613 860 21244715 12 1 rs13002679 rs7594621 
F3_2 F4_1 2 84921433 106053343 855 21131910 12.03 1 rs1192295 rs7583367 
F3_2 F4_2 2 84921433 106053343 855 21131910 12.03 1 rs1192295 rs7583367 
F3_1 F5_1 2 85731858 101343140 462 15611282 6.94 1 rs6750610 rs2137671 
F3_1 F5_2 2 86627316 100615241 336 13987925 5.66 1 rs1105865 rs17437101 
F3_2 F5_1 2 85628983 100403354 410 14774371 6.41 1 rs2229668 rs2115601 
F3_2 F5_2 2 86843488 100403354 314 13559866 5.5 1 rs308903 rs2115601 
F4_1 F4_2 2 36879521 106511846 4478 69632325 63.25 1 rs10167726 rs933793 
F4_1 F5_1 2 85731858 101378095 467 15646237 6.96 1 rs6750610 rs6740105 
F4_1 F5_2 2 86364353 101337982 407 14973629 6.15 1 rs2241434 rs11123842 
F4_2 F5_1 2 85731858 100232743 387 14500885 6.25 1 rs6750610 rs12616127 
F4_2 F5_2 2 87852863 100421767 301 12568904 4.89 1 rs10180746 rs1568786 
F5_1 F5_2 2 88295232 189122229 5495 100826997 83.63 1 rs1441649 rs7582137 
F6_1 F6_2 2 75390741 101480885 1131 26090144 17.23 1 rs17010840 rs2043534 
F7_1 F7_2 2 86013029 101318308 432 15305279 6.39 1 rs13386681 rs2942883 
F8_1 F8_2 2 56029444 139104124 4638 83074680 74.04 1 rs6712017 rs4550720 




2 2 72184 151622783 9819 151550599 167.9 1 rs300758 rs1519756 
 
 
Supplementary Table 5 Description of IBD tracts inferred over the FAME3 critical region. All genetic map positions are from hg19 
 
 



















F1_1 F1_2 5 38139 180682862 11879 180644723 204.04 1 rs10076494 rs2545093 
F3_1 F3_2 5 38139 180682862 11879 180644723 204.04 1 rs10076494 rs2545093 
F4_1 F4_2 5 10585111 16741099 479 6155988 7.44 1 rs7712927 rs10051930 
F8_1 F8_2 5 5110692 18362647 1223 13251955 22.26 1 rs814790 rs2950483 








2 5 38139 180682862 11879 180644723 204.04 1 rs10076494 rs2545093 
Supplementary Table 6 RefSeq genes overlapping the FAME1, FAME2, FAME3 and 
FAME4 critical regions. Genes coloured red were found in at least one gene-expression 
dataset 
FAME1 genes FAME2 genes FAME3 genes FAME4 genes 
AARD ACTR1B ADCY2 ABCC5 
ANXA13 ACTR3BP2 ANKH ABCC5-AS1 
ATAD2 ADRA2B ANKRD33B ABCF3 
C8orf76 ANKRD20A8P BASP1 ACTL6A 
COL14A1 ANKRD23 C5orf49 ADIPOQ 
COLEC10 ANKRD36 CCT5 ADIPOQ-AS1 
DEPTOR ANKRD36B CMBL AHSG 
DERL1 ANKRD39 CTD-2201E9.1 ALG3 
DSCC1 ARID5A CTD-2350J17.1 AP2M1 
EIF3H ASTL CTNND2 ATP11B 
ENPP2 CIAO1 DAP B3GNT5 
EXT1 CNNM3 DNAH5 BCL6 
FAM83A CNNM4 FAM105A C3orf70 
FAM83A-AS1 COX5B FAM134B CCDC39 
FBXO32 DUSP2 FAM173B CCDC50 
HAS2 FAHD2A FASTKD3 CHRD 
HAS2-AS1 FAHD2B FBXL7 CLCN2 
KLHL38 FAHD2CP FLJ33360 CLDN1 
LINC01151 FAM178B LINC01018 CLDN16 
LOC101927543 FAM95A LINC01194 CRYGS 
LOC105375734 FER1L5 LOC100120744 DCUN1D1 
MAL2 GGT8P LOC100505625 DGKG 
MED30 GPAT2 LOC101929284 DNAJB11 
MIR3610 ITPRIPL1 LOC101929412 DNAJC19 
MIR4663 KANSL3 LOC101929454 DVL3 
MRPL13 KCNIP3 LOC101929505 ECE2 
MTBP LINC00342 LOC101929524 EHHADH 
NOV LINC01125 LOC285692 EHHADH-AS1 
RAD21 LMAN2L LOC285696 EIF2B5 
RAD21-AS1 LOC100506076 LOC401177 EIF2B5-AS1 
SAMD12 LOC100506123 LOC442132 EIF4A2 
SAMD12-AS1 LOC10192703 LOC729506 EIF4G1 
SLC30A8 LOC442028 MARCH6 EPHB3 
SNTB1 LOC654342 MARCH11 ETV5 
TAF2 MAL MED10 FAM131A 
TBC1D31 MIR3127 MIR4278 FETUB 
TNFRSF11B MRPS5 MIR4454 FGF12 
UTP23 NCAPH MIR4454 FGF12-AS1 
WDYHV1 NEURL3 MIR4458 FLJ42393 
ZHX1 PROM2 MIR4636 FLJ46066 
ZHX1-C8orf76 SEMA4C MIR4637 FXR1 
ZHX2 SNRNP200 MIR6131 GMNC 
 STARD7 MIR887 GNB4 
 STARD7-AS1 MTRR HRG 
 TEKT4 MYO10 HTR3D 
 TMEM127 NSUN2 HTR3E 
 TMEM131 OTULIN HTR3E-AS1 
 TRIM43 PAPD7 IDF2BP2-AS1 
 TRIM43B ROPN1L IGF2BP2 
 VWA3B ROPN1L-AS1 IL1RAP 
 ZAP70 SEMA5A KCCAT211 
 ZNF2 SNHG18 KCNMB2 
 ZNF514 SNORD123 KCNMB2-AS1 
  SRD5A1 KCNMB3 
  TAS2R1 KLHL24 
  TRIO KLHL6 
  UBE2QL1 KLHL6-AS1 
  ZNF622 KNG1 
   LAMP3 
   LINC00501 
   LINC00578 
   LINC00888 
   LINC01014 
   LINC01206 
   LINC01208 
   LINC01209 
   LINCR-002 
   LIPH 
   LOC100131635 
   LOC100505609 
   LOC101928739 
   LOC101928882 
   LOC101928992 
   LOC101929106 
   LOC102724604 
   LOC102724699 
   LOC105374244 
   LOC105374250 
   LOC105374266 
   LOC253573 
   LOC344887 
   LPP 
   LPP-AS1 
   LPP-AS2 
   MAGEF1 
   MAP3K13 
   MAP6D1 
   MCCC1 
   MCF2L2 
   MFN1 
   MIR1224 
   MIR1248 
   MIR28 
   MIR4448 
   MIR548AQ 
   MIR5588 
   MIR7977 
   MIR944 
   MRPL47 
   NDVFB5 
   OSTN 
   OSTN-AS1 
   P3H2 
   P3H2-AS1 
   PARL 
   PEX5L 
   PEX5L-AS2 
   PIK3CA 
   POLR2H 
   PSMD2 
   PYDC2 
   RFC4 
   RNU6-1 
   RNU6-2 
   RNU6-7 
   RNU6-8 
   RNU6-9 
   RPL39L 
   RTP2 
   RTP4 
   SENP2 
   SNAR-I 
   SNORA4 
   SNORA63 
   SNORA81 
   SNORD2 
   SNORD66 
   SOX2 
   SOX2-OT 
   SST 
   ST6GAL1 
   TBCCD1 
   TBL1XR1 
   THPO 
   TMEM207 
   TMEM41A 
   TP63 
   TPRG1 
   TPRG1-AS1 
   TPRG1-AS2 
   TRA2B 
   TTC14 
   USP13 
   UTS2B 
   VPS8 
   VWA5B2 
   YEATS2 
   ZMAT3 
   ZNF639 
 
 
Supplementary Table 7 Gene prioritization results for the FAME1, FAME2, FAME3 
and FAME4 loci; ordered by the sum of the page rank  
FAME1 genes FAME2 genes FAME3 genes FAME4 genes Combined Page Rank 
AARD GPAT2 ANKRD33B HTR3D 0.013296541 
KLHL38 TRIM43B TAS2R1 TP63 0.009211528 
KLHL38 TRIM43B TAS2R1 KLHL6 0.009104841 
KLHL38 TRIM43B TAS2R1 HRG 0.009034682 
KLHL38 TRIM43B TAS2R1 KCNMB3 0.008910074 
KLHL38 TRIM43B TAS2R1 EHHADH 0.008910074 
KLHL38 TRIM43B TAS2R1 FETUB 0.00890013 
KLHL38 TRIM43B TAS2R1 TBCCD1 0.008708937 
AARD ASTL ANKRD33B HTR3D 0.008231326 
KLHL38 NCAPH TAS2R1 TP63 0.007722105 
KLHL38 NCAPH TAS2R1 FETUB 0.007617178 
KLHL38 NCAPH TAS2R1 KLHL6 0.007601198 
KLHL38 NCAPH TAS2R1 HRG 0.007509636 
KLHL38 NCAPH TAS2R1 KCNMB3 0.007391684 
KLHL38 NCAPH TAS2R1 EHHADH 0.007391684 
KLHL38 ADRA2B TAS2R1 TP63 0.007302448 
AARD GGT8P ANKRD33B HTR3D 0.007220685 
KLHL38 ADRA2B TAS2R1 FETUB 0.00719668 
KLHL38 ADRA2B TAS2R1 KLHL6 0.007180214 
KLHL38 ADRA2B TAS2R1 HRG 0.007088137 
KLHL38 TRIM43 TAS2R1 TP63 0.007002472 
FAM83A TRIM43B TAS2R1 TP63 0.006991272 
KLHL38 ADRA2B TAS2R1 KCNMB3 0.006968735 
KLHL38 ADRA2B TAS2R1 EHHADH 0.006968735 
KLHL38 TRIM43 TAS2R1 FETUB 0.006891715 
KLHL38 TRIM43 TAS2R1 KLHL6 0.006875687 
FAM83A TRIM43B TAS2R1 KLHL6 0.006868785 
KLHL38 TRIM43 TAS2R1 HRG 0.006777664 
FAM83A TRIM43B TAS2R1 HRG 0.006776381 
COLEC10 TRIM43B TAS2R1 TP63 0.006746034 
FAM83A TRIM43B TAS2R1 KCNMB3 0.006658786 
FAM83A TRIM43B TAS2R1 EHHADH 0.006658786 
FAM83A TRIM43B TAS2R1 TBCCD1 0.006658786 
KLHL38 TRIM43 TAS2R1 KCNMB3 0.006652532 
KLHL38 TRIM43 TAS2R1 EHHADH 0.006652532 
SLC30A8 TRIM43B TAS2R1 TP63 0.006643974 
COLEC10 TRIM43B TAS2R1 KLHL6 0.006620877 
COLEC10 TRIM43B TAS2R1 HRG 0.006526535 
ANXA13 TRIM43B TAS2R1 TP63 0.006526535 
SLC30A8 TRIM43B TAS2R1 KLHL6 0.006517515 
SLC30A8 TRIM43B TAS2R1 HRG 0.006418317 
COLEC10 TRIM43B TAS2R1 KCNMB3 0.006403794 
COLEC10 TRIM43B TAS2R1 EHHADH 0.006403794 
COLEC10 TRIM43B TAS2R1 TBCCD1 0.006403794 
HAS2 TRIM43B TAS2R1 TP63 0.006403794 
ANXA13 TRIM43B TAS2R1 KLHL6 0.006398553 
ANXA13 TRIM43B TAS2R1 HRG 0.006298893 
SLC30A8 TRIM43B TAS2R1 KCNMB3 0.006294698 
SLC30A8 TRIM43B TAS2R1 EHHADH 0.006294698 
SLC30A8 TRIM43B TAS2R1 TBCCD1 0.006294698 
HAS2 TRIM43B TAS2R1 KLHL6 0.006272579 
EXT1 KCNIP3 LOC285696 FGF12 0.006216727 
ANXA13 TRIM43B TAS2R1 KCNMB3 0.00617169 
ANXA13 TRIM43B TAS2R1 EHHADH 0.00617169 
ANXA13 TRIM43B TAS2R1 TBCCD1 0.00617169 
HAS2 TRIM43B TAS2R1 HRG 0.00617169 
HAS2 TRIM43B TAS2R1 KCNMB3 0.006047487 
HAS2 TRIM43B TAS2R1 EHHADH 0.006047487 
HAS2 TRIM43B TAS2R1 TBCCD1 0.006047487 
EXT1 KCNIP3 LOC285696 KCNMB2 0.005595839 








4.3.1 Selecting best matched HapMap population
We implemented a goodness-of fit test that compared the genotypes for the FAME cohort
to the expected genotypes from selected populations (e.g. Caucasians (CEU), Chinese
(CHB), Tuscans (TSI) etc.) in order to get the best matched population allele frequencies
for our analysis using the popHetTest from LINKDATAGEN74,77. We used the HapMap
Phase 3 frequency data from Human Genome version 19 (hg19), which contains allele
frequencies for all 11 HapMap populations73. Sixteen individuals best matched the TSI
population while the remaining six best matched the CEU population. The population
allele frequencies are very similar between the TSI and CEU populations so we chose the
TSI allele frequencies as representative of all individuals in our analysis. LINKDATAGEN
was then used to generate FAME genotypes from HapMap SNPs to be used in the IBD
analysis.
4.3.2 Gene prioritization data cleaning
In a first pre-processing step we removed arrays that were obvious outliers. Secondly,
we applied adaptive removal of unwanted variation to each dataset individually using the
Bioconductor-package RUVcorr78. Note that we applied RUV with housekeeping genes as
our negative controls (excluding housekeeping genes that were also implicated in epilepsy
or potential candidates). Thirdly, all datasets were scaled and centered before combining
them into a large dataset.
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Chapter 5
An introduction to malaria
5.1 Background
Malaria is an infectious disease that is responsible for an estimated 500,000 deaths and
more than 200 million clinical cases, annually79. Approximately half of the population live
in regions with malaria transmission, predominantly in developing countries in sub-tropical
regions of the world (Figure 5.1A)79. Malaria is caused by the parasite Plasmodium, which
is transmitted to humans through the bite of an infected female Anopheles mosquito.
There are 6 species of Plasmodium that infect humans, with the most common being
P. falciparum and P. vivax 80. The species P. falciparum is dominant in Sub-Saharan
Africa (Figure 5.1B) and is responsible for nearly all malaria deaths with more than 70%
occurring in children under the age of 579. This translates to the death of one child every
two minutes. While P. falciparum is by far the deadliest Plasmodium species that infects
humans, P. vivax, which is most common outside of Africa (Figure 5.1C), causes the most
morbidity as this species can lie dormant in the human host for undefined periods of time
and result in relapse infections79.
Due to the burden of this disease much work has been done to control malaria and
a strategy has been implemented to reduce malaria incidence and mortality rates by at
least 90% from 2016 to 203081. However, control efforts have been hampered by the
emergence of antimalarial drug resistance, which threatens to undo much of the progress
made to-date79,82. As such, identifying the genomic mechanisms underlying antimalarial
drug resistance is crucial.
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A Malaria cases per 100,000
B P.falciparum vector proportion











Malaria cases per 100,000 head of population
Proportion of P. falci arum cases
Proportion of P. vivax cases
Figure 5.1: The burden of malaria across the globe. Countries colored in light-grey do not have
malaria transmission. Data was sourced from http://www.who.int/malaria/publications/country-
profiles/en/ for the year 2016 and plotted in R using the package rworldmap. A The number of
reported confirmed cases of malaria, per 100,000 individuals in the population. B The proportion
of confirmed cases of malaria that were P.falciparum infections. C The proportion of confirmed
cases of malaria that were P.vivax infections.
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In order to understand the mechanisms of resistance it is important to identify the genes
that are under selection in response to antimalarial drug use. As discussed in Chapter 1,
IBD analysis can be used to identify loci under positive selection and here we motivate the
need for identifying loci under positive selection in the Plasmodium parasite. We begin
by giving a brief overview of the parasite’s biology and some of the challenges faced when
performing genomic analyses of Plasmodium, followed by an introduction to antimalarial
drug resistance and statistical methods for identifying selection signatures. While both P.
falciparum and P. vivax are burdensome in their own right, we focus on P. falciparum for
the remainder of this thesis.
5.1.1 The life cycle of malaria
The malaria life cycle is complicated as it involves two hosts and a number of parasite
morphologies. Furthermore, the ploidy of Plasmodium does not remain constant. Here we
explain a simplified life cycle only touching on the relevant concepts. The following was
summarised from Klein83.
Malaria is transmitted to humans through the bite of an infected female Anopheles
mosquito when the mosquito takes a blood meal (Figure 5.2). During the blood meal,
Plasmodium parasites are released into the human host’s blood stream as haploid sporo-
zoites where they make their way to the liver. Once inside the liver the sporozoites
undergo asexual replication. It is during this stage of an infection where some P. vivax
become dormant and do not asexually replicate until sometime later, possibly months or
years after the initial infection resulting in a relapse infection. Following replication, the
parasites burst out of the liver cells and re-enter the blood stream as merozoites. While
in the blood stream, the merozoites rapidly invade red blood cells. Most merozoites will
reproduce asexually within the cells then rupture out, destroying the red blood cell, and
will continue to invade and destroy more red blood cells in this manner. This stage of the
infection leads to the clinical symptoms of malaria, which include fever, headaches and
anaemia. Rather than reproducing asexually within the red blood cells, a small number
of merozoites will form male and female gametocytes instead; the sexual forms of the
parasite.
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2. Sporozoites enter liver
and infect hepatocytes
asexual replication
3. Liver cells rupture and
merozoites released
5. Sexual cycle
(merozoites produce gametocytes instead)
1. Transmission to human







6. Transmission to mosquito
(ingests gametocytes via bite)







Figure 5.2: The life cycle of the malaria parasite. This image was sourced from Klein83. The ring,
trophozoite and schizont stages were excluded from our description in the main text for simplicity.
When a mosquito takes a blood meal of a malaria infected individual, it ingests the
gametocytes, which make their way to the mosquito midgut. Within the mosquito midgut
the red blood cells containing the gametocytes disintegrate and the male and female ga-
metocytes are able to fuse together to form diploid zygotes. It is here that sexual repro-
duction takes place, allowing for meiosis and hence recombination between the male and
female gametocytes. Following meiosis, the zygotes traverse the midgut wall and develop
into oocysts. Within an oocyst, sporozoites are formed, which replicate asexually. The
sporozoites then burst from the oocyst and make their way to the salivary glands of the
mosquito where they are ready to be released into the human host during another blood
meal.
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5.1.2 The P. falciparum genome
The genome of P. falciparum comprises 22.9 Mb distributed among 14 haploid? nuclear
chromosomes, in addition to mitochondrial and apicoplast DNA5. The nuclear chromo-
somes range in size from 0.6 Mb to 3.3 Mb, with lengths increasing as chromosome nomen-
clature increases (opposite to the human genome). Unlike other species of Plasmodium, P.
falciparum has an extremely high AT content with a composition of approximately 80%
AT. In contrast, P. vivax has an AT composition more comparable to humans of 55%5.
5.1.3 Challenges of sequencing the malaria genome
Plasmodium can be extracted from a malaria infected individual through a blood sample,
where all Plasmodium obtained from a single blood sample constitute an isolate. The
Plasmodium genome can then be sequenced using NGS technologies, however one challenge
of sequencing the genome is the abundance of human DNA that is also present in the
sample84. Such contamination can greatly reduce the coverage of the Plasmodium genome
sequenced, resulting in poor quality data. This is further exacerbated when there is low
parasitemia (parasites quantity in the blood)84. An alternative source of contamination is
the presence of multiple species of Plasmodium in the isolate85. For example, individuals
living in countries with both P. falciparum and P.vivax transmission, such as Papua New
Guinea and Southeast Asia, may have both species present within an isolate, resulting from
multiple infections. Contamination cannot be avoided when sequencing the Plasmodium
genome, however pre-sequencing techniques are implemented to minimise contamination
from other sources, such as separating white blood cells from red blood cells to reduce the
amount of human DNA in the sample84. Furthermore, aligning the sequences to multiple
reference genomes, including the human genome and multiple species of Plasmodium, can
improve data quality.
Following sequence alignment and data filtering procedures, variant calling is typically
performed. This may appear trivial for high coverage, good quality data, given the haploid
status of the Plasmodium genome. However, this is not always the case as individuals can
be infected with multiple, genetically-distinct strains of the same species of Plasmodium,
giving the appearance of a ploidy > 1 isolate86. The number of strains contributing to an
infection is termed the multiplicity of infection (MOI). An individual infected with a single
strain has MOI = 1 while an individual infected with 3 strains has MOI = 3. Multiple
?Plasmodium becomes diploid briefly while in the mosquito host and is otherwise haploid.
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infections can arise in two ways87;
1. Multiple mosquitos, each carrying a unique strain of Plasmodium, take separate
blood meals of the same individual and transmit their strain.
2. A single mosquito carrying multiple strains of Plasmodium takes a blood meal of
one individuals and transmits multiple strains.
While it is possible for an individual to be infected with many strains of the same
species of Plasmodium in geographical regions with high malaria transmission87, the ability
to sequence all strains contributing to an infection is limited, even in infections with high
parasitemia. Strains are often present at different proportions within an infection87,88
and extracting large quantities of all strains from a single blood sample is simply not
possible. However, as control efforts have intensified in recent years, the number of multiple
infections has decreased, with infections commonly containing either one (MOI = 1) or
two (MOI = 2) strains87 (Figure 5.3). While MOI = 2 isolates can be treated as though
they are diploid, variant callers for diploid genomes typically assume 50:50 representation
of alleles in the mixture, which is not the case if MOI = 2 isolates have strains in different
proportions, potentially resulting in calling errors. As such, care should be taken when
processing Plasmodium data, and stringent filtering criterion may be required to produce
a good quality dataset with confident variant calls.
In addition to the challenges of contamination and MOI, the genome of P. falciparum
contains regions that are challenging to sequence and statistically analyse89. The high AT
content of P. falciparum results in many highly-repetitive regions of the genome5 with
variable coverage and ambiguous alignments89. The genome also contains hypervariable
gene families such as the var, stevor and rif genes. These are predominantly located in
subtelomeric regions of the chromosomes as well as towards centromeres, and undergo ec-
topic recombination (recombination between non-homologous loci)90. As such, the genome
of P. falciparum is highly-polymorphic at these loci and difficult to align to a reference
genome. A blacklist has been created containing problematic regions of the genome, which
includes highly-repetitive and highly-polymorphic regions, as well as telomeres. This con-
stitutes approximately 10% of the genome (2.5 Mb). The remaining genome is referred to
as the core genome89.
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Figure 5.3: The proportion of isolates collected from Thailand between 2001 and 2010 with
multiplicity of infection between 1 and 5, where MOI is denoted here as COI (complexity of
infection). The total number of isolates collected was 1,731 and the image was sourced from
Galinsky et al.87.
5.2 Antimalarial drug resistance
Malaria once inhabited much of world and, with the discovery and development of a
number of antimalarial drugs, has been successfully eradicated from many countries91.
However, there is currently no vaccine for malaria and in the last 60 years’ parasites have
developed resistance to most antimalarial drugs used to treat infections, hampering control
efforts and threatening to undo much of the progress made to date80.
One of the most widely available antimalarial drugs, that is also considered the most
successful antimalarial drug, is chloroquine. Chloroquine was introduced for treatment of
malaria infections in 1946, and made considerable progress with reducing the morbidity
and mortality of the disease92. However, within 10 years of its introduction, P. falciparum
isolates from Cambodia were beginning to have reduced sensitivity to the drug and in 1957
chloroquine resistance was confirmed (Figure 5.4A)92. Specifically, the haplotype CVIET
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at codons 72-76 of Pfcrt, the chloroquine resistance transporter gene, was found to confer
with reduced sensitivity to chloroquine93,94. This haplotype rapidly spread throughout
South and Southeast Asia, and by the 1970s, chloroquine resistance had further spread
from South Asia to Sub Saharan Africa92. While resistance was developing throughout
Southeast Asia, two independent sources of chloroquine resistance emerged in Colombia
and Venezuela, carrying a second haplotype in Pfcrt, SVMNT. Soon after its emergence,
SVMNT had swept throughout much of South America and also spontaneously emerged in
Papua New Guinea93,94. Within 50 year of the introduction of chloroquine, resistance to
the drug was present in almost every country with malaria transmission, and the efficacy
of chloroquine as an antimalarial drug reduced considerably.
In response to the emergences of chloroquine resistance, new antimalarial drugs were
developed, including sulphadoxine and pyimethamine, mefloquine and piperaquine. How-
ever, it was not long before resistance to these drugs also emerged80.
More recently artemisinin was introduced as an antimalarial drug and has been used in
combination with partner drugs, including sulphadoxine and pyimethamine, mefloquine
and piperaquine, for treatment of P. falciparum infections80. Artemisinin combination
therapies (ACT) are recommended as the first-line treatment for malaria infections in
countries with endemic malaria and have been crucial in the recent developments with
reducing the global burden of this disease79. Artemisinin was first introduced in 2002,
however in 2007 resistance was reported in Cambodia95 and has since emerged in 5 coun-
tries in the greater Mekong subregion96 (Figure 5.4B). More than 20 point mutations in
Pfk13, the kelch13 propeller domain, have been associated with artemisinin resistance on
a number of different haplotype backgrounds97. The emergence of artemisinin resistance
has been described as a global health crisis98 and there are growing concerns of resistance
developing in Africa, where more than 90% of malaria deaths occur. Furthermore, it is
feared that Plasmodium may develop resistance to multiple drugs simultaneously, in which
case the partner drug used in combination with artemisinin would be inefficient.
Programs have been developed in an attempt to monitor and control the spread of
artemisinin resistance80, however, if unsuccessful, could have catastrophic consequences
for the progress of malaria elimination efforts.
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A Spread of chloroquine resistance










Figure 5.4: A timeline of the emergence and spread of antimalarial resistance. A The emergence
and spread of chloroquine resistance. Data was sourced from98. B The emergence and spread of
artemisinin resistance. Data was sourced from WHO99.
5.3 Selection of antimalarial drug resistant variants
Chloroquine resistance emerged independently in four geographical locations on two hap-
lotype grounds93,94. The short time interval over which resistance to chloroquine spread
and the increase in resistance-haplotype frequencies is consistent with a hard-selective
sweep. In contrast, the emergence of a great number of artemisinin-resistant variants on
many haplotype backgrounds at low frequencies is consistent with a soft selective sweep97.
In order to advance malaria control and elimination, it is crucial to identify loci like Pfcrt
and Pfk13 that are under positive selection and are associated with antimalarial drug
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resistance.
5.3.1 Methods for identifying selection
There are a number of methods that can identify loci under selection that differ in the
nature of the selection signature they aim to identify, which in turn depends on the time
since the selection pressure began100. When an allele is selected for, it increases in fre-
quency in the population, along with neighbouring alleles, such that the stretch of genome
surrounding the selected allele is relatively homogeneous. As more time passes and the
allele reaches high frequencies, new alleles neighbouring the favoured allele are introduced,
initially at low frequencies as they have only recently appeared101. This type of positive
selection can be readily detected by allele frequency-based methods like Tajima’s D102,
that operate by identifying genomic regions with an abundance of rare alleles, consistent
with more ancient positive selection100. Tajima’s D is ideal for detecting hard sweeps
where the selected allele’s frequency is near fixation, however does not perform well when
selection acts on standing variation or in the case of a soft-selective sweep21,103.
Alternatives to frequency-based methods are LD-based methods. These methods op-
erate by identifying haplotypes that are unusually long relative to their frequency in the
population101. The premise here is that recently selected alleles are situated on long hap-
lotypes as there have not been many recombination events to shorten the haplotypes and
break down LD. A number of LD-based methods initially utilize the extended haplotype
homozygosity (EHH) method, which simply measure the amount of LD-decay around a
core haplotype104. As the distance from the core haplotype increases, EHH decreases.
A core haplotype with an unusually high EHH and population frequency is indicative of
recent positive selection. A popular method that uses EHH is the integrated haplotype
score (iHS)101. iHS compares the decay of EHH between two alleles (the derived allele
and the ancestral allele) at a given locus, by calculating the area under the curve defined
by EHH for each allele. A region with slowly decaying EHH for the derived allele, relative
to the ancestral allele, provides evidence for recent positive selection. Methods that make
use of EHH can readily identify a hard selective sweep, however have reduced power to
identifying selection on standing variation or as a soft selective sweep21,105. This is because
these types of selection are not the result of a single, long haplotype that is common in
the population. Rather, multiple haplotype backgrounds are present as a result of novel
variants increasing haplotype diversity in addition to recurrent variants21.
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An alternative LD-based method is IBD analysis, which identifies loci under positive
selection if an abundance of IBD is detected, relative to other loci in the genome21. Like
other LD-based methods, IBD analysis is ideal for hard selective sweeps, however it also
has high power to detect selection acting on standing variation and as a soft selective
sweep21,105. This is because IBD analysis can take advantage of IBD segments inferred
between different pairs of individuals, reflecting genetically diverse haplotypes, although
genetic signatures may not be as prominent as with hard selective sweeps.
5.3.2 Detecting selection in malaria
Antimalarial drug resistance is a relatively recent occurrence. Therefore, methods for
identifying loci under selection in Plasmodium should be intended for recent selective
pressures. Additionally, methods should be able to determine selection acting on standing
variation as well as hard and soft selective sweeps, as these types of selection have been
found to play a role in antimicrobial resistance97,106,107. Given this criterion, LD-based
methods, such as IBD analysis and iHS, appear to be the most appropriate methods for
this task.
Although IBD analysis has higher power to detect more complicated selective sweeps
than iHS21,105, selection signatures are most commonly identified in malaria using the
iHS methodology108,109,110,111. This is unfortunate as iHS requires phased haplotype data
to determine selection, which is problematic for isolates with MOI > 1, as information
on the number of strains in an infection and the respective proportions that each strain
contributes to the infection must be known. This information is not trivial to extract from
sequencing data and as such, isolates with MOI > 1 are typically excluded from analysis,
which can greatly reduce the power of an analysis86.
Part of the reasoning behind the regular use of iHS as opposed to IBD analysis for
positive selection in Plasmodium is the lack of IBD methodologies for haploid species. In
fact, there have been no reported IBD analyses performed on haploid microorganisms to
identify loci under positive selection. Furthermore, none of the available selection methods
are equipped to handle the added complexities that arise from multiple infections. As such,
the development of an IBD tool that is specifically designed for haploid species that can
accommodate multiple infections would be beneficial for disease elimination and control
efforts of malaria, and other diseases.
In the next chapter I describe how the framework for IBD detection developed in
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Chapter 2 can be modified for plasmodium IBD detection in the presence of MOI ≥ 1,
and describe a new selection statistic that makes use of IBD signals.
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Chapter 6
Detecting selection signals in P.
falciparum using IBD analysis
This chapter has been submitted for publication and is currently under review. The
manuscript is publicly available on BioRxiv112 and has been re-formatted to meet the
requirements of this thesis.
6.0.1 Background
The progress of malaria control and elimination efforts is under threat with the emer-
gence of antimalarial drug resistance79. As discussed in Chapter 5, there is a need for
a methodology that can readily identify positively-selected loci, in the form of multiple
sweeps, that have arisen due to antimalarial drug pressure. Furthermore, a methodology
that is suitable for isolates with multiple infections is desirable to avoid the reduction in
power that results from excluding such isolates from analysis.
In Chapter 6 we introduce isoRelate, a freely available R package (https://github.com-
bahlolab/isoRelate) that performs IBD analysis on recombining haploid species, such as
the malaria-causing parasite Plasmodium and the bacterium Staphylococcus aureus, that
also includes multiple infections. Unlike other selection methods such as iHS101, IBD
mapping of microorganisms can also be used to infer fine-scale population structure and
allows the ability to monitor disease control and transmission, as well as to determine if
an antimicrobial drug-resistant haplotype has spread or arisen independently at different
geographical locations. Furthermore, IBD mapping has the potential to uncover multidrug
resistance and, for diseases that experience relapse infections such as malaria caused by
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P. vivax, may be able to distinguish between new or relapsing infections in drug efficacy
and cohort studies.
Using isoRelate, we demonstrate the ability of IBD analyses to detect signals of recent
positive selection using WGS data for a previously published global P. falciparum dataset
of 2,550 isolates97. We make comparisons with other popular methodologies that also try
to detect recent positive selection. Additionally, we use isoRelate to explore P. falciparum
population structure between geographical regions; confirm the global spread of resistance
to the antimalarial drug chloroquine as well as explore resistance to artemisinin as a soft
selective sweep, and investigate the ability of IBD to detect multidrug resistance.
6.1 Datasets
6.1.1 MalariaGEN genetic crosses dataset
To validate our method’s ability to recapitulate recombination events and thus IBD shar-
ing we made use of a previously published P. falciparum genetic cross. WGS data was
retrieved for 98 P. falciparum lab isolates that were generated as part of the MalariaGEN
consortium Pf3k project89. This dataset included the parent and progeny (first gener-
ation) of crosses between the pairs of parent strains 3D7 and HB3, 7G8 and GB4, and
HB3 and Dd2. We retrieved all available Pf3k data in VCF file format from data release
5 (https://www.malariagen.net/data/pf3k-5). SNPs were excluded if they were not in a
core region of the genome89, or if they had Quality of Depth ≤ 15 or Mapping Quality
≤ 50, or if less than 90% of samples were not covered by at least 5 reads, or they were not
polymorphic or if their MAF was less than 1% (using a read depth estimator). Samples
were also excluded if less than 90% of their SNPs were not covered by at least 5 reads.
Appendix C Table 1 shows the number of isolates and SNPs before and after filtering of
each genetic cross.
We visualized parental recombination breakpoints in the progeny using the haplotypes
displayed in the online data application (https://www.malariagen.net/apps/pf-crosses/1.0/).
We selected haplotypes that were constructed following GATK variant calling113 with all
other in the online application parameters at default values89. This allowed us to pro-
duce a gold standard IBD datasets with known recombination events. We then assessed
isoRelate’s inferred IBD segment locations against this dataset.
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6.1.2 MalariaGEN global P. falciparum dataset
WGS was performed on 2,512 P. falciparum field isolates sampled from 14 countries across
Africa and Southeast Asia as part of the MalariaGEN consortium Pf3k project97,114. We
retrieved all available Pf3k data in VCF file format from release 5. We merged all nuclear
chromosome VCF files and applied filters to the 2,512 samples and 1,057,870 biallelic
SNPs.
Variants were filtered using GATK’s SelectVariants and VariantFiltration modules113.
SNPs were excluded if there were more than 3 SNPs within a 30 base pair window, or
if they were not in a core region of the genome, or if they had Variant Quality Score
Recalibration (VQSR) < 0. Moreover, to reduce the possibility of spurious SNP calls
further filters for Quality of Depth (QD), Strand Odds Ratio (SOR), Mapping Quality
(MQ) and MQ Rank Sum (MQRankSum) were applied (QD > 15, SOR < 1, MQ > 50,
MQRankSum > −2). This filtering left 561,695 SNPs in the dataset.
Next, separating the data by country of origin, SNPs were excluded if less than 90%
of samples were not covered by at least 5 reads or they were not polymorphic. Samples
were also excluded if less than 90% of their SNPs were not covered by at least 5 reads.
Following this, countries were grouped into broader geographical regions of West Africa,
Central Africa or Southeast Asia, and the intersection of SNPs within a region was taken.
Lastly, within each country, SNPs with MAF less than 1% (using read depths) were
removed. Appendix C Table 2 displays the number of isolates and SNPs before and after
filtering of each country. Nigeria was excluded from all downstream analyses due to the
low number of SNPs remaining after filtering.
6.1.3 Papua New Guinea dataset
WGS data was available for 38 P. falciparum isolates from Madang, Papua New Guinea,
sampled in 2007 and sequenced at the Wellcome Trust Sanger Institute (WTSI), Hinxton,
UK as part of the MalariaGEN consortium (http: //www.malariagen.net/about; study ID:
1021-PF-PG-MUELLER). The sequencing data was processed by replicating the analysis
processing steps of the MalariaGen Pf3k field isolates for compatibility (Appendix C).
6.1.4 Simulated data with known selective sweeps
To assess the ability of IBD to detect the selective sweeps illustrated in Figure 1.5, we
simulated SNP data in the presence of various sweeps using the forward population genetic
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simulator, SLiM115, under an evolutionary model for P. falciparum. Specifically, we sim-
ulated a 2.27 Mb region, which is approximately the length of P. falciparum chromosome
12, under four different scenarios; no selection and positive selection via hard sweeps, soft
sweeps and standing variation.
We generated an initial population that resembles P. falciparum assuming a constant
effective population size of 100,000116, a mutation rate of 1.7 × 10−9 per base pair per
generation117 and a recombination rate of 7.4 × 10−7 per base pair per generation89.
The forward simulation was run over 400,000 generations, after which a sample of 10,000
haplotypes was randomly drawn to undergo selective pressures as follows. We note that
it would have been desirable to run the simulation over more generations116, however this
was not computationally feasible with the forward simulator.
Under the scenario of no selection, SLiM was run on the sampled population with all
alleles having the same fitness (i.e. selection coefficient s = 0). A hard sweep was generated
by sampling one haplotype to introduce a new allele with a selection coefficient of either
s = 0.01, s = 0.1 or s = 0.5. Alternatively, selection on standing variation was introduced
by adding a selective advantage of s = 0.01, s = 0.1 or s = 0.5 to an existing allele with
a population frequency of either f = 0.01, f = 0.05 or f = 0.1. Finally, soft sweeps were
generated such that a new allele would arise and spread throughout the population on
multiple haplotype backgrounds. We introduced the new allele at random generations,
where, at each generation, one haplotype was sampled that was not already carrying the
allele, and the allele was inserted. For each soft sweep, the selected allele had identical
selection coefficients on each haplotype of either s = 0.01, s = 0.1 or s = 0.5. The number
of generations between the introduction of the new allele was randomly sampled from a
Poisson distribution with mean 3 generations. The allele was introduced a total of 30, 10
and 5 times over the course of each soft sweep for selection coefficients s = 0.01, s = 0.1 and
s = 0.5, respectively. We needed to introduce the allele on more haplotype backgrounds
when smaller selection coefficients were used as we wanted multiple haplotypes to sweep
through the population without the allele being lost straight away. We generated 10
replicates for each scenario (no selection = 1, hard sweep = 3, standing variation = 9, soft
sweep = 3), randomly assigning the genetic position of the selected allele, and sampled
200 haplotypes at generations 50, 100, 200 and 500 following the initial sampling of the
population, resulting in a total of 150 simulated datasets. The dominance coefficient of




We applied the Fws metric, a characterization of within host diversity, to each countries
SNP sets to determine isolates that had multiple infections114. An isolate was classified as
having multiple infections if Fws < 0.95. For each country PED and MAP files for down-
stream analysis were extracted using moimix118. Heterozygous SNP calls were retained
for isolates assigned as having MOI greater than 1, otherwise heterozygous SNPs were set
to having a missing value at those SNPs to signify the likelihood of a genotyping error.
6.2.2 IBD detection and segment filtering
The methodology implemented in isoRelate is identical to that described in Chapter 2 for
XIBD model 1, and here we detail the specifications required for analysis of isolates with
MOI ≥ 1. The extension to haploid species with multiple infections essentially concerns
replacing the sex of the individuals in XIBD with MOI status. An isolate with MOI = 1
consists of a single strain and is analyzed as if it were haploid; thus sharing either 0 or 1
allele IBD with any other isolate. An isolate with MOI > 1 consists of multiple genetically
distinct (and possibly related) strains, and is considered diploid; sharing 0, 1 or at most
2 alleles IBD with other isolates. Here we make the assumption that an isolate with MOI
> 1 actually has MOI = 2, arguing that the current coverage of WGS data struggles to
identify more than two clones contributing to an isolate. This assumption will be incorrect
for some isolates; however, the progress of malaria control efforts has lead to a decrease
in the number of multiple infections, with the majority of multiple infections consisting of
two strains87 (Figure 5.3).
We compute the allele frequencies for each country separately for P. falciparum. This
is necessary due to the highly divergent sets of SNPs observed in P. falciparum globally119.
To perform IBD analyses between isolate from different countries, SNPs were included in
the analysis if the population allele frequencies between the pair of countries differed by
less than 0.3. A MAF concordance threshold of 0.3 was arbitrarily used in the analysis as
this threshold resulted in the inclusion of at least 75% of SNPs present in both populations,
for all pairwise-population comparisons. Population allele frequencies for the combined
countries were then calculated using all isolates from pairs of countries being examined.
SNPs with MAF less than 1% were removed from the analysis along with SNPs with
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missing genotype data for more than 10% of isolates. Similarly, isolates with missing
genotype data for more than 10% of SNPs were removed and a genotyping error rate of
1% was included in the model. Appendix C Tables 2 and 3 give the number of isolates
and SNPs before and after filtering for each country and pairwise-country dataset.
IBD segments that contain less than 20 SNPs or have lengths less than 50,000bp are
excluded, as they are likely to represent distant population sharing that is not relevant to
recent selection. IBD analyses were performed between all pairs of isolates that remained
once filtering procedures had been applied.
6.2.3 Identifying selection signals and assessing significance from IBD
In order to assess cohort level IBD sharing and thus investigate selection, we developed
a test statistic that overcomes some of the limitations of other selection statistics. In
particular, we developed a statistic that does not require phased data and that takes
into account relatedness observed between isolates. This test statistic is better suited for
analyses of microorganisms, like Plasmodium, that experience strong positive selection of
various types in addition to mixed infections. Using ideas previously applied in algorithms
such as EIGENSTRAT120 we were able to derive a test statistic that showed approximate
normality and thus can be interpreted probabilistically using distributional assumptions.
The test statistic was calculated as follows:
We created a matrix of binary IBD status with rows corresponding to SNPs and
columns corresponding to isolate pairs. For each column, we subtract the column mean
from all rows to account for the amount of relatedness between each pair. Following this
we subtract the row mean from each row and divide by the square root of pi(1−pi), where
pi is the population allele frequency of SNP i. This adjusts for differences in SNP allele
frequencies, which can affect the ability to detect IBD. Next we calculate row sums and
divide these values by the square root of the number of pairs. These summary statistics
are then normalized genome-wide such that they follow a standard normal distribution
with a mean of 0 and standard deviation of 1. Negative z-scores are difficult to interpret
when investigating positive selection; therefore we square the z-scores such that the new
summary statistics follow a chi-squared distribution with 1 degree of freedom (Figure 6.1).
This produces a set of genome wide test statistics {XiR,s}, where XiR,s is the chi-square
distributed test statistic for IBD sharing from isoRelate at SNP s.
We calculate p-values for {XiR,s}, after which we perform a − log 10 transformation of
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the p-values to produce our final summary statistics, used to investigate the significance of
selection signatures. Finally, a 5% genome-wide significance threshold was used to assess
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Figure 6.1: Chi-square quantile-quantile plots for the normalization step in the calculation of
{XiR,s} for the global P. falciparum dataset. Expected quantiles (χ2(df = 1)) are on the x-axis
and sample quantiles are on the y-axis.
6.2.4 Comparing methods for the detection of selection
We performed a standard analysis of selection signals using the scikit-allel v0.201.1 package
in Python 2.7121,122. To compute selection statistics on simulated data we calculated the
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iHS for SNPs passing a MAF filter of 1%101. We note that SNPs were removed from
analysis if they were not in a core region of the genome as defined by Miles et al.89.
We report the iHS if the EHH104 decays to 0.05 before reaching the final SNP examined
within a maximum gap distance of 2 Mb spanning the EHH region, otherwise iHS was set
to missing. To standardize iHS we binned all SNPs into 100 equally sized bins partitioned
on allele frequencies and then subtracted the mean and divided by the standard deviation
of iHS within that bin. We computed log 10 p-values using the normalized iHS from a
standard normal distribution.
To detect selection using haploPS123, SNPs passing a MAF filter of 1% that were
in core regions of the genome were analysed. We first calculated the adjusted haploPS
score for haplotypes identified at core frequencies of 5% to 95% in increments of 5%.
This score is calculated by comparing the lengths of the identified haplotypes to the
lengths of other haplotypes that are present as similar frequencies in the dataset. Regions
were considered to be under positive selection if the adjusted haplotype score was less
than 0.05. Since haplotypes are identified across multiple core frequencies, similar regions
of positive selection are detected across these frequencies. We stacked the significant
haplotypes around each SNP, identified across the different core frequencies, and calculated
the number of significant haplotypes that overlap each SNP. Regions that have undergone
strong positive selection in the form of a hard sweep will typically be inferred as positively
selected across multiple core frequencies, therefore the number of significant haplotypes
that overlap each SNP within these regions should be larger than those in regions that
have not undergone selection.
Since a large number of analyses were carried out (10 replications for each of the 15
scenarios of sweeps, with haplotypes sampled at 4 time points following selection), results
were summarised as follows. For isoRelate and iHS, we calculated the genetic distance
between the SNP with the largest− log10 p-value and the selected allele. While for haploPS
we calculated the distance between the selected allele and the SNP with the most number
of significant haplotypes inferred across the core frequencies. Boxplots were created for
each combination of scenarios from the 10 replications. Boxplots centered around zero
with a small interquartile range are indicative of a sweep being consistently detected, and
a method performing well.
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6.2.5 Relatedness networks
To examine the haplotype sharing between isolates within and between countries, both as
genome-wide averages and at a regional level, we generated relatedness networks using the
R package igraph124. Each node in the network represents a unique isolate and an edge is
drawn between two nodes if the isolates are IBD anywhere within interval. Isolates with
MOI = 1 are represented by circle nodes while isolates with MOI > 1 are represented by
squares. Node colors are unique for isolates from different countries.
6.2.6 Detecting multidrug resistance
To investigate multidrug resistance, whereby parasites are resistance to multiple antimalar-
ial drugs, we extract all pairs who are IBD over a drug resistant gene of interest, gene1.
Here a pair is classified as IBD if they have an IBD segment that partially or completely
overlaps gene1. From this subset of pairs, we calculate our selection signal, XiR, as per
usual and investigate the distribution of these statistics across the genome. We examine
all loci with significant XiR for known antimalarial drug resistant genes. If resistant genes
are identified in any of the loci, then we take this as evidence of joint-inheritance of these
genes with gene1. This subset of pairs can then be examined for resistance haplotypes in
gene1 and associated genes for evidence of multidrug resistance.
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6.3 Results
6.3.1 Validation of isoRelate
We validated our methodology by applying isoRelate to the MalariaGEN Pf3k genetic
cross dataset89 to detect known recombination events. This dataset contains the parents
and offspring of three P. falciparum strain crosses; 3D7 x HB3, 7G8 x GB4, and HB3 x Dd2.
There are 21, 40 and 37 isolates for the three crosses respectively, and 11,612 SNPs, 10,903
SNPs and 10,637 informative SNPs remaining following filtering procedures (Appendix C
Table 1). We combined the results for all three crosses and found that isoRelate detected
98% of all reported IBD segments, with an average concordance between inferred and
reported segments of 99%. Additionally, isoRelate detected segments with 99% accuracy;
meaning only 1% of segments were likely to be false positives. We did not infer IBD
between any of the founders. This is expected given the documented origins of these three
strains, which were derived from very different geographic regions114. False negatives,
where IBD was not inferred between parents and offspring, were observed predominantly
in genomic regions located between recombination events. Moreover, identical segment
boundaries were detected between all replicate isolates. We note that our methodology
has been extensively tested on simulated data for the human X chromosome and as such
we have not performed simulation studies here63.
6.3.2 Analysis of selection signal methodologies on simulated data
Multiplicity of infection = 1
We compared the selection signatures generated by isoRelate to those detected by the inte-
grated haplotype score (iHS)101 and haploPS123, where iHS makes use of the EHH104 and
is designed to identify strong signals of recent positive selection, while haploPS determines
strong positive selection by comparing the lengths of identified haplotypes with other hap-
lotypes genome-wide at similar frequencies. Both iHS and haploPS require knowledge of
haplotype phase, which is currently not possible for isolates with MOI > 1 as deconvolu-
tion of the contributing haplotypes for each isolate is currently not feasible. In contrast,
isolates with MOI = 1 are derived from single haploid haplotypes. Therefore we per-
formed initial comparisons of isoRelate, iHS and haploPS using only isolates with MOI =
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1. isoRelate and iHS produce selection statistics that follow known distributions. We thus
generated quantile-quantile plots for SNP specific test statistics for both of these methods
(Appendix C Figures 1 - 2).
No method is able to detect a sweep with a selection coefficient of s = 0.01, regardless
of the type of sweep (Figures 6.2 - 6.6). Alternatively, sweeps with selection coefficients of
s = 0.1 and s = 0.5 are more readily identified. While it is unfortunate that sweeps with
small selection coefficients are not detected, we anticipate that selection coefficients for
variants associated with antimalarial drug resistance will be larger than 0.01 as parasites
carrying the resistant variants are far more likely to survive drug treatment and reproduce.
For analysis of hard sweeps, HaploPS outperforms isoRelate and iHS, particularly as
the selection coefficient increases (Figure 6.2). Specifically, haploPS is able to detect a
hard sweep with selection coefficient s 0.1 at least 500 generations after its introduction
while isoRelate and iHS are limited to less than 500 generations. In contrast, isoRelate
and iHS are better able to detect a soft selective sweep than haploPS, with comparable
performances to a hard sweep (Figure 6.3). This is surprising as iHS it is expected to
have reduced performance for sweeps on multiple haplotype backgrounds21,34. However,
data was simulated such that the selected allele (i.e. the derived allele) is identical on all
haplotype backgrounds in a soft sweep (i.e. recurrent mutations). This means that iHS
should still detect a soft sweep of this kind as the decay of EHH is compared between the
derived allele and the ancestral allele. Only one haplotype carrying the derived allele is
examined when iHS is calculated, therefore the results should be similar to those of a hard
sweep with the same selection coefficient.
As expected, selection on standing variation is better detected when the initial fre-
quency of the selected allele is low (Figures 6.4 - 6.6). Nonetheless, haploPS has limited
ability to detect selection on standing variation, even with an initial allele frequency of 1%.
In contrast, isoRelate has the greatest ability to detect selection on standing variation,
although this is limited to less than 200 generations after the sweep is introduced.
Across all scenarios of positive selection considered here, isoRelate has the greatest
ability to detect a sweep that occurred less than 200 generations after its introduction.
Hughes and Verra (2001) used three generations per year as a conservative estimate of the
average generation time in P. falciparum. Given this, isoRelate should be able to detect
sweeps that occurred up to approximately 66 years ago, depending on selection coefficient,




























Figure 6.2: Simulation results from hard sweeps for different selection coefficients. Boxplots
show the distance between the genetic position of the sweep and the SNP with the largest − log10
p-value (isoRelate and iHS) or the SNP with most number of significant haplotypes overlapping it
(haploPS), calculated across 10 replicates for each scenario. Boxplots centered around zero with a



































Figure 6.3: Simulation results from soft sweeps for different selection coefficients. Boxplots show
the distance between the genetic position of the sweep and the SNP with the largest − log10 p-
value (isoRelate and iHS) or the SNP with most number of significant haplotypes overlapping it
(haploPS), calculated across 10 replicates for each scenario.
119
isoRelate iHS





































Figure 6.4: Simulation results from standing variation with initial allele frequency f = 0.01 for
different selection coefficients. Boxplots show the distance between the genetic position of the
sweep and the SNP with the largest − log10 p-value (isoRelate and iHS) or the SNP with most































Figure 6.5: Simulation results from standing variation with initial allele frequency f = 0.05 for
different selection coefficients. Boxplots show the distance between the genetic position of the
sweep and the SNP with the largest − log10 p-value (isoRelate and iHS) or the SNP with most



























Figure 6.6: Simulation results from standing variation with initial allele frequency f = 0.1 for
different selection coefficients. Boxplots show the distance between the genetic position of the
sweep and the SNP with the largest − log10 p-value (isoRelate and iHS) or the SNP with most
number of significant haplotypes overlapping it (haploPS), calculated across 10 replicates for each
scenario.
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Multiplicity of infection ≥ 1
isoRelate does not require phased or deconvoluted data, therefore we performed a sec-
ondary analysis on 100 isolates with MOI which could exceed 1. Each isolate was assigned
MOI according to a zero-truncated Poisson distribution with mean 1. Haplotypes were
randomly sampled for each isolate from the 200 haplotypes initially generated for each of
the simulation parameter combinations previously examined. Random sampling of hap-
lotypes produces isolates with clonal infections. Both iHS and haploPS were run on only
the MOI = 1 isolates with clonal isolates removed while isoRelate was run on all isolates
using unphased data.
On average 56% of isolates in each of the 150 datasets have MOI = 1 (Appendix C
Table 4). After the removal of clonal isolates, approximately 49 isolates with MOI = 1
remain for analysis with iHS and haploPS in each dataset, while all 100 isolates are used
in the analysis of isoRelate. Results for hard sweeps and soft sweeps are comparable to
the previous analysis of 200 MOI = 1 isolates, while there is reduced ability to detect
selection on standing variation for all three methods (Appendix C Figures 3-7). However,
isoRelate detects sweeps that have occurred recently (< 100 generations) more frequently
than iHS and haploPS by being able to use the multiclonal isolates.
6.3.3 Population analysis of P. falciparum
To demonstrate the ability of isoRelate to investigate a haploid species with known selec-
tion signals, we performed IBD mapping of 2,550 P. falciparum isolates from 14 countries
across Africa, Southeast Asia and Papua New Guinea as part of the MalariaGEN Pf3K
dataset. The samples in this dataset were collected during the years 2001 to 2014 (Ap-
pendix C Table 2) and details of the collection process and sequencing protocols have been
described elsewhere97,114. We define within-country analyses as all pairwise IBD compar-
isons between isolates from the same country (14 analyses in total) while between-country
analyses as all pairwise-country comparisons (91 analyses in total) where pairs of isolates
contain one isolate from each country.
After all filtering procedures were complete, 2,377 isolates remained for analysis with
994 isolates (42%) classified as having multiple infections (Appendix C Tables 2 and 5).
The mean number of SNPs remaining post filtering for within-country analyses was 31,018
SNPs with the least number of SNPs in the analysis of Papua New Guinea (18,270 SNPs)
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and the largest number of SNPs in the analysis of Guinea (44,528 SNPs) (Appendix C
Table 2). SNPs for between-country analyses were selected if they appeared in both
countries at similar frequencies, which resulted in an average of 12,271 SNPs per analysis
with the smallest number of SNPs in the analysis between Mali and Papua New Guinea
(1,945 SNPs) and the largest number of SNPs in the analysis between Guinea and Malawi
(29,138 SNPs) (Appendix C Table 3). These highly varying numbers of informative SNPs
largely reflect geographical isolation and distance but are also influenced by the quality of
the WGS data with poorer quality sequencing leading to fewer SNPs. Analyses with so
few SNPs, such as Mali and Papua New Guinea, are unlikely to detect selection signatures
since smaller IBD segments will fail to be detected, however are still useful for identifying
closely related isolates that are expected to share large IBD segments over many SNPs.
6.3.4 Investigating levels of relatedness
We calculated the proportion of pairs IBD at each SNP and investigated the distributions
of these statistics across the genome (Figure 6.7, Appendix C Table 6, Appendix C Figure
8). We identified higher levels of relatedness in Southeast Asia than in Africa or in Papua
New Guinea, with isolates from Cambodia displaying the highest average sharing across
the genome (5%). The Cambodian dataset consists of isolates collected from four study
locations; therefore we stratified the relatedness proportions by study location to identify
sites with extremely high amounts of relatedness. We detected high relatedness between
87% (2,890/3,321) of pairs from the Pailin Province of Cambodia, with on average 29% of
pairs IBD per SNP (Appendix C Tables 7 and 8, Appendix C Figures 9 and 10). Isolates
from Pailin contribute 16% of the Cambodian dataset and inflate the overall signal seen in
Cambodia. We also detected high amounts of relatedness, including many clonal isolates,
in the Thai Province of Sisakhet, which borders Cambodia, reflecting similar transmission
dynamics between regions in close proximity.
Relatedness proportions can also be used to identify genomic regions with particularly
high amounts of sharing that may be under positive selection as previously shown for IBD
studies in human populations21,22 (Figure 6.7). We observe higher levels of relatedness over
several known P. falciparum antimalarial drug resistance genes such as Pfcrt (chloroquine
resistance transporter) and Pfdhfr (dihydrofolate reductase) in addition to several regions
suspected of being associated with antimalarial drug resistance. In particular, a large
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Figure 6.7: The proportion of pairs within each country who are IBD at each SNP, displayed
genome wide. Chromosome boundaries are indicated by grey dashed vertical lines and positive
control genes are identified gene symbols by tick marks on the top x-axis. Countries that are part
of the African continent are shades of red and orange while countries in Southeast Asia are shades
of blue and Papua New Guinea is pink.
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a number of promising candidate genes suspected of being associated with pyrimethamine
resistance108,125. Many of these signals also show substantial continent and/or country
variation (Figure 6.7).
Relatedness-networks can be created using clustering techniques to identify groups of
isolates sharing a common haplotype. We constructed a relatedness-network to investi-
gate clusters of isolates sharing near-identical genomes, reflecting identical infections or
’duplicate’ samples (Figure 6.8). Southeast Asia has a number of large clusters containing
highly related isolates with the five largest clusters belonging to Cambodia, containing
between 12 and 68 isolates, indicative of clonal expansions. The largest cluster contains
mostly isolates from the Pursat Province of Cambodia, however the remaining isolates are
from the Pailin Province and the Ratanakiri Province of Cambodia, suggesting common
haplotypes between western and eastern Cambodia. In contrast, we did not find any iso-
lates within Guinea or Mali to be highly related, nor did we find isolates from different
countries to be highly related (Appendix C Table 9, Appendix C Figures 11 - 16).
Some clusters would separate into multiple disjoint clusters if even a single isolate were
removed from the group. Isolates which, if removed, would result in disjoint clusters were
generally observed to have MOI > 1, where their genome data consists of at least two ge-
netically distinct haplotypes. Such isolates have potentially come from individuals who are
traveling between geographical locations and become infected with P. falciparum strains
unique to those regions, resulting in IBD that connects multiple, otherwise unconnected


























































































































































































































































































































































































































































































































Figure 6.8: Relatedness network showing connections between pairs of isolates identified as
having high proportions of IBD sharing. Each node identifies a unique isolates and an edge is
drawn between two isolates if they share more than 90% of their genome IBD. Isolates with MOI
= 1 are represented by circles while isolates with MOI > 1 are represented by squares. There are
264 clusters in this network comprising 805 isolates (out of 2,377 isolates) in total. Isolates that
do not share more than 90% of their genome IBD with any other isolate are omitted from the
network.
6.3.5 Analysis of selection signals over the chloroquine resistance locus,
Pfcrt
To assess the significance of a selection signature we transformed the IBD results for
each analysis to account for variations in relatedness between isolates and SNP allele
frequencies, then performed normalization allowing us to calculate a new summary metric
for each SNP, − log 10 p-values. The genome-wide distributions of the − log 10 p-values
for within-country analyses are shown in Figure 6.9 and the top five signals of selection for
each country are reported in Appendix C Table 10. We examined in detail the selection
signals overlapping the known P. falciparum chloroquine resistance transporter gene, Pfcrt,
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Figure 6.9: − log 10(p-values) of XiR calculated by transforming and normalizing the IBD pro-
portions within each country. Dashed horizontal lines represent a 5% significance threshold. Grey
dashed vertical lines indicate chromosome boundaries. Positive control genes are identified by gene
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Figure 6.10: Selection signals within each country on chromosome 7 between 300,000-750,000bp,
surrounding the Pfcrt locus. Coloured points correspond to − log 10(p-values) of the XiR test
statistic for all SNPs and the dashed horizontal lines represent the 5% significance threshold. Solid
lines are the proportion of pairs IBD over the interval, extrapolated between adjacent SNPs. The
Pfcrt gene and the var gene locations are indicated on the upper x-axis. Note that the var gene
clusters are blacklisted for the IBD interrogation.
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All countries except Malawi and Myanmar have at least one significant SNP within
12kb of Pfcrt based on a 5% genome-wide significance threshold. Malawi withdrew the use
of chloroquine as an antimalarial drug in 1993, which resulted in the disappearance of the
molecular marker of chloroquine resistance (K76T mutation) in Malawian P. falciparum
populations126. Thus we would not expect to see a signature of selection over Pfcrt in
Malawi. Additionally, none of the between-country analyses involving isolates from Malawi
reach significance within 60kb of the Pfcrt locus.
Surprisingly, an increase in IBD proportions is observed over Pfcrt in Myanmar how-
ever the closest significant SNP is located 45kb downstream of Pfcrt. In contrast, little
to no increase in IBD is observed in the region surrounding Pfcrt in Cambodia and Laos,
although significant SNPs are identified within close proximity to Pfcrt. Both Cambodia
and Laos have many isolates sharing large proportions of their genome IBD; potentially
adding noise to the summary statistics resulting in inflated significance.
In most countries the highest proportion of IBD on chromosome 7 occurs downstream
of Pfcrt, with higher levels of IBD extending further downstream of Pfcrt than upstream,
including over a known set of var genes, which were excluded from the IBD analysis due
to their complex genetic structure which leads to significant mapping problems. This
potentially indicates that Pfcrt is regulating a gene downstream or alternatively a second
region in close proximity to Pfcrt is under selection. A secondary signal immediately
downstream of the var genes cluster on chromosome 7 has been previously identified in
isolates sampled from The Gambia127.
We investigated relatedness over Pfcrt between isolates from different countries and
confirmed the spread of chloroquine resistance throughout Southeast Asia and Africa,
while also confirming an independent origin of chloroquine resistance in Papua New
Guinea93,94 (Figure 6.11). However we were unable to determine the exact haplotypes
at codons 72-76 of the Pcfrt gene, of which CVIET and SVMNT have been associated
with chloroquine resistance93,94, due to low quality data resulting in missing genotype
calls for many isolates in addition to unknown haplotype phase for MOI > 1 isolates.
In particular the largest cluster in Figure 3 contains 48% of all isolates, of which
78% have missing genotype calls at codons 73-75 collectively. All isolates in this cluster
have the wild type C allele at the C72S variant codon 72. Additionally 95% of these
isolates have the chloroquine resistant K76T mutation (codon 76). Thus we speculate the

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6.11: Relatedness network showing connections between pairs of isolates inferred IBD
over Pfcrt (chr7: 403,222-406,317). Each node identifies a unique isolates and an edge is drawn
between two isolates if they were inferred IBD anywhere over Pfcrt. Isolates with MOI = 1 are
represented by circles while isolates with MOI > 1 are represented by squares. There are 178
clusters in this network comprising of 1,563 isolates in total, with the largest cluster containing
1,134 isolates. Isolates that are not IBD over Pfcrt are omitted from the network. A Isolates are
coloured according to country. B Isolates are coloured if they carry the K78T mutation associated
with chloroquine resistance
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and spread to Africa93. All isolates from Papua New Guinea have the C72S mutation and
K76T mutation (and missing genotype calls at codons 73-75) consistent with the presence
of the SVMNT haplotype94 and these isolates form a separate IBD cluster (bottom of
Figure 6.11).
6.3.6 Analysis of selection signals over the artemisinin resistance locus,
Pfk13
Parasite resistance to the antimalarial drug artemisinin has been associated with muta-
tions in the P. falciparum kelch 13 gene, Pfk13, located on chromosome 13 at 1,724,817-
1,726,997128,129. We detected selection signals of marginal significance over Pfk13 in
Cambodia and Thailand (Figure 6.9), which is not surprising given that artermisinin re-
sistance has only recently been identified in Cambodia in 2007 and is currently confined
to Southeast Asia130. Given the samples from Cambodia and Thailand were collected
between 2009 to 2013 (Appendix C Table 2), the resistance mutations are expected to be
at low frequencies within these populations, producing very weak signals of selection.
Artemisinin resistance has arisen as a soft selective sweep, involving at least 20 indepen-
dent Pfk13 mutations97. Relatedness networks over Pfk13 identify many disjoint clusters
of related isolates, with at least 9 clusters containing isolates that carry the most common
mutation associated with artemisinin resistance, C580Y97 (Figure 6.12). We identified
isolates from Cambodia, Thailand and Vietnam as carriers of this mutation at frequencies
of 40%, 26% and 1% respectively. Additionally, relatedness is detected between isolates
from Cambodia and Thailand that have the C580Y mutation as well as isolates from Cam-
bodia and Vietnam with this mutation, suggesting that some resistance-haplotypes have
swept between countries131.
6.3.7 Investigating global inheritance of genomic locations
We investigated the IBD analyses results between countries to determine if any other
genomic locations had experienced a global spread like that of chloroquine. We identified a
signal on chromosome 6 as having done so, not only between Africa and Southeast Asia, but
also Papua New Guinea. In fact, significant IBD sharing is detected in all pairwise-country
analyses over the interval chr6: 1,102,005-1,283,312. This interval contains 32 genes of
which several have been identified as promising drug resistance candidates108,125,132. The






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6.12: Relatedness network showing connections between pairs of isolates inferred IBD
over Pfk13 (chr13: 1,724,817-1,726,997). Each node identifies a unique isolates and an edge is
drawn between two isolates if they were inferred IBD anywhere over Pfk13. Isolates with MOI = 1
are represented by circles while isolates with MOI > 1 are represented by squares. There are 242
clusters in this network comprising of 1,148 isolates in total, with the largest cluster containing
335 isolates. Isolates that are not IBD over Pfk13 are omitted from the network. A Isolates are

















Figure 6.13: Genome-wide selection signatures within Ghana stratified by pairs who are IBD
(blue points) or non-IBD (yellow points) over Pfmdr1 (chr5: 957,890-962,149). The dashed hori-
zontal line represent a 5% significance threshold and the dashed vertical lines identifies the chro-
mosome boundaries. Genomic positions of the genes Pfmdr1, Pfcrt and Pfglurp are indicated by
ticks on the upper x-axis.
6.3.8 Detection of multidrug resistance from selection signatures
We explored selection signatures to determine if multidrug resistance could be identified.
Specifically, we investigated the P. falciparum multidrug resistance gene 1 (Pfmdr1 ), which
has been associated with chloroquine resistance and amodiaquine resistance when the
Pfmdr1 N86Y mutation is present along with the Pfcrt K76T mutation133. Figure 6.13
displays genome-wide selection signals in Ghana, stratified by pairs who are IBD over
Pfmdr1 and pairs who are not IBD over Pfmdr1. A significant signal of selection is
observed over Pfcrt in both stratified groups, suggesting Pfcrt is under selection jointly
with Pfmdr1 as well as independently of Pfmdr1. Of the isolate pairs who are IBD over
Pfmdr1, 13% are also IBD over Pfcrt while 6% are IBD over Pfcrt and carry both the
N86Y mutation and the K76T mutation. The median proportion of genome inferred IBD
between these pairs is 1%, alleviating concerns that joint inheritance of both variants is due
to highly related pairs. An additional selection signal is identified over Pfglurp (glutamine-
rich protein, a candidate vaccine antigen) also suggesting joint selection of both Pfmdr1
134
and Pfglurp.
6.3.9 Analysis of selection signal methodologies on global P. falciparum
dataset
We compared the selection signatures generated by isoRelate within countries to those
detected by iHS101. The EHH algorithm requires knowledge of haplotype phase, which is
currently not possible for isolates with MOI > 1 as the number of strains in an infection
and the proportions they contribute to the mixed infection must be known, in addition to
having quality data sequenced at high coverage. In contrast, haplotype phase is trivial for
isolates with MOI = 1, therefore we performed comparisons of isoRelate and iHS using
only isolates with MOI = 1, on the same SNPs (Appendix C Table 11, Appendix C Figure
17). The largest − log 10 p-value for a single SNP within each of 12 interesting genes is
reported in Appendix C Table 12.
Although there is some overlap in the selection signatures produced by iHS and isoRe-
late, there is a surprising dissimilarity between the results. iHS detects selection at Pfglurp,
Pfama1 and Pftrap more frequently than isoRelate, however has difficulty detecting selec-
tion in Southeast Asia and Papua New Guinea. In contrast isoRelate commonly detects
selection over Pfdhfr, Pfmdr1, Pfcrt and Pfdhps. Additionally prominent signals are also
detected on chromosome 6 and chromosome 12 by isoRelate, in regions that, as yet, have
no reported candidate genes.
The genes Pfglurp, Pfama1 and Pftrap detected by iHS encode surface proteins that
undergo balancing selection134,135 and hence have been investigated as vaccine targets.
We anticipate selection on extremely recent mutations in these genes that are at low
frequency within the population, in which case iHS is more likely to detect this selection
than isoRelate. This is simply because iHS profiles are calculated relative to the number
of isolates in a population while isoRelate profiles are calculated relative to the number of
pairwise combinations in the population, which heavily dilutes excess IBD sharing of low
frequency haplotypes.
Additionally, iHS assumes that all samples are independent, meaning there is no re-
latedness between isolates. This assumption is violated in all countries, particularly in
Southeast Asia where there are many highly related isolates, preventing iHS from decay-
ing to a threshold at some SNPs, resulting in missing iHS values. On average 84% of
SNPs in African countries have missing iHS values, while 94% of SNPs in Southeast Asian
135
countries have missing values, contributing to the lack of signals detected in Asia. To
avoid such loss of information, related isolates could be removed from iHS analyses at the
risk of reduced power due to smaller sample sizes. However in some instances the sample
size would reduce significantly, as is the case with Cambodia, which would experience an
80% reduction in sample size if isolates sharing more than 10% of their genome IBD were
removed. Considering the number of SNPs with missing values, iHS does surprisingly well
in African countries.
6.4 Discussion
Relatedness mapping of microorganisms is useful for investigating the genetic mechanisms
involved in diseases. We demonstrate this on a global whole-genome sequenced P. fal-
ciparum dataset using a new IBD method, isoRelate, which provides novel insights into
the geographical spread of antimalarial drug resistance, including multidrug resistance, as
well as population structure.
IBD inference of P. falciparum genomes allows us to compare different levels of relat-
edness between geographical regions. Here we identified the Pailin Province of Cambodia
as having many highly related isolates, either as a result of intensified malaria control
efforts following the emergence of artemisinin resistance in 2007130 or as an artifact of
the sampling collection procedures, in which case greater efforts may need to be made to
attain independence for population genetic studies. As such, we propose genome wide IBD
summaries as a means of monitoring malaria control, whereby intensified control regimes
reduce malaria transmission and genetic diversity136,137, resulting in more relatedness be-
tween strains and higher proportions of IBD.
Our algorithm allows us to infer IBD status at any genomic location, which lead us
to develop a new summary measure of IBD sharing in populations at genomic locations,
resulting in a novel measure for detecting selection. We developed a statistical frame-
work to test the significance of selection signatures, which, unlike iHS, accounts for the
level of relatedness between isolates. Using the IBD approach we were able to identify
both known resistance loci, underpinned by known resistance genes, including Pfcrt and
Pfk13, and several novel signals of selection, one of which has been previously reported
on chromosome 6108,125,132. Quantifying relatedness is important in analyses wishing to
investigate selection, as highly related isolates add noise to the results, making it harder
136
to identify selection signatures. Ideally related isolates would be excluded from analyses,
however as disease control reduces transmission, highly related isolates will become promi-
nent (Daniels et al. 2015) and removing these isolates could greatly reduce the power of
the analysis.
We generated relatedness networks to provide insights into the number of haplotypes
within a genomic interval as well as their origin, which has immediate applications for mon-
itoring the geographic spread of antimicrobial drug resistant haplotypes. We visualized
the spread of chloroquine resistance across Southeast Asia and Africa using such networks,
confirming an independent origin of resistance in Papua New Guinea93,94. We also exam-
ined relatedness over Pfk13 and were able to visualize a number of founder haplotypes
carrying the C580Y mutation, associated with artemisinin resistance, also confirming that
resistance to artemisinin has arisen as a soft selective sweep97.
IBD analyses require several criteria to be met. This includes the availability of a
good quality reference genome and the fact that the organism must recombine as one of
its main sources of creating genetic variation. As such these methods do not appear to
be applicable to Mycobacterium tuberculosis for example, but will work with any other
organism that shares these criteria with P. falciparum. Amongst these are P. vivax 138
and some species of Staphylococcus 139. Thus isoRelate will have broader application than
just P. falciparum. Furthermore, isoRelate can be applied to any dense genomic data that
produces SNP genotypes, which includes WGS, RNA sequencing and SNP arrays.
isoRelate is the first algorithm to implement an IBD-based selection detection approach
applicable for field isolates with possible multi-clonality. We have shown that our approach
can dissect complex signals of selection, including selection on standing variation. This
method will be invaluable for the identification and genomic surveillance of drug resistance





IBD analysis is a valuable tool with a plethora of applications, including identification of
candidate disease genes, detecting unknown relatedness and identifying selection signa-
tures. Analysis is commonly performed on autosomal chromosomes as methodologies are
typically developed for diploid genomes. As such, the X chromosome is generally excluded
from analysis as it requires special treatment to account for differences in chromosomal
numbers between males and females. Exclusion of the X chromosome is not only common
in IBD analysis but also linkage analysis and GWAS, resulting in much fewer discoveries
on the X chromosome relative to other chromosomes140. This is unfortunate as evidence
suggests that the X chromosome plays an important role in human disease140,141,142. The
lack of IBD methodologies for the X chromosome not only affects human analysis, but
analysis of organisms with haploid genomes, such as the malaria-causing parasite Plas-
modium and bacterium Mycobacterium tuberculosis, limiting our understanding of other
diseases.
This thesis describes a novel methodology for IBD analysis of both diploid and haploid
chromosomes in organisms that undergo recombination, with both human and non-human
applications. Chapter 2 introduces the methodology XIBD, which is an extension of the
HMM developed by Purcell et al.41 and Albrechtsen et al.18. The methodology described
in this chapter was published in Bioinformatics in 201663.
Chapter 3 evaluates the performance of XIBD on a simulated dataset, varying LD with
different ploidies, demonstrating improved IBD performance as haploid chromosomes are
included in the analysis and identifying an LD filtering threshold of R2 ≥ 0.8. We also
138
perform comparisons between XIBD, GERMLINE and fastIBD and determine that XIBD
performs similarly, or otherwise outperforms these tools.
In Chapter 4 we present the results of an analysis using XIBD on a cohort of 11 families
with a rare form of epilepsy. We discover unknown-relatedness between four families; are
able to refine the disease critical region; and provide evidence of a founder effect, with at
least four distinct founders responsible for the disorder. This information can help in the
identification of causal variants as it constrains the expectations regarding the number of
variants and who should carry them. The findings from this chapter were published in
Human Genetics in 2016143.
Following the description of our methodology in Chapter 3 and application to an
epilepsy cohort in Chapter 4, we introduce the burdensome disease malaria and the par-
asite responsible for malaria, Plasmodium. In Chapter 5 we discuss the need for an IBD
methodology that is applicable to haploid organisms, like Plasmodium, that can be used to
identify loci under positive selection. This is motivated by the emergence of antimalarial
drug resistance and the importance of identifying the genetic mechanisms underpinning
such resistance.
Chapter 6 then details how the IBD model described in Chapter 2 can be applied to
isolates with single or multiple infections of haploid microorganisms. Here, we perform
an IBD analysis on a global P. falciparum dataset, the deadliest species of Plasmodium
that infects humans, and demonstrate its usefulness in a number of applications, most im-
portantly in determining loci under positive selection. We identify previously known loci
under selection due to antimalarial drug pressure, including Pfcrt associated with chloro-
quine resistance, in addition to several loci suspected of being associated with antimalarial
drug resistance. Furthermore, we confirm the spread of chloroquine resistance throughout
Southeast Asia and Africa; confirm independent origins of resistance to artemisinin; and
infer fine-scale population structure within and between countries. The work presented
in Chapter 6 is being prepared for submission to Molecular Biology and Evolution. A
preprint is available on BioRxiv112.
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7.2 Importance and implications of the methodology and
results
The methodology presented in Chapter 2 allows for novel insights into relatedness on the
X chromosome, which is often neglected in analyses. This method will be extremely useful
for disorders that have an X-linked component, which, according to the Online Mendelian
Inheritance in Man, account for 6.4% of phenotypes with a known molecular basis and
includes disorders such as epilepsy, autism and intellectual disability141. The development
of an IBD methodology for the X chromosome should pave the way for a greater number
of discoveries of X-linked genes causal for these, and other, disorders.
The work presented in Chapters 5 and 6 highlights the importance of applying IBD
analysis to organisms other than humans. Following identification of two novel loci under
positive selection in P. falciparum, on chromosomes 6 and 12 respectively, molecular anal-
yses are now underway to identify any associations with antimalarial drug resistance. In
particular, the locus on chromosome 12, which was identified in 11 countries throughout
Africa, Southeast Asia and Papua New Guinea (PNG), is under investigation. Approx-
imately 20 field isolates from PNG, some of which were included in our analysis, have
been cultured and are undergoing screening to determine which antimalarial drug(s), if
any, the isolates have reduced sensitivity towards. If drug screening successfully identifies
reduced sensitivity, a list of candidate variants extracted from the PNG WGS data within
the locus on chromosome 12 will be produced. CRISPR knockout will then be performed
to confirm which variants are associated with antimalarial drug resistance.
The IBD methodology described in Chapter 6 can also be applied to species other
than P. falciparum. Future analyses will include longitudinal studies of P. vivax, which
can remain dormant within the human liver for months or years after the initial infection
before resurfacing, to investigate whether an infection is recurrent or not. An infection
can be classified as recurrent if a large amount of relatedness in inferred with previous
infections. Bright et al.144 performed a similar analysis using IBS to confirm that three
relapse infections in a patient from Africa were all caused by meiotic siblings that were
the result of a single meiosis event within a mosquito.
An additional analysis that is beyond the scope of this thesis, is to explore IBD within
the highly-polymorphic var gene family. The var genes encode hypervariable surface
proteins that are crucial for P. falciparum to evade the human immune response to infec-
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tion145. A number of conserved var genes have been associated with chloroquine resistance
as a result of their physical linkage to Pfcrt 146. Additional insights into the mechanisms
of drug resistance could be gained if more conserved var genes are identified that are asso-
ciated with drug resistance. However, identifying conservation, or IBD, over the var genes
requires de novo assembly of sequenced data, which is difficult because of the high AT
content of P.falciparum 147, in addition to the high polymorphism resulting from complex
recombination processes whereby var genes undergo ectopic recombination90 in addition
to recombination during both meiosis and mitosis within the mosquito and human hosts,
respectively145. It is unclear whether IBD approaches will be successful given the com-
plexity of the var genes and other avenues may need to be explored to determine var gene
conservation.
An interesting extension of IBD analysis in Plasmodium is to determine IBD between
strains within an infection, i.e., detect IBD between strains within an isolate with MOI
> 1. We are currently developing a model to do exactly this using B-allele frequency
data (i.e., the proportion of reads that map to the alternative allele at a locus), similar to
models used to infer copy number variation in human studies. This model is likely to be
complex and presents some challenges due to the AT bias of the P. falciparum genome, the
unknown number of strains in an infection and the relative contribution of each strain to
the infection. Furthermore, such a model may be redundant with the recent development
of DEpolid86, a deconvolution method that estimates the number of strains in an infection,
the relative contribution of each strain to the infection and the haplotype of each strain.
With haplotype data available, IBD analysis as described in Chapter 2 could be applied
directly to this data, eliminating the need for a second model. DEploid has the potential
to revolutionize genomic analyses of Plasmodium, and organisms with similar properties
to Plasmodium, advancing the wealth and quality of knowledge of a number of diseases.
In conclusion, this PhD thesis describes the successful development and application of
an IBD methodology for diploid and haploid genomes, for both human and non-human
applications. It has provided new insights into the rare epilepsy disorder, FAME, as well
as the deadliest malaria-causing parasite, P. falciparum. We anticipate our methodology
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[40] Gonçalo R Abecasis, Stacey S Cherny, William O Cookson, and Lon R Cardon.
Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. Nature
Genetics, 30(1):97–101, December 2001.
[41] Shaun Purcell, Benjamin Neale, Kathe Todd-Brown, Lori Thomas, Manuel A R
Ferreira, David Bender, Julian Maller, Pamela Sklar, Paul I W de Bakker, Mark J
Daly, and Pak C Sham. PLINK: A Tool Set for Whole-Genome Association and
Population-Based Linkage Analyses. The American Journal of Human Genetics, 81
(3):559–575, September 2007.
[42] S Bercovici, C Meek, Y Wexler, and D Geiger. Estimating genome-wide IBD sharing
from SNP data via an efficient hidden Markov model of LD with application to gene
mapping. Bioinformatics, 26(12):i175–i182, June 2010.
[43] Peter M Krawitz, Michal R Schweiger, Christian Rödelsperger, Carlo Marcelis, Uwe
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Abstract
Summary: XIBD performs pairwise relatedness mapping on the X chromosome using dense single
nucleotide polymorphism (SNP) data from either SNP chips or next generation sequencing data. It
correctly accounts for the difference in chromosomal numbers between males and females and es-
timates global relatedness as well as regions of the genome that are identical by descent (IBD).
XIBD also generates novel graphical summaries of all pairwise IBD tracts for a cohort making it
very useful for disease locus mapping.
Availability and implementation: XIBD is written in R/Rcpp and executed from shell scripts that are
freely available from http://bioinf.wehi.edu.au/software/XIBD along with accompanying reference
datasets.
Contact: henden.l@wehi.edu.au
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Genomic regions that have been inherited from a common ancestor
are said to be identical by descent (IBD). Identification of IBD regions
has proven useful in many applications, including discovery and quan-
tification of unknown or misspecified familial relatedness (McPeek
and Sun, 2000) and disease mapping where a region inherited in mul-
tiple affected individuals is indicative of a critical region containing
disease susceptibility genes (Albrechtsen et al., 2009).
Several methods have been proposed for inferring IBD, however
few allow for analysis of the X chromosome. This is unfortunate as
the X chromosome allows for inference of more distant relatedness
than autosomes since fewer recombination events occur, resulting in
IBD segments that are sustained over longer periods of time.
Current IBD analysis of the X chromosome is based on identity by
state sharing, which is non-probabilistic and does not necessarily
imply IBD (Browning and Browning, 2013; Gusev et al., 2009).
Here we present XIBD; the only hidden Markov model (HMM) that
infers IBD on the X chromosome in addition to the autosomes,
where IBD is detectable between individuals with a recent common
ancestor, within 25 generations, rather than more distant related-
ness. Many IBD methodologies rely on large cohorts to estimate al-
lele frequency data or to infer linkage disequilibrium structure.
XIBD can be applied to as few as two samples with the option to use
HapMap allele frequency data for 11 populations. Furthermore, it
can be applied to either single nucleotide polymorphism (SNP) chip
or next generation sequencing (NGS) data (exome or genome wide).
2 Methods
XIBD implements a first order continuous time HMM to infer IBD
between pairs of individuals using unphased genotype data, where
time is the genetic map distance in centimorgans (cM). While the
model is continuous time, IBD is estimated at the genotyped pos-
itions only. The memoryless assumption of a Markov process is un-
likely to hold due to recombination, however McPeek and Sun
(2000) have shown it to be a good approximation and like
Albrechtsen et al. (2009) and Epstein et al. (2000), we also make
this assumption.
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The hidden states in the Markov model are the number of alleles
shared IBD between a pair of individuals, which depend on the gen-
ders of the individuals being compared. Assuming the pair are not
inbred, if at least one individual is male, then 0 or 1 allele will be
shared IBD and the state space is Z ¼ f0; 1g. Alternatively, if both
individuals are female then 0, 1 or 2 alleles will be shared IBD with
Z ¼ f0;1; 2g.
The initial state probabilities of sharing 0, 1 or 2 alleles IBD are
denoted x0, x1 and x2 respectively, where
P2
i¼0 xi ¼ 1. These prob-
abilities can be calculated using identity coefficients if relationships
are known. We use IdCoefs (Abney, 2009) for autosomes and have
implemented the equivalent for the X chromosome. Individuals may
be distantly related with unknown relationships, therefore these val-
ues must be calculated using an alternative approach. We use the
method-of-moments approach described in Purcell et al. (2007) to
estimate these probabilities. The estimated values are used in the
analysis as they can be accurately calculated for known and un-
known relationships and avoid misspecified pedigrees leading to in-
correct global estimates.
Since there are two state spaces in the model, we require two
transition probability matrices. These can be computed by solving
Kolmogorov’s forward (or backward) equation given the transition
rate matrices (Supplementary information, Eqs. S1 and S2). The
transition rate matrices require the number of meiosis m separating
the pair of individuals, estimated as in Purcell et al. (2007), and the
recombination rate h estimated by Ott (1999).
The genotypic state space for an individual also depends on their
gender. Let A and a denote the reference allele and alternative allele
respectively. Since male X chromosomes are haploid, they cannot
have heterozygous genotype calls. Therefore the male genotypic
state space is G ¼ fA; ag while the female genotypic state space is
G ¼ fAA;Aa; aag. A pair of genotypes makes up the observation for
each marker in the model. Hence, the observation state space differs
for each of the three pairwise combinations of genders and this dif-
ference leads to three sets of emission probabilities (Supplementary
Information, Table S1). The emission probabilities are functions of
the individuals’ genders, the state space, the observed genotype pair
and the population allele frequencies. The population allele frequen-
cies are calculated from either a reference dataset such as HapMap
(http://hapmap.ncbi.nlm.nih.gov/) or the input dataset itself. We in-
clude a genotyping error term into our calculation of the emission
probabilities as implemented by Albrechtsen et al. (2009)
(Supplementary Information, Tables S2 and S3) and accommodate
missing data.
Dense marker datasets allow for better detection of small IBD
tracts and hence more distant relatedness. However, the presence of
LD can result in unwanted background sharing. To avoid this, we
allow the user to select one of two models to accommodate for LD.
1. Like Purcell et al. (2007), model 1 assumes the markers are in
linkage equilibrium, which may require thinning of datasets
prior to use. However datasets with denser markers in LD can
be used at the expense of false IBD segments being reported
(Brown et al., 2012).
2. Like Albrechtsen et al. (2009), LD is implicitly accounted for in
model 2 using conditional emission probabilities (Supplementary
Information, Tables S4–S6). Pairwise LD between markers is cal-
culated using the squared correlation (R2) of reference genotypes
using PLINK (Purcell et al., 2007).
Markers in high LD (R2 > 0:99) and markers with low minor al-
lele frequency (MAF < 0:01) are removed from the analysis.
Unlike Purcell et al. (2007) and Albrechtsen et al. (2009), refer-
ence datasets are provided with XIBD. These datasets are the com-
bined HapMap Phase II and III genotypes and allele frequencies
from build 19 (The International HapMap Consortium, 2003);
allowing the user to choose between the 11 HapMap population.
Furthermore, given a homogeneous population, we allow the user to
calculate the necessary frequencies from the input dataset itself or to
specify their own homogeneous reference dataset of matching
population.
Global relatedness estimates (x0, x1, x2 and m) are reported for
each pair of individuals analyzed, as well as inferred IBD tracts from
the Viterbi algorithm and posterior probabilities from the forward–
backward algorithm (Rabiner, 1989). IBD results are reported in
spreadsheets. These can be cumbersome to investigate when many
shared regions are inferred. However, XIBD also produces novel
graphical summaries that allow the user to visualize shared regions
in multiple individuals (Fig. 1).
Unlike other algorithms, XIBD does not require a large cohort
for accurate IBD inference. In Shaw et al. (2015), XIBD was imple-
mented on a single pair of male individuals with X-linked intellec-
tual disability, to verify that a detected variation was contained
within a small shared IBD tract on the X chromosome, thus leading
to the conclusion that the variant was causal, rather than a technical
artifact.
Results from simulation studies can be found in the
Supplementary Information, Figures S1 and S2. We note that
pseudo-autosomal regions are excluded from analysis. Finally,
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Fig. 1. Summary figure produced by XIBD of simulated IBD segments in-
herited up to 25 generations from the common ancestor. Pair identifiers are
given on the y-axis. i.e. 23_1/23_2 are individuals 1 and 2 from generation 23,
respectively. The x-axis displays the genetic map position in base-pairs with
tick markers indicating the SNP positions. The ideogram for the X chromo-
some is below. Blue rectangles are regions where pairs share one allele IBD
while yellow rectangles represent two alleles shared IBD
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XIBD can also be extended for use on non-human haploid organ-
isms to identify shared IBD tracts. We encourage feedback from
users.
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IBD coefficient calculation for the
X chromosome
IBD coefficients can be calculated for autosomes given a pedigree as in Lange148. We
extend this algorithm to the X chromosome below, excluding pseudoautosomal regions.
The mathematical detail was performed by David Wakeham (member of the Bahlo lab in
2012/2013 summer). The corresponding R script was prepared by myself and is available
as part of the XIBD R package.
The IBD coefficients, ω0, ω1 and ω2, calculate the probability that two individuals will
share 0, 1 or 2 alleles IBD at a randomly chosen locus, conditional on common ancestry.
In order to calculate these probabilities, information on the specific allele configuration at
a locus must be known, where allele configurations define identity states. Let FF, FM and
MM denote a pair of females, a pair containing one female and one male, and a pair of
males, respectively. The sets of identity states for each of the three combinations of pairs
(by gender) are given in Figure B.1. When the maternal and paternal alleles are unknown
(i.e. unphased data) the identity states can be reduced to form condensed identity states
as in Figure B.2.
Let ∆k denote the probability of a condensed identity state Sk. These probabilities
are referred to as identity coefficients and are used to calculate the IBD coefficients. The
IBD coefficients for two females (FF) expressed in terms of identity coefficients are
ω0 = ∆2 + ∆4 + ∆6 + ∆9
ω1 = ∆3 + ∆5 + ∆8
ω2 = ∆1 + ∆7
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A The 15 identity states for pairs of female X chromosomes. B The 5 identity states for pairs of
chromosomes where one chromosome belongs to a female and the other chromosome belongs to a
male. C The 2 identity states for pairs of male chromosomes.
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Figure B.2: Condensed identity states for unphased data. A The 9 condensed identity states
for pairs of female chromosomes. B The 4 condensed identity states for pairs of chromosomes
where one chromosome belongs to a female and the other chromosome belongs to a male. C The
2 condensed identity states for pairs of male chromosomes.
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Similarly, for FM the IBD coefficients are
ω0 = ∆2 + ∆4
ω1 = ∆1 + ∆3
ω2 = 0,




The relationship between IBD coefficients and identity coefficients is straightforward,
however the calculation of identity coefficients is more complex. Let Ψk be the probabil-
ity of a random condensed identity state, whereby Ψk describes a random sample with
replacement of ci alleles for both individuals at a (randomly chosen) locus on the X chro-
mosome, where ci is the number of copies of the X chromosome that individual i has. The
probabilities Ψk can be expressed in terms of the identity coefficients ∆k for two females
as follows, where Ψ̄ and ∆̄ are simply vectors containing Ψk and ∆k, respectively.
Ψ̄FF =









































0 0 0 0 0 0 14 0 0
0 0 0 0 0 0 0 14 0
0 0 0 0 0 0 0 0 14

∆̄FF
The coefficient matrix is invertible (upper triangular, determinant product of diagonal


















0 0 2 0 0 0 −2 −1 0
0 0 0 2 0 0 0 −1 −2
0 0 0 0 2 0 −2 −1 0
0 0 0 0 0 2 0 −1 −2
0 0 0 0 0 0 4 0 0
0 0 0 0 0 0 0 4 0
0 0 0 0 0 0 0 0 4

Ψ̄FF
We can do the same for a FM pair
Ψ̄FM =





0 0 12 0
0 0 0 12
 ∆̄
FM ⇒ ∆̄FM =

1 0 −12 0
0 1 −12 −1
0 0 2 0
0 0 0 2
 Ψ̄
FM
while the condition for MM is trivial, Ψ̄MM = ∆̄MM . It just remains to calculate Ψk,
which are done using generalized kinship coefficients. Generalized kinship coefficients are
the probabilities of particular partitions of genes148. If P is a partition of sampled genes,
we define Φ(P ) to be the probability that the IBD relation induces P on the sampled
genes. Let Gni denote the n-th allele sampled from individual i at a locus on chromosome






j , such that;
ΨFF1 = φ({G1i , G2i , G1j , G2j})
ΨFF2 = φ({G1i , G2i }, {G1j , G2j})
ΨFF3 = 2φ({G1i , G2i , G1j}, {G2j})
ΨFF4 = φ({G1i , G2i }, {G1j}, {G2j})
ΨFF5 = 2φ({G1i , G1j , G2j}, {G2i })
ΨFF6 = φ({G1i }, {G2i }, {G1j , G2j})
ΨFF7 = 2φ({G1i , G1j}, {G2i , G2j})
ΨFF8 = φ({G1i , G1j}, {G2i }, {G2j})
ΨFF9 = φ({G1i }, {G2i }, {G1j}, {G2j}).






ΨFM1 = φ({G1i , G2i , G1j})
ΨFM2 = φ({G1i , G2i }, {G1j})
ΨFM3 = 2φ({G1i , G1j}, {G2i })
ΨFM4 = φ({G1i }, {G2i }, {G1j}).
Finally, for MM we get
ΨMM1 = φ({G1i , G1j})
ΨMM2 = φ({G1i }, {G1j}).
We can determine Φ(P ) using boundary conditions and recurrence relations, where we
define a block to be a member of a partition; F, M to be female and male; and j and k to
be the mother and father of i, respectively.
Boundary conditions
(B1) If F is involved in ≥ 3 or M is involved in ≥ 2 blocks, φ(P ) = 0. Cannot have that
many X chromosome genes pairwise non-IBD.
(B2) If genes sampled from distinct founders occur in the same block, then φ(P ) = 0.
Founder are not related.
(B3) If only founders contribute sampled genes, and neither (B1) or (B2) apply, then
φ(P ) = 2m2−m1
where m1 is the total number of genes sampled from F founders and m2 is the
number of F founders sampled. There are m1−m2 comparison events, iid Bn(0.5)
Recurrence rules
(R1) Assume G1i , . . . , G
s
i are sampled from i for s ≥ 1 and occur in one block, P =
{{G1i , . . . , Gsi , . . . }} ∪ P ′. If i is M, then
φ({G1i , . . . , Gsi , . . . }, P ′) = φ({Gj , . . . }, P ′)
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since i receives their X gene from j. If i is F then
φ({G1i , . . . , Gsi , . . . }, P ′) = (1− 21−s)φ({Gj , Gk, . . . }, P ′)
+2−sφ({Gj , . . . }, P ′)
+2−sφ({Gk, . . . }, P ′)
since there is 2−s chance all sampled from j and 2−s chance all sampled from k.




i , . . . , G
s+t
i sampled from F and
P = {{G1i , . . . , Gsi , . . . }, {G
s+1
i , . . . , G
s+t
i }} ∪ P ′. Then
φ({G1i , . . . , Gsi , . . . }, {G
s+1
i , . . . , G
s+t
j }, P ′) = 2−(s+t)φ({Gj , . . . }{Gk, . . . }, P ′)
+2−(s+t)φ({Gk, . . . }{Gj , . . . }, P ′)
This is because there is 2−(s+t) chance that genes in the first block all come from
j, and all genes in the second block come from k. Similarly with j and k swapped.






C.1.1 Processing of Papua New Guinea Dataset
Picard Tools version 2.2.1 was used with the MarkIlluminaAdapters module to soft clip
reads containing adapter sequences149. Following this paired-end reads were mapped to the
Pf3D7 v3 reference genome with bwa-mem with the mark secondary hits option enabled150.
The Genome Analysis Toolkit (GATK) version 3.5 was used with the RealignIndels walker
to perform local realignment around intervals113 and Picard-tools MarkDuplicates module
was used to remove PCR duplicates. Next, GATK’s BaseRecalibrator walker was used
to correct base-quality scores using the entire P. falciparum genetic crosses version 1.0
data as known sites of variation89. Quality assessment of the aligned BAM files were
performed with FastQC version 0.10.1151 and Picard Tools CollectAlignmentMetrics and
CollectInsertSizeMetrics module. Finally, coverage analysis was performed using GATK’s
Depth of Coverage walker with the conditions that reads had to have a mapping quality
score of at least 20 and bases had to have a minimum quality of 20. As a result, 29 isolates
were removed as less than 90% of their bases were not covered to at least 5 reads or did
not map at all to the reference genome.
Variants were called using GATK’s HaplotypeCaller walker in gVCF mode and geno-
types were jointly called using GATK’s GenotypeGVCF walker. Following this, variant
quality score recalibration was performed for SNPs using the VariantRecalibrator walker.
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The P. falciparum genetic crosses data was used as training data and the calibration model
was trained using the QD, MQ, FS, SOR and DP tags in the VCF file. Annotation was
performed using snpEff version 4.1 and a custom annotation was added to the final VCF
file using the RegionType annotations obtained from the P. falciparum genetic crosses
data using bcftools version 1.1152,153. We applied the same filtering procedure to the iso-
lates and SNP calls as for the MalariaGEN pf3k field isolates. The final VCF file consisted
of 38 isolates and 29,631 SNPs.
C.2 Supplementary tables and figures
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Appendix C Table 1. The number of isolates and SNPs before and after filtering procedures 
for the P. falciparum genetic cross dataset. 
 
 Pre VCF filtering Post VCF filtering Post isoRelate filtering 
Cross No. isolates No. SNPs No. isolates No. SNPs No. isolates No. SNPs 
3D7 x HB3 21 15,398 21 11,612 21 11,612 
7G8 x GB4 40 14,426 40 10,903 40 10,903 




































Appendix C Table 2. The sample collection years and the number of isolates and SNPs after filtering procedures within each country.  
 
    Post VCF filtering Post isoRelate filtering 
Region Country Collection year (min)a Collection Year (max)a No. isolates No. SNPs No. isolates No. SNPs 
Africa DR of the Congo 2013 2013 104 60,969 104 31,676 
Africa Ghana 2009 2013 563 258,289 563 28,483 
Africa Guinea 2011 2011 100 101,425 100 44,528 
Africa Malawi 2011 2011 357 154,265 357 40,225 
Africa Mali 2007 2007 84 46,668 84 19,339 
Africa Senegal 2001 2011 131 52,664 131 26,757 
Africa The Gambia 2008 2008 57 46,576 57 43,360 
Southeast Asia Bangladesh 2012 2012 45 34,708 45 32,322 
Southeast Asia Cambodia 2009 2012 521 58,987 521 28,448 
Southeast Asia Laos 2011 2012 84 46,447 84 33,006 
Southeast Asia Myanmar 2011 2013 57 33,179 57 29,997 
Southeast Asia Thailand 2011 2013 140 40,502 140 28,218 
Southeast Asia Vietnam 2011 2012 96 42,011 96 29,617 
Oceania PNGb 2007 2007 38 29,631 37 18,270 
 
a Minimum and maximum collection years were obtained from pf3k metadata.  







Appendix C Table 3. The number of isolates and SNPs included in the IBD analyses 
between pairs of countries. 
 
Region A Region B Country A Country B No. isolates No. SNPs 
Africa Africa DR of the Congo Ghana 667 19,167 
Africa Africa DR of the Congo Guinea 204 19,236 
Africa Africa DR of the Congo Malawi 461 20,110 
Africa Africa DR of the Congo Mali 188 16,439 
Africa Africa DR of the Congo Senegal 235 16,529 
Africa Africa DR of the Congo The Gambia 161 16,192 
Africa Southeast Asia DR of the Congo Bangladesh 149 10,970 
Africa Southeast Asia DR of the Congo Cambodia 625 7,775 
Africa Southeast Asia DR of the Congo Laos 188 7,814 
Africa Southeast Asia DR of the Congo Myanmar 161 7,211 
Africa Southeast Asia DR of the Congo Thailand 244 7,353 
Africa Southeast Asia DR of the Congo Vietnam 200 7,390 
Africa Oceania DR of the Congo PNG 142 2,813 
Africa Africa Ghana Guinea 663 26,656 
Africa Africa Ghana Malawi 920 26,595 
Africa Africa Ghana Mali 647 16,127 
Africa Africa Ghana Senegal 694 18,138 
Africa Africa Ghana The Gambia 620 19,478 
Africa Southeast Asia Ghana Bangladesh 608 11,689 
Africa Southeast Asia Ghana Cambodia 1084 12,457 
Africa Southeast Asia Ghana Laos 647 10,334 
Africa Southeast Asia Ghana Myanmar 620 9,398 
Africa Southeast Asia Ghana Thailand 703 10,680 
Africa Southeast Asia Ghana Vietnam 659 10,046 
Africa Oceania Ghana PNG 600 4,118 
Africa Africa Guinea Malawi 457 29,138 
Africa Africa Guinea Mali 184 18,079 
Africa Africa Guinea Senegal 231 18,497 
Africa Africa Guinea The Gambia 157 21,457 
Africa Southeast Asia Guinea Bangladesh 145 11,937 
Africa Southeast Asia Guinea Cambodia 621 10,270 
Africa Southeast Asia Guinea Laos 184 11,458 
Africa Southeast Asia Guinea Myanmar 157 10,129 
Africa Southeast Asia Guinea Thailand 240 10,428 
Africa Southeast Asia Guinea Vietnam 196 10,756 
Africa Oceania Guinea PNG 134 4,834 
Africa Africa Malawi Mali 441 14,493 
Africa Africa Malawi Senegal 488 16,373 
Africa Africa Malawi The Gambia 414 19,049 
Africa Southeast Asia Malawi Bangladesh 402 12,405 
Africa Southeast Asia Malawi Cambodia 878 12,233 
Africa Southeast Asia Malawi Laos 441 12,638 
Africa Southeast Asia Malawi Myanmar 414 10,837 
Africa Southeast Asia Malawi Thailand 497 11,657 
Africa Southeast Asia Malawi Vietnam 453 11,591 
Africa Oceania Malawi PNG 391 4,988 
Africa Africa Mali Senegal 215 17,458 
Africa Africa Mali The Gambia 141 13,899 
Africa Southeast Asia Mali Bangladesh 129 8,997 
Africa Southeast Asia Mali Cambodia 605 5,941 
Africa Southeast Asia Mali Laos 168 5,805 
Africa Southeast Asia Mali Myanmar 141 5,622 
Africa Southeast Asia Mali Thailand 224 5,507 
Africa Southeast Asia Mali Vietnam 180 5,555 
Africa Oceania Mali PNG 122 1,945 
Africa Africa Senegal The Gambia 188 16,364 
Africa Southeast Asia Senegal Bangladesh 176 9,275 
Africa Southeast Asia Senegal Cambodia 652 6,486 
Africa Southeast Asia Senegal Laos 215 6,315 
Africa Southeast Asia Senegal Myanmar 188 5,885 
Africa Southeast Asia Senegal Thailand 271 6,017 
Africa Southeast Asia Senegal Vietnam 227 6,011 
Africa Oceania Senegal PNG 169 2,274 
Africa Southeast Asia The Gambia Bangladesh 102 9,882 
Africa Southeast Asia The Gambia Cambodia 578 7,305 
Africa Southeast Asia The Gambia Laos 141 7,979 
Africa Southeast Asia The Gambia Myanmar 114 7,305 
Africa Southeast Asia The Gambia Thailand 197 7,398 
Africa Southeast Asia The Gambia Vietnam 153 7,504 
Africa Oceania The Gambia PNG 94 2,984 
Southeast Asia Southeast Asia Bangladesh Cambodia 566 13,736 
Southeast Asia Southeast Asia Bangladesh Laos 129 15,029 
Southeast Asia Southeast Asia Bangladesh Myanmar 102 14,751 
Southeast Asia Southeast Asia Bangladesh Thailand 185 14,666 
Southeast Asia Southeast Asia Bangladesh Vietnam 141 14,207 
Southeast Asia Oceania Bangladesh PNG 83 4,218 
Southeast Asia Southeast Asia Cambodia Laos 605 24,921 
Southeast Asia Southeast Asia Cambodia Myanmar 578 17,479 
Southeast Asia Southeast Asia Cambodia Thailand 661 21,199 
Southeast Asia Southeast Asia Cambodia Vietnam 617 23,394 
Southeast Asia Oceania Cambodia PNG 558 5,395 
Southeast Asia Southeast Asia Laos Myanmar 141 19,045 
Southeast Asia Southeast Asia Laos Thailand 224 21,164 
Southeast Asia Southeast Asia Laos Vietnam 180 26,419 
Southeast Asia Oceania Laos PNG 121 5,994 
Southeast Asia Southeast Asia Myanmar Thailand 197 21,293 
Southeast Asia Southeast Asia Myanmar Vietnam 153 18,666 
Southeast Asia Oceania Myanmar PNG 94 5,124 
Southeast Asia Southeast Asia Thailand Vietnam 236 21,069 
Southeast Asia Oceania Thailand PNG 177 5,572 
































Appendix C Figure 1. Chi-squared QQ plots from isoRelate’s selection statistic over three 
scenarios of positive selection. These plots correspond to one replicate of each scenario, 



















Appendix C Figure 2. Normal QQ plots from iHS’s selection statistic over three scenarios 
of positive selection. These plots correspond to one replicate of each scenario, where t is the 
number of generations since the sweep was introduced. The same replicates were used in 















Appendix C Table 4. The average percentage of isolates with various simulated MOI. The 
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Appendix C Figure 3. Simulation results from hard sweeps for different selection 
coefficients when MOI ³ 1 is incorporated into the simulation. isoRelate was run on all 
isolates while iHS and haploPS were run on MOI = 1 isolates only. Boxplots show the 
distance between the genetic position of the sweep and the SNP with the largest –log10 p-
value (isoRelate and iHS) or the SNP with most number of significant haplotypes 































Appendix C Figure 4. Simulation results from soft sweeps for different selection 
coefficients when MOI ³ 1 is incorporated into the simulation. isoRelate was run on all 
isolates while iHS and haploPS were run on MOI = 1 isolates only. Boxplots show the 
distance between the genetic position of the sweep and the SNP with the largest –log10 p-
value (isoRelate and iHS) or the SNP with most number of significant haplotypes 



































Appendix C Figure 5. Simulation results from standing variation with initial allele frequency f = 
0.01 for different selection coefficients when MOI ³ 1 is incorporated into the simulation. isoRelate 
was run on all isolates while iHS and haploPS were run on MOI = 1 isolates only. Boxplots show the 
distance between the genetic position of the sweep and the SNP with the largest –log10 p-value 
(isoRelate and iHS) or the SNP with most number of significant haplotypes overlapping it (haploPS), 
calculated across 10 replicates for each scenario. 
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Appendix C Figure 6. Simulation results from standing variation with initial allele frequency f = 
0.05 for different selection coefficients when MOI ³ 1 is incorporated into the simulation. isoRelate 
was run on all isolates while iHS and haploPS were run on MOI = 1 isolates only. Boxplots show the 
distance between the genetic position of the sweep and the SNP with the largest –log10 p-value 
(isoRelate and iHS) or the SNP with most number of significant haplotypes overlapping it (haploPS), 
calculated across 10 replicates for each scenario. 
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Appendix C Figure 7. Simulation results from standing variation with initial allele frequency f = 0.1 
for different selection coefficients when MOI ³ 1 is incorporated into the simulation. isoRelate was 
run on all isolates while iHS and haploPS were run on MOI = 1 isolates only. Boxplots show the 
distance between the genetic position of the sweep and the SNP with the largest –log10 p-value 
(isoRelate and iHS) or the SNP with most number of significant haplotypes overlapping it (haploPS), 
calculated across 10 replicates for each scenario. 
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Appendix C Table 5. The number of isolates with MOI = 1 and MOI > 1 within each 
country.  
 
Region Country MOI = 1 MO1 > 1 
Africa DR of the Congo 47 57 
Africa Ghana 243 320 
Africa Guinea 51 49 
Africa Malawi 134 223 
Africa Mali 40 44 
Africa Senegal 110 21 
Africa The Gambia 40 17 
Southeast Asia Bangladesh 21 24 
Southeast Asia Cambodia 396 125 
Southeast Asia Laos 49 35 
Southeast Asia Myanmar 45 12 
Southeast Asia Thailand 107 33 
Southeast Asia Vietnam 69 27 

















Appendix C Table 6. Summary of relatedness between pairs of isolates within the same country. 
  




% of pairs 
IBDa 
% of pairs 
identicalb  
Ave. % of pairs IBD per 
SNPc 
Ave. % of genome 
IBDd 
Ave. length of IBD 
(kb)e 
Africa DR of the 
Congo 
104 5,356 5.41 0.06 0.12 1.06 185 
Africa Ghana 563 158,203 4.62 0.01 0.06 0.78 144 
Africa Guinea 100 4,950 10.24 0 0.16 1.46 189 
Africa Malawi 357 63,546 5.82 0.11 0.24 2.24 302 
Africa Mali 84 3,486 12.22 0 0.15 0.83 160 
Africa Senegal 131 8,515 25.18 0.38 1.13 2.94 357 
Africa The Gambia 57 1,596 16.85 0.69 1.59 5.44 386 
Southeast 
Asia 
Bangladesh 45 990 10.51 0.1 0.27 1.3 205 
Southeast 
Asia 
Cambodia 521 135,460 33.41 0.95 5.38 13.72 429 
Southeast 
Asia 
Laos 84 3,486 17.87 0.49 2.06 8.86 531 
Southeast 
Asia 
Myanmar 57 1,596 42.36 0.94 2.6 3.82 300 
Southeast 
Asia 
Thailand 140 97,30 52.15 1.12 3.18 3.8 280 
Southeast 
Asia 
Vietnam 96 4,560 20.68 2.79 4.31 8.25 431 
Oceania PNG 37 666 25.08 0.75 1.19 1.68 220 
 
a Percentage of all pairs inferred IBD at any genomic location. 
b Percentage of all pairs with identical genomes. 
c Average percentage of pairs IBD calculated genome-wide. 
d Average percentage of genome IBD calculated from IBD pairs only, excluding identical pairs. 
e Average length of inferred IBD segments (kb), excluding segments from identical pairs.
 
Appendix C Figure 8. Summary of Appendix C Table 6. A. The percentage of pairs with 
any inferred IBD at least 50 kb in length within each country and the percentage of pairs with 
identical genomes. B. The average percentage of pairs IBD against the average IBD length in 
base-pairs.
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Appendix C Table 7. Summary of relatedness between pairs of isolates within the same country, stratified by study location. Only 








% of pairs 
IBD 
% of pairs 
identical  
Ave. % of pairs IBD per 
SNP 
Ave. % of genome 
IBD 
Ave. length of IBD 
(kb) 
Africa Ghana Kassena 501 125,250 4.83 0.01 0.06 0.78 143 
Africa Ghana Kintampo 62 1,891 3.07 0.53 0.68 6.04 572 
Africa Malawi Chikwawa 310 47,895 6.31 0.11 0.27 2.35 322 
Africa Malawi Zomba 47 1,081 4.9 1.39 1.99 16.89 653 
Africa Mali Kolle 46 1,035 12.95 0 0.18 1.09 191 
Africa Mali Faladje 30 435 14.48 0 0.17 0.7 143 
Africa Mali Bandiagar
a 
8 28 3.57 0 0.03 0.71 150 
Africa Senegal Thies 127 8,001 25.25 0.4 1.19 3.09 367 










































31 465 29.03 2.37 3.71 4.74 352 
Southeast 
Asia 
Vietnam Bu Gia 
Map 
64 2,016 19.3 3.52 5.22 10.5 464 
 
Appendix C Figure 9. Summary of Appendix C Table 7. A. The percentage of pairs with 
any inferred IBD at least 50 kb in length within each site and the percentage of pairs with 
identical genomes. B. The average percentage of pairs IBD against the average IBD length in 
base-pairs.




































































% of pairs 
IBD 
% of pairs 
identical 
Ave. % of pairs IBD 
per SNP 
Ave. % of 
genome IBD 
Ave. length of 
IBD (kb) 
Africa Ghana Kassena Kintampo 563 31,062 3.86 0 0.03 0.55 112 
Africa Malawi Chikwaw
a 
Zomba 357 14,570 4.26 0 0.04 0.84 121 
Africa Mali Kolle Faladje 76 1,380 13.84 0 0.16 0.74 148 
Africa Mali Kolle Bandiaga
ra 
54 368 6.25 0 0.05 0.57 115 
Africa Mali Faladje Bandiaga
ra 
38 240 5.83 0 0.04 0.58 122 
Africa Senega
l 
















































































Bu Dang 65 64 18.75 0 0.54 2.59 212 
 
Appendix C Figure 10. Summary of Appendix C Table 8. A. The percentage of pairs with 
any inferred IBD at least 50 kb in length between sites within a country and the percentage 
of pairs with identical genomes. B. The average percentage of pairs IBD against the average 
IBD length in base-pairs.

















Vietnam: Phuoc Long/Bu Gia Map
Vietnam: Phuoc Long/Bu Dang







































Appendix C Table 9. Summary of relatedness between pairs of isolates from different countries.  
 






% of pairs 
IBD 
% of pairs 
identical 
Ave. % of pairs IBD 
per SNP 
Ave. % of 
genome IBD 
Ave. length of 
IBD (kb) 
Africa Africa DR of the 
Congo 
Ghana 667 58,552 4.12 0 0.03 0.52 108 
Africa Africa DR of the 
Congo 
Guinea 204 10,400 5.25 0 0.04 0.52 109 
Africa Africa DR of the 
Congo 
Malawi 461 37,128 3.1 0 0.02 0.49 102 
Africa Africa DR of the 
Congo 
Mali 188 8,736 5.99 0 0.04 0.52 108 
Africa Africa DR of the 
Congo 
Senegal 235 13,624 6.55 0 0.04 0.54 110 




161 5,928 6.87 0 0.05 0.53 111 
Africa Africa Ghana Guinea 663 56,300 6.41 0 0.07 0.79 131 
Africa Africa Ghana Malawi 920 200,99
1 
1.83 0 0.01 0.58 110 
Africa Africa Ghana Mali 647 47,292 8.37 0 0.09 0.64 130 
Africa Africa Ghana Senegal 694 73,753 8.88 0 0.07 0.62 120 
Africa Africa Ghana The 
Gambia 
620 32,091 6.01 0 0.06 0.57 115 
Africa Africa Guinea Malawi 457 35,700 2.81 0 0.02 0.63 98 
Africa Africa Guinea Mali 184 8,400 9.83 0 0.09 0.65 132 
Africa Africa Guinea Senegal 231 13,100 13.98 0 0.12 0.65 120 
Africa Africa Guinea The 
Gambia 
157 5,700 9.67 0 0.09 0.6 115 
Africa Africa Malawi Mali 441 29,988 4.16 0 0.03 0.56 117 
Africa Africa Malawi Senegal 488 46,767 4.6 0 0.03 0.59 119 
Africa Africa Malawi The 
Gambia 
414 20,349 2.55 0 0.02 0.45 94 
Africa Africa Mali Senegal 215 11,004 12.5 0 0.12 0.67 133 
Africa Africa Mali The 
Gambia 
141 4,788 15.35 0 0.17 0.61 121 
Africa Africa Senegal The 
Gambia 
188 7,467 22.24 0 0.24 0.77 133 
Africa Southeast 
Asia 




149 4,680 2.2 0 0.03 0.49 103 
Africa Southeast 
Asia 




625 54,184 1.7 0 0.03 0.39 81 
Africa Southeast 
Asia 
DR of the 
Congo 
Laos 188 8,736 2.66 0 0.05 0.41 86 
Africa Southeast 
Asia 




161 5,928 2.34 0 0.04 0.47 98 
Africa Southeast 
Asia 
DR of the 
Congo 
Thailand 244 14,560 1.41 0 0.03 0.48 102 
Africa Southeast 
Asia 
DR of the 
Congo 












0.92 0 0.01 0.65 1285 
Africa Southeast 
Asia 





620 32,091 2.44 0 0.03 0.61 124 
Africa Southeast 
Asia 
Ghana Thailand 703 78,820 1.7 0 0.02 0.56 113 
Africa Southeast 
Asia 










621 52,100 4.07 0 0.05 0.41 86 
Africa Southeast 
Asia 





157 5,700 4.98 0 0.07 0.55 112 
Africa Southeast 
Asia 
Guinea Thailand 240 14,000 3.3 0 0.05 0.56 116 
Africa Southeast 
Asia 












0.71 0 0.01 0.45 94 
Africa Southeast 
Asia 





414 20,349 1.72 0 0.02 0.49 103 
Africa Southeast 
Asia 
Malawi Thailand 497 49,980 0.98 0 0.01 0.44 93 
Africa Southeast 
Asia 










605 43,764 2.02 0 0.04 0.57 120 
Africa Southeast 
Asia 





141 4,788 8.02 0 0.14 0.69 144 
Africa Southeast 
Asia 
Mali Thailand 224 11,760 6 0 0.11 0.58 120 
Africa Southeast 
Asia 










652 68,251 1.88 0 0.03 0.47 99 
Africa Southeast 
Asia 





188 7,467 7.31 0 0.11 0.65 133 
Africa Southeast 
Asia 
Senegal Thailand 271 18,340 3.14 0 0.06 0.55 107 
Africa Southeast 
Asia 










578 29,697 3.09 0 0.05 0.39 82 
Africa Southeast 
Asia 





114 3,249 10.62 0 0.16 0.48 97 
Africa Southeast 
Asia 
The Gambia Thailand 197 7,980 5.56 0 0.09 0.47 99 
Africa Southeast 
Asia 
The Gambia Vietnam 153 5,472 3.86 0 0.06 0.48 102 
Africa Oceania DR of the 
Congo 
PNG 142 3,952 0.66 0 0.01 0.87 182 
Africa Oceania Ghana PNG 600 20,831 0.48 0 0.01 0.96 189 
Africa Oceania Guinea PNG 134 3,400 0.88 0 0.01 0.83 176 
Africa Oceania Malawi PNG 391 12,138 0.33 0 0 0.66 140 
Africa Oceania Mali PNG 122 3,192 0.5 0 0.01 3.57 749 
Africa Oceania Senegal PNG 169 4,978 0.26 0 0 1.38 288 



















































































Thailand Vietnam 236 13,440 20.52 0 0.2 0.75 126 
Southeast 
Asia 
Oceania Bangladesh PNG 83 1,710 0.53 0 0.01 0.53 112 
Southeast 
Asia 
Oceania Cambodia PNG 558 19,277 0.48 0 0.01 0.44 92 
Southeast 
Asia 
Oceania Laos PNG 121 3,108 0.13 0 0 1.26 266 
Southeast 
Asia 
Oceania Myanmar PNG 94 2,109 0.14 0 0 0.63 133 
Southeast 
Asia 
Oceania Thailand PNG 177 5,180 0.29 0 0 0.69 147 
Southeast 
Asia 
Oceania Vietnam PNG 133 3,552 0.48 0 0 0.29 62 
 
Appendix C Figure 11. Summary of Appendix C Table 9. A. The percentage of pairs with 
any inferred IBD at least 50 kb in length between countries in Africa and the percentage of 
pairs with identical genomes. B. The average percentage of pairs IBD against the average 
IBD length in base-pairs. 
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Appendix C Figure 12. Summary of Appendix C Table 9. The percentage of pairs with any 
inferred IBD at least 50 kb in length between countries in Africa and Southeast Asia and the 
percentage of pairs with identical genomes. 
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Appendix C Figure 13. Summary of Appendix C Table 9. The average percentage of pairs 

























































Appendix C Figure 14. Summary of Appendix C Table 9. A. The percentage of pairs with 
any inferred IBD at least 50 kb in length between Africa and PNG and the percentage of 
pairs with identical genomes. B. The average percentage of pairs IBD against the average 
IBD length in base-pairs. 
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Appendix C Figure 15. Summary of Appendix C Table 9. A. The percentage of pairs with 
any inferred IBD at least 50 kb in length between Southeast Asian countries and the 
percentage of pairs with identical genomes. B. The average percentage of pairs IBD against 
the average IBD length in base-pairs. 



























































Appendix C Figure 16. Summary of Appendix C Table 9. A. The percentage of pairs with 
any inferred IBD at least 50 kb in length between Southeast Asia and PNG and the 
percentage of pairs with identical genomes. B. The average percentage of pairs IBD against 
the average IBD length in base-pairs. 

















































Appendix C Table 10. The top 5 selection signals within each country and the IBD 
proportion/XiR test statistic for the SNP with the largest –log10(p-value) within the selection 
interval. 
Country Chromosome Start End IBD percentage XiR 
DR of the Congo 6 1040011 1292764 1.34 315.48 
DR of the Congo 7 383527 688642 0.37 40.67 
DR of the Congo 10 1421301 1570694 0.24 31.95 
DR of the Congo 11 1950959 2003228 0.26 10.67 
DR of the Congo 12 761260 909881 0.5 39.51 
Ghana 2 756399 862030 0.27 39.44 
Ghana 6 1070251 1294804 0.84 70.96 
Ghana 7 210646 699826 0.13 77.21 
Ghana 10 1350374 1571407 0.41 28.63 
Ghana 12 721251 968375 0.53 69.44 
Guinea 4 614998 698534 1.03 48.44 
Guinea 6 1050336 1294804 1.39 269.69 
Guinea 7 350609 659941 0.99 79.74 
Guinea 12 760468 1029068 1.52 92.96 
Guinea 12 1745700 1897010 0.67 30.13 
Malawi 6 1081929 1294804 1 116.74 
Malawi 8 372767 779813 0.69 150.8 
Malawi 10 1400002 1570653 0.36 79.86 
Malawi 11 1790115 2003228 0.45 18.07 
Malawi 12 780748 1079903 0.71 68.74 
Mali 6 1001323 1292769 3.82 79.33 
Mali 7 360243 679897 3.24 109.95 
Mali 10 1430096 1571407 1.03 46.47 
Senegal 2 720032 861423 0.72 4.68 
Senegal 3 901428 993530 0.72 5.45 
Senegal 4 615405 748410 2.14 9.74 
Senegal 6 1050336 1292769 6.62 323.28 
Senegal 7 252368 619957 3.01 74.82 
The Gambia 4 540033 779909 7.64 1447.64 
The Gambia 4 930011 1143943 2.07 19.4 
The Gambia 7 331248 719023 2.51 50.01 
The Gambia 8 105218 219366 2.07 12.62 
The Gambia 8 420318 649599 2.57 27.68 
Bangladesh 4 620279 679065 0.71 19.87 
Bangladesh 6 1191624 1294070 1.01 95.06 
Bangladesh 7 175076 718355 1.62 69.07 
Bangladesh 8 467370 580545 2.02 695.78 
Bangladesh 12 766623 989679 0.91 99.4 
Cambodia 8 420692 979511 8.94 64.92 
Cambodia 10 550118 799419 6.8 38.57 
Cambodia 13 1901748 2389910 9.26 73.76 
Cambodia 14 35796 999557 4.92 46.27 
Cambodia 14 1250576 1999655 6.8 65.82 
Laos 1 93378 199493 2.81 25.87 
Laos 3 71014 359186 3.18 68.25 
Laos 4 540009 899970 3.82 201.13 
Laos 8 425234 599944 3.56 55.12 
Laos 13 75051 139950 3.18 71.22 
Myanmar 4 545154 697350 7.52 76.87 
Myanmar 6 1020329 1294426 8.15 110.64 
Myanmar 7 450016 739678 4.82 36.25 
Myanmar 11 1890328 2003228 4.26 50.42 
Myanmar 12 631425 895415 10.34 94.4 
Thailand 6 1002288 1294426 6.1 72.33 
Thailand 7 405600 679897 7.87 80.05 
Thailand 8 415327 698268 13.71 80.57 
Thailand 11 1910597 2003233 6.55 81.83 
Thailand 12 701638 977430 9.48 90.67 
Vietnam 4 540009 679043 6.07 45.38 
Vietnam 6 742857 959371 5.26 37.65 
Vietnam 9 79451 498806 5.26 38.38 
Vietnam 11 1900435 2003233 6.1 100.19 
Vietnam 12 561246 1246071 6.71 113.73 
PNG 5 803678 1099386 1.8 10.89 
PNG 7 357431 849589 6.76 131.64 
PNG 11 1900435 2001345 2.1 9.71 
PNG 12 750192 999517 2.25 25.58 









Appendix C Table 11. The number of MOI = 1 isolates and SNPs included in the analysis of 
selection signatures within countries using iHS and isoRelate. 
 
Region Country No. isolates No. SNPs 
Africa DR of the Congo 47 34,382 
Africa Ghana 243 30,361 
Africa Guinea 51 61,546 
Africa Malawi 134 57,302 
Africa Mali 40 26,316 
Africa Senegal 110 21,317 
Africa The Gambia 40 35,059 
Southeast Asia Bangladesh 21 20,928 
Southeast Asia Cambodia 396 28,101 
Southeast Asia Laos 49 35,391 
Southeast Asia Myanmar 45 26,843 
Southeast Asia Thailand 107 25,335 
Southeast Asia Vietnam 69 32,761 



























Appendix C Table 12. Positive control genes in P.falciparum where there is evidence of 
selection in either drug resistance, vaccine candidate or anti-folate resistance genes. The gene 
identifiers, names and locations were obtained from PlasmoDB. The type of signal 
(balancing or positive) and corresponding references are also given. 
Gene ID Name Location Description Signal Reference 
PF3D7_1133400 AMA1 Pf3D7_11_v3: 
1,293,856 - 
1,295,724 (+) 
apical membrane antigen 
1 
balancing Polley, S. D. & 
Conway, D. J. 
(2001) 
PF3D7_0709000 CRT Pf3D7_07_v3: 




positive Mu, J. et al. 
(2010) 
PF3D7_0304600 CSP Pf3D7_03_v3: 
221,323 - 222,516 
(-) 
circumsporozoite protein balancing Weedall, G. D., 
et al. (2007) 
PF3D7_0417200 DHFR Pf3D7_04_v3: 





positive Nwakanma, D. 
C. et al. (2014) 
PF3D7_0810800 DHPS Pf3D7_08_v3: 




positive Nwakanma, D. 
C. et al. (2014) 





balancing Baum, J et al. 
(2003) 
PF3D7_1035300 GLURP Pf3D7_10_v3: 
1,399,195 - 
1,402,896 (+) 
glutamate-rich protein balancing Conway, D.J. 
(1997) 
PF3D7_1343700 K13 Pf3D7_13_v3: 
1,724,817 - 
1,726,997 (-) 
kelch protein K13 positive Miotto, O. et al 
(2013) 
PF3D7_0523000 MDR1 Pf3D7_05_v3: 




positive Nwakanma, D. 
C. et al. (2014) 





balancing Tetteh, K. K. A. 
et al. (2009) 
PF3D7_0206800 MSP2 Pf3D7_02_v3: 




balancing Tetteh, K. K. A. 
et al. (2009) 





positive Weedall, G. D., 










Appendix C Figure 17. Comparison of –log10 (p-values) generated by isoRelate (blue) and iHS 
(yellow) within each country. Grey dashed vertical lines indicate chromosome boundaries and ticks 
on the upper x-axis mark twelve positive control genes (Supplementary Table 10)
 
